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ABSTRACT 
mRNAs containing nonsense codons encode truncated polypeptides that can 
interfere with the function of their corresponding full-length polypeptides. However, 
levels of most nonsense mRNAs are reduced in eukaryotic and prokaryotic cells 
when compared to that of corresponding functional mRNAs. Genes that encode 
proteins responsible to selectively reduce levels of nonsense mRNA have been 
identified only in lower eukaryotes. Here, I describe the cloning of a putative 
human group I RNA helicase whose amino acid sequence is 60% identical to that 
of UPF1, a bona fide yeast group I RNA helicase required for rapid degradation of 
nonsense mRNA. Besides the seven RNA helicase consensus motifs, UPF1 and 
its human homologue share two similar zinc finger-like domains, which are absent 
in other group I RNA helicases. Blocking of protein expression by antisense RNA 
derived from the human gene increased levels of nonsense immunoglobulin heavy 
chain mRNA in a mouse hybridoma line. I, thus, have identified the first 
mammalian protein that regulates levels of nonsense mRNA, and I have named it 
NORF1 (Il.Qnsense mRNA reducing factor 1). 
xx iv 
INTRODUCTION 
Nonsense codons are able to decrease the stability of mRNA (or pre-
mRNA) in simple and complex eukaryotic organisms. Recently, the greatest 
advances to understand how nonsense mRNA levels are reduced have been 
made in yeast. For example, cis-specific nonsense mRNA targeting sequences 
(Peltz et al., 1993) and genes whose products are required for reducing levels of 
nonsense mRNA (UPFINMD genes) (Leeds et al., 1991, 1993; He and 
Jacobson, 1995; Lee and Culbertson, 1995) have been discovered. In 
eukaryotic cells, it seems that the effect of a nonsense codon on mRNA depends 
on its position and also that levels of nonsense mRNA are reduced in the 
nucleus and cytoplasm (reviewed in Peltz et al., 1994). However, no mammalian 
nonsense mRNA reduction factor (NORF) has as yet been identified. 
Using a combination of searching nucleic and protein sequence 
databases with the UPF1 amino acid sequence and screening complementary 
DNA (cDNA) libraries, I isolated a human cDNA clone that encodes a structural 
homologue of yeast UPF1, a protein that rapidly induces the degradation of 
nonsense mRNA. I also showed in RNA antisense experiments that the 
mammalian protein controls levels of nonsense immunoglobulin µ heavy chain 
2 
mRNA (nonsense µ mRNA). Therefore, I named this protein NORF1 (for 
nonsense mRNA reducing factor 1). 
CHAPTER II 
REVIEW OF RELATED LITERATURE 
Nonsense Codons: Definition. Generation and Significance 
Definition 
Genetic information must be relayed through RNA (mRNA) before it is 
disseminated within a cell as a functional protein. After mRNA is transcribed 
from a gene, it is transported into the cytoplasm. There, ribosomes use the 
mRNA as a template and along with amino acid-charged t-RNAs, and 
translational initiation, elongation, and termination factors, synthesize a complete 
protein. The ribosomes translate the mRNA from the authentic start to the 
authentic stop signal as they move along the mRNA (a functional mRNA 
molecule). Through a number of processes to be described below, a mRNA can 
contain a premature stop signal (nonsense codon) that would end protein 
synthesis (Crick et al., 1961). In this case, an incomplete, truncated, polypeptide 
would be synthesized. Analyses of lower eukaryotic and mammalian cells 
containing mRNAs with nonsense codons (nonsense mRNA) have generally 
3 
4 
found that the average (steady-state) level of nonsense mRNA is lower when 
compared to the same mRNA without a nonsense codon. 
Generation 
Nonsense mRNAs can be generated by many different processes, such 
as inaccurate or incomplete RNA splicing, incorrect RNA editing, mutations of 
DNA or RNA, or the inaccurate assembly of DNA fragments leading to 
nonproductive gene rearrangements. Studies of intron splicing in pre-processed 
mRNAs (pre-mRNA) have found that incorrect splicing can lead to the imprecise 
assembly of exons, exon skipping, or the failure to remove an intron altogether 
(intron retention) (Senapathy, 1986; Senapathy et al., 1990; Carothers et al., 
1993; Stover et al., 1993). All the events can lead to a change in the 
translational reading frame of the mRNA and the new reading frame may contain 
a premature translational stop, or nonsense codon (Legrain and Rosabash, 
1989; He et al., 1993). 
The rearrangement of immunoglobulin (lg) and T cell receptor gene 
segments as well as hypermutation of immunoglobulin genes, may also result in 
the production of a nonsense mRNA (Baumann et al., 1985, Lozano et al., 
1993). Many mRNAs with nonsense codons can also arise from random 
mutations occurring within the cell's genome. Examples include single 
nucleotide (nt) changes (Orkin and Kazazian, 1984; Satoh et al., 1988; Jack et 
al., 1989; Kadowaki et al., 1990; Hamosh et al., 1992; Longo et al., 1992; Bach 
6 
et al., 1993; Dietz et al., 1993; Gibson et al., 1993; Naylor et al., 1993; Das et al., 
1994), insertions (Myerowitz and Costigan, 1988; Naylor et al., 1993; Das et al., 
1994; Boles and Proia, 1995), or deletions (Krawczak and Cooper, 1991; Naylor 
et al., 1993; Sherrat et al., 1993, Das et al., 1994). 
Significance 
The presence of a nonsense codon in an mRNA usually results in a 
decrease in the steady state level of nonsense mRNA that is not due to 
decreased transcriptional rates (Cheng and Maquat, 1993; Urlaub et al., 1989; 
Jack et al., 1989; Paw and Neufeld, 1988). It has been hypothesized that this 
process, which we call nonsense codon-mediated mRNA reduction, is used by a 
cell to eliminate nonsense mRNAs that could be translated into a 
shorter/truncated protein or a protein with a new amino acid sequence. 
However, if nonsense mRNA levels are not decreased, shorter proteins with the 
new amino acid sequence could interfere with the full-length corresponding 
polypeptide. For example, when a nonsense codon is present in the human p-
globin gene at certain positions, levels of the nonsense mRNA are not 
decreased (Table 1) (Kazazian et al., 1992; Thein, 1992; Hall and Thein, 1994). 
Because levels of nonsense p-globin mRNA increases, a truncated p-globin 
encoded by the nonsense mRNA can accumulate in the cell. Patients with a 
heterozygous mutation in the p-globin gene produce the truncated and full length 
P-globin protein, but still have p-thalassemia. It has been hypothesized that the 
6 
truncated p-globin protein is interfering in a dominant-negative fashion with the 
function of the complete p-globin protein (Kazazian et al., 1992; Thein, 1992). 
Humans with this heterozygous condition are diagnosed with partial P-
thalassemia, a disease manifesting itself with symptoms of anemia and bone 
deformation. 
The most striking evidence that nonsense codon-mediated RNA 
degradation is important for an organism comes from experiments with the 
nematode Caenorhabditis elegans (Pulak and Anderson, 1993). In C. elegans a 
nonsense codon within one allele of the myosin heavy chain gene unc-54 has no 
effect on the viability of the heterozygotic worm or on the ability of muscle cells to 
form a functional muscle. When the heterozygotic worm has a defect in the 
nonsense codon-mediated RNA degradation system, (SMG2 mutation), the unc-
54 mRNA with the nonsense codon is not degraded and a truncated myosin 
heavy-chain polypeptide translated from the nonsense mRNA interferes with the 
assembly of muscular structure in the worm. This leads to defective muscle 
function so that the worms are unable to swim. Pulak and Anderson (1993) 
conclude that the shorter myosin heavy-chain polypeptide acts in a dominant-
negative fashion and suggest that a nonsense mRNA surveillance mechanism is 
important to avoid the accumulation of dominant-negative or gain-of-function 
polypeptides. 
There are also many other examples of human diseases that correlate 
with the presence of nonsense mRNA and in some cases with the presence of a 
7 
shorter polypeptide. For example, certain mutations in the apolipoprotein E 
(APO E) gene lead to the generation of a nonsense APO E mRNA. Individuals 
with these mutations produce a truncated APO E receptor that is not able to help 
remove cholesterol from the blood and suffer from elevated plasma cholesterol 
levels and hyperlipoproteinemia (Lohse et al., 1992; see Table 1). The table lists 
other examples where a nonsense mRNA is made but whether a shorter 
polypeptide can cause the disease is not clear. 
Nonsense mRNA Reduction: Who. Where and How (Translation. Location and 
Models of Reduction) 
Translation 
How a cell is able to differentiate between a nonsense codon and a 
normal translational stop codon is unknown. Ribosomes, charged t-RNAs, 
initiation, elongation, and termination factors are all thought to be essential to 
recognize codon triplets and translate mRNA (reviewed in Stansfield and Tuite, 
1994). Therefore, it is thought that the same translational machinery is 
necessary for the recognition of a nonsense codon. The inhibition of translation 
using the translation elongation inhibitor cycloheximide results in increased 
levels of nonsense mRNAs (Qian et al., 1993; Lozano et al., 1994; Menon and 
Neufeld, 1994; Li et al., unpublished results). These results support the 
hypothesis that translation is needed to reduce levels of nonsense mRNA. 
Table 1. --Human Diseases Associated With a Nonsense Codon Mutationa 
Gene Nucleotide Disease Symptoms Truncated Nonsense Reference 
Change Protein mRNA 
Reduction 
p-globin FS >NC, NC p-thalassemia I Cell membrane damage Yes No Hall & Thein, 1994 
and destruction of red cells 
alphaTTP FS> NC Vitamin E deficiency I Ataxia & Peripheral N.D. N.D. Hentati et al., 1996 
neuropathy 
BRACA1 NC Breast and Ovarian cancer N.D. N.D. Serova et al., 1996 
BRACA2 NC Breast cancer N.D. N.D. Tavtigian et al., 1996 
apo E2 FS> NC Type 3 Hyperlipoproteniemia I Yes N.D. Feussner et al., 1996 
RB FS> NC Retinoblastoma I retinal tumors that can N.D. Yes Kato et al., 1994 
proceed to the brain 
SCH NC Schwannomas I benign tumors of the N.D. N.D. Bijlsma et al., 1994 
cranium and spine, Neurofibromatosis 
gp91-phox FS> NC Chronic granulomatous disease N.D. N.D. Rabbani et al., 1993 
(superoxide deficiency) I recurrent life-
threating infections 
hMLH1&2 NC Heridetiary nonpolyposis colon cancer N.D. N.D. Luce et al,. 1996 
ARSA FS> NC Metrochromatic leukodystrophy N.D. Yes Pastor-Soler et al., 1994 
(arylsulfatase A) I defective myelin sulfatide 
degradation leads to demyelination and 
death. 
I)) 
Table 1. cont --Human Diseases Associated With a Nonsense Codon Mutationa 
GP 1b alpha FS> NC Bernard-Soulier syndrome (absence of Yes N.D. Simsek et al., 1994 
platelet glycoprotein lb/IXN complex) I 
giant platelets that cannot promote clotting 
CDKN2 FS> NC Putative melanoma susceptibility gene N.D. N.D. Walder et al., 1995 
IL-2R y NC Severe combined immunodeficeincy I N.D. N.D. Noguchi et al., 1993 
immunodeficiency disease (T cell def.) 
GHRH-R NC Laron syndrome I Pituitary adenomas and N.D. N.D. Hashimoto et al., 1995 
severe growth failure 
WASP FS> NC Wiskott-Aldrich syndrome I X-linked N.D. N.D. Wengler et al., 1995 
NC 
immunodeficiency, thrombocytopenia and 
eczema 
btk FS> NC X-linked agammaglobulinemia I inherited N.D. N.D. Duriez et al., 1994 
immunodeficiency disease (B cell def.) 
XPAC NC Xeroderma pigmentosum I Skin cancer N.D. N.D. Satokata et al., 1992 
LAMC2 FS> NC Herlitz's Junctional epidermolysis bullosa N.D. Yes Vailly et al., 1995 
(laminin-5) I skin blistering at sites of 
pressure or trauma 
p53 NC CMML, AML, CML, Burkitt's lymphoma, Yes, No No, Yes Kawasaki et al., 1994 
Bladder cancer, endometrial carcinoma 
PHKA2 NC X-linked liver glycogenosis type 1 I N.D. N.D. Hendricks et al., 1995 
hepatomegaly, hypoglycemia, gout 
WT1 NC Denys-Drash syndrome I nephropathy, and N.D. N.D. Baird et al., 1992 
Wilms tumors 
co 
Table 1. cont --Human Diseases Associated With a Nonsense Codon Mutation8 
HEXAand FS> NC Tay-Sach or Sandhoff disease respectively N.D. Yes Mcinnes et al., 1992 
HEXB (lysosomal P-hexosaminidase) I motor and 
mental deterioration, blindness 
a-II p-3 FS> NC Glanzmann's thrombasthenia I defect in No N.D. Schlegel et al., 1995 
platelet alpha llb beta 3 protein 
subunit A FS> NC Subunit A coagulation factor 13 deficiency I N.D. Yes Vreken et al., 1995 
coagulation deficiency 
CD18 FS> NC Leukocyte adherence deficiency I recurrent N.D. N.D. Back et al., 1992 
infections due to deficiency in surface 
expression of leukocyte integrin molecules 
CHM FS> NS Choroideremia I X linked progressive N.D. N.D. Sankila et al., 1992 
degeneration of the choroid and retina 
APKD1 NC Autosomal dominant polycystic kidney N.D. No Turco et al., 1995 
disease / 1: 1000 persons, massive 
kidneys, hematuria, hypertension, and 
renal failure 
ACTH-R NC Isolated gluocorticoid deficiency I N.D. N.D. Tsigos et al., 1993 
progressive primary adrenal insufficiency 
COL7A1 FS> NC Hallopeau-Siemens dystrophic No Yes Hilal et al., 1993 
epidermolysis bullosa / loss of dermal 
adherence with abnormal anchoring fibrils 
COL10A1 FS> NC Schmid metaphyseal dysplasias (type 1 O Yes N.D. Bonaventure et al., 1995 
collagen) I metaphyseal dysplasia, poor 
collagen assembly 
COL4A3 FS> NC Alport syndrome (type IV collagen)/ N.D. N.D. Ding et al., 1995 
Deafness, hematuria, proteinuria and renal 
failure ...... 
0 
PBDA 
cytb5r 
FBN1 
APOE 
Spectrin-P 
OA1 
ASM 
Table 1. cont --Human Diseases Associated With a Nonsense Codon Mutation3 
FS > NC lntermitent porphyria I skin lesions 
FS > NC Cytochrome b5 reductase deficiency I 
syanosis or mental retardation 
NC Marfan syndrome (aberrant fibrillin) I 
connective tissue disorder affecting the 
skeleton, eye, and cardiovascular system 
NC Apolipoprotein E deficiency I elevated 
plasma cholesterol levels, 
hyperlipoproteinemia 
FS > NC Hereditary elliptocytosis I 
FS >NC Ocular albinism I impaired visual acuity, 
retinal hypopigmentation 
FS>NC, NC Niemann-Pick disease I neuronopathic 
N.D. 
N.D. 
Yes 
Yes 
Yes 
N.D. 
Yes 
N.D. 
N.D. 
No 
No 
N.D. 
No 
N.D. 
Mgone et al., 1993 
Vieira et al., 1995 
Dietz et al., 1994 
Lohse et al., 1992 
Wilmotte et al., 1994 
Bassi et al., 1995 
Takahashi et al., 1992 
SMN FS >NC Spinal muscular atrophy I degeneration of N.D. N.D. Bussaglia et al., 1995 
motor neurons of the spinal cord 
8This is a partial list of various human diseases correlating with the presence of a nonsense codon in a gene. Nucleotide 
changes are either mutations that generate a nonsense codon (NC) or cause a frame shift (FS) that leads to the 
generation of a nonsense codon. In both cases, translation is presumabely truncated and, thus, only a shorter 
polypeptide could be produced. N.D., not determined. 
-->. 
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Although treatment of cells with cycloheximide seems to support the role of 
translation in nonsense mRNA reduction, these experiments are difficult to 
interpret, since the treatment itself may inhibit the production of (a) factor(s) 
necessary during the process of nonsense mRNA reduction. Other evidence 
supporting the role of translation in nonsense mRNA reduction comes from 
experiments using modified RNA constructs that contain a stem-loop structure 
that inhibits translation by virtue of its strong secondary structure (Belgrader et 
al., 1993). mRNAs containing these elements upstream of a nonsense codon do 
not undergo nonsense mRNA reduction suggesting the importance of translation 
in the nonsense mRNA reduction process. 
Location of Nonsense mRNA Reduction 
As mentioned above, the translational process is thought to be involved in 
nonsense mRNA reduction. Because the translational process is only known to 
occurs in the cytoplasm, it would be expected that the reduction of nonsense 
mRNA also occurs in the cytoplasm. Indeed, a number of experiments in yeast 
have found that nonsense mRNA reduction occurs in the cytoplasm and occurs 
by degradation. First, the activity of a cytoplasmic yeast 5' to 3' exonuclease 
(Xrn1p) correlates with the reduction of a nonsense mRNA. When a mutant 
strain lacks XRN1, cytoplasmic mRNA decay does not occur and a nonsense 
mRNA (the PGK1 allele) has the same stability as a wild-type mRNA (Muhlrad 
and Parker, 1994). Second, the presence of a yeast factor associated with 
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cytoplasmic ribosomes (Upf1 p) (Atkin et al., 1995) correlates with reduction of 
nonsense mRNA. When yeast are missing Upf1 p, the levels of nonsense mRNA 
associated with polyribosomes increases (He et al., 1993). Both these 
experiments suggest that a nonsense codon in an mRNA is recognized by the 
translational machinery and that the reduction in the level of the message is due 
to degradation. 
There are also experiments in mammalian cells that suggest that the 
reduction of nonsense mRNA occurs in the cytoplasm. Cytoplasmic nonsense 
mRNA reduction has been demonstrated for p-globin mRNA (Orkin and 
Kazazian, 1984 review) and lg µ mRNA (Li and Jack, unpublished observations). 
In these experiments, p-thalassemic patients producing p-globin nonsense 
mRNAs had no changes in the half-life of the nonsense pre-mRNA. But the half-
life of mature nonsense mRNA was reduced to only 30 minutes when compared 
to the wild type p-globin mRNA half life of 16 hours (Maquat, et al., 1981; Ross 
and Pizarro, 1983). In the lg µ mRNA studies, northern blot analysis was used 
to determine the levels of cytoplasmic µ and nonsense µ mRNA at different time 
points after the addition of the transcripitional inhibitors actinomycin and 5, 6-
dichloro-1-beta-D-ribofuranosylbenzimidazole (ORB). The result indicated that 
nonsense µ mRNA had a half-life of 4 hours, whereas functional µ mRNA had a 
half-life of 16 hours. This suggests that the degradation of the µ nonsense 
mRNA is occurring in the cytoplasm. 
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Although the evidence discussed above suggests that nonsense codons 
in mRNAs are recognized in the cytoplasm by the translational machinery, a 
number of observations suggest that the levels of nonsense mRNAs are also 
reduced in the nucleus of a mammalian cell. Examples include the human 
triosephosphate-isomerase (TPI) mRNA in both mouse and human cell lines 
(Cheng and Maquat, 1993), the secretory major urinary protein (MUP) mRNA in 
mouse cells (Belgrader and Maquat, 1994), ~-globin mRNA in nonerythroid cells 
(Takeshita et al., 1984; Baserga and Benz, 1992), viral nonsense mRNA 
encoded by avian sarcoma virus (src) (Simpson and Stoltzfus, 1994) and lg µ 
mRNA (Li and Jack, unpublished observations). However, differences in nuclear 
levels of functional and nonsense mRNA can be explained by the presence of 
small contaminants of cytoplasmic mRNA that co-purified with the nuclei during 
the isolation procedure. To address this problem, Belgrader and coworkers 
examined purified nuclei by light and electron microscopy and found that the 
nuclei were free of any detectable cytoplasmic remnants (Belgrader et al., 1994). 
These observations do not, however, address the possibility that cytoplasmic 
nonsense mRNA molecules are attached to the outside of the nuclei and, thus, 
co-purify with nuclei and increase the signal of "nuclear" mRNA. 
There are also observations suggesting that the presence of a nonsense 
codon in a pre-mRNA may also affect its splicing. The presence of a nonsense 
codon in an immunoglobulin kappa light-chain gene results in inefficient nuclear 
pre-mRNA splicing (Lozano et al., 1994). This effect on splicing is thought to 
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lead to the decrease in cytoplasmic levels of completely spliced kappa mRNA. 
Splicing experiments using K nonsense pre-mRNA and lysates from either 
mouse B cells or endothelial cells suggests that inefficient splicing of K nonsense 
pre-mRNA can be reproduced in vitro (Aoufouchi et al., 1996) but only if B cell 
extracts are used. This suggests that the splicing inefficiency caused by the 
nonsense codon can only occur in B cell splicing extracts. Unfortunately, in 
these in vitro experiments controls were done to test for the presence of possible 
translational machinery molecules (ribosomes and other factors) that could 
sterically inhibit the splicing machinery. In addition to the ability of nonsense 
codons to affect splicing efficiency, it has also been found that certain nonsense 
codons can affect exon skipping, cryptic splicing, or intron retention (Naeger et 
al., 1992, Dietz et al., 1993, Dietz and Kendzior, 1994, Lozano et al., 1994). 
Dietz has proposed that nonsense codons could be recognized within nuclear 
pre-mRNA by a nuclear scanner. In this model, introns are "looped-out" by 
splicing factors, which would align the exons as in an mRNA. A nuclear scanner 
could look for nonsense codons within the exons of these pre-mRNA. But the 
idea that a nonsense codon could influence exon skipping, cryptic splicing, or 
intron retention is problematic considering that nonsense codon recognition is 
thought to be recognized by translational machinery (in the cytoplasm). It is 
more likely that the nonsense codons that have these types of effects are 
influencing the splicing process itself by changing splice site 
recognition, even if they are not located near a splicing junction. Until more is 
known about how the splicing machinery works, it is difficult to understand 
exactly how these nonsense codons are affecting the splicing process. 
Models to Explain Nonsense mRNA Reduction 
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To determine how the translational machinery is able to recognize and 
reduce the levels of nonsense mRNA, many experiments have manipulated the 
location of nonsense codons in mRNAs. 
Models to Explain Nonsense mRNA Reduction in Yeast 
Model 1 
It has been suggested that there might be a nonsense codon-recognition 
factor associated with the translational machinery of yeast (Figure 1.4) and after 
a certain percentage of the mRNA has been translated, this factor falls off 
gradually or by encountering a cis-element in the substrate mRNA (Figure 1.5) 
(Peltz et al., 1993). After this nonsense codon-recognition factor is removed 
from the translation machinery, the nonsense mRNA would not be targeted for 
degradation. In support of this hypothesis it has been found that the position of a 
nonsense codon determines whether nonsense mRNA levels are decreased 
when compared to levels of functional mRNA. Levels of nonsense mRNA from 
the yeast genes, URA3 (Losson et al., 1983), URA 1 (Pelsy and Lacroute, 1984), 
PGK1 (Peltz et al., 1993), HIS4 (Hagan et al., 1995), and CYC1 (Yun and 
Figure 1. Models for the recognition and degradation of mRNA containing 
nonsense codons in yeast. 1) Normal translation of a mRNA by ribosomes 
2) A nonsense mRNA that is not protected by ribosomes is a target for 
cytoplasmic nucleases. 3) A nonsense mRNA with a sequence downstream 
of the nonsense codon acts as a target for a nonsense/sequence specific 
decay. 4) Ribosomes containing a nonsense codon recognition factor 
(Small diamonds) recognize a nonsense codon and target it for decay. 5) 
Ribosomes containing the factor loose the factor after a certain distance or 
after contact with a cis mRNA element. This renders the mRNA immune to 
NMRD. Adapted from Peltz et al., (1993). 
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Sherman, 1995), show almost complete decay when the nonsense mutation is in 
the 5' regions of the mRNA and normal levels when the nonsense codon is in the 
3' region of the mRNA. This is called the position effect of nonsense codons on 
mRNA levels. 
Model 2 
Another hypothesis suggests that the presence of elements downstream 
of a nonsense codon triggers rapid mRNA decay (Figure 1.3), possibly by 
providing a site for 40S ribosomal translation reinitiation (Peltz et al., 1993). 
Experiments supporting this hypothesis found that the removal of a specific RNA 
sequence element 3' (an AUG rich region) from an early nonsense codon yeast 
pgk1 mRNA eliminated the rapid decay of the message. The authors' main 
conclusion was that translational reinitiation is involved; first, because three AUG 
codons lie within the downstream element; second, the insertion of a stem-loop 
structure 5' of the downstream element inhibited the rapid mRNA decay; and 
inhibitors of translation that reduce the ability of ribosomes to reinitiate translation 
at downstream start codons also stabilize mRNA with nonsense codons without 
affecting the stability of a wild type transcript (Peltz and Jacobson, 1993). 
Model 3 
Alternatively, recent work with the yeast CYC1 mRNA suggests a different 
model, the translation initiation model (Figure 2) (Yun and Sherman, 1995). This 
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Figure 2. Schematic representation of the translational initiation model to 
explain effects of translation initation and termination changes on mRNA 
stability. The distributaion of 40S and BOS ribosomal subunits on various 
mRNA species are outlined. Adapted from Yun and Sherman (1995). 
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model describes a number of possible effects that cis-mRNA elements (including 
a stability element) have upon the stability of the CYC1 mRNA. First, a CYC1 
mRNA is transported out of the nucleus (Figure 2.A) and a 40S ribosomal 
subunit scans the mRNA and begins translation at the bona fide AUG as a 
complete BOS ribosome (Figure 2.8). When the normal initiator AUG codon is 
changed (mutated), translation does not initiate (Figure 2.C), even when there is 
an AUG codon within the coding region (Figure 2.0). It may be possible that 
translation initiation factors are only associated with the 40S subunit for a brief 
period of time and are not present when a 40S subunit encounters a 
downstream AUG. These mRNAs are stabilized by the 40S subunit that keeps 
scanning down the mRNA and can cover the sensitive region. Premature 
termination can occur at UAA mutations at different locations (Figure 2.E, F, G) 
but the mRNA is only degraded if the UAA lies inside the sensitive region (Figure 
2.E and F), but not when it is outside this region (Figure 2.G). This degradation 
occurs by exposing a sensitive element within the sensitive region. The 
scanning of the 40S subunit can be disrupted by inserting an ATG TAA 
sequence, because of the formation and quick release of BOS ribosomes (Figure 
2.H, I). These nonsense codons also cause degradation of the mRNA, because 
they expose the sensitive element(s). However, no premature termination or 
destabilization occurs when the sequence ATGTAA is inserted outside of the 
initiation region (Figure 2.J), because the scanning 40S subunit can protect the 
message. The authors also suggest that the exposure of the stability element 
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could lead to interactions of elements with the 5' cap or the poly(A)-tail, which 
triggers decapping and degradation. All these models have been formulated 
considering results from experiments with yeast cells. The same types of 
elements and/or observations involving the nonsense mRNA reduction system 
have not yet been found in higher eukaryotic cells. Nevertheless, these results 
indicate that there may be special trans-acting factors and cis-mRNA elements 
involved in the nonsense codon mRNA recognition system in yeast but these 
results do not directly address how the reduction occurs. 
Model 4 
Experiments in yeast have addressed the question of how mRNAs 
containing a nonsense codon are degraded. Using temperature sensitive mRNA 
decay mutants, it has been found that the normal route of decay of wild-type 
yeast mRNAs is 1) shortening of the poly(A)-tail, 2) removal of the 5' cap of the 
mRNA, and 3) 5' to 3' exonuclease degradation (reviewed in Beelman ar.d 
Parker, 1995) (Figure 3.A). Mulhrad and Parker (1994) demonstrated that the 
decay process of yeast mRNA containing a nonsense codon is similar but not 
identical to that of a wild-type mRNA. His lab demonstrated that the pgk1 mRNA 
containing a nonsense codon does not have its poly(A)-tail shortened like a 
normal PGK1 transcript but instead proceeds directly to the decapping step and 
then is degraded by the same 5' to 3' exonuclease that degrades wild type PGK1 
mRNAs (Figure 3.B) (Muhlrad and Parker, 1994). These results indicate that the 
steps in mRNA degradation are not the same for nonsense and functional mRNA 
23 
Figure 3. General mRNA decay pathway in yeast. (A) Pathway depicting what 
is thought to be the common decay pathway of a mRNA in yeast. Breifly, the 
process involves shortening of the poly (A) tail, deadenylation dependent 
decapping and subsquent 5' to 3' exonucleitic decay. (8) Pathway depicting the 
probable pathway for a nonsense codon mRNA in yeast. Breifly, the process 
involves deadenylation independent decapping by the NMRD mechanism and 
subsquent 5' to 3' exonucleitic decay similar to the decay of normal yeast 
mRNAs. Figure adapted from Muhlrad and Parker, (1994). 
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and that the recognition of the nonsense codon may be the key step to activating 
the quick decapping of the mRNA and subsequent degradation by a common 
yeast exonuclease. However, it is not clear how the nonsense codon 
degradation system is able to recognize the nonsense codon and then activate 
the decapping of the mRNA. 
Models to Explain Nonsense mRNA Reduction in Mammalian Cells 
Model 1 
As in yeast, it has been suggested that there might be a position effect of 
a nonsense codon on mammalian mRNA levels. Studies involving the TPI gene 
have shown that the levels of nonsense mRNA containing nonsense codons in 
upstream exons are decreased when compared to levels of functional mRNA but 
as the nonsense codon is relocated towards the 3' exons of the gene the levels 
of nonsense mRNA increase (Cheng et al., 1994). From these results Cheng 
and coworkers (1994) have concluded that there is also a position effect of 
nonsense codons upon mammalian mRNAs. These results also suggest that 
there may be a nonsense codon recgonition factor associated with a translated 
mRNA but this mammalian system is more complex than studies of intron-less 
yeast genes and could involve splice-site changes, possible TPI specific cis-
mRNA elements, and other nuclear and/or cytoplasmic factors outlined in other 
models described below. 
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Model 2 
Studies of a human nonsense 13-globin mRNA in transgenic mice as well 
as a study done on mouse lg µ mRNA have given some clues to the process of 
nonsense mRNA reduction in higher eukaryotic cells. Experiments that have 
looked at the 13-globin mRNA and its mutant form have found that the 5' end of 13-
globin nonsense mRNAs have shorter, capped, 5' ends. Lim and Maquat (1992) 
have suggested that these nonsense mRNAs were attacked by a 5'-3' 
exonuclease and then capped or re-capped to confer immunity to further 
exonucleolytic attack. Although this model remains to be tested, evidence for 
the existence of a 5'-3' exonuclease has been strengthened by recent results 
from the lab of Brawerman. Coutts and Brawerman (1993) have identified a 
mouse sarcoma 5'-3' exonuclease that appears to cleave capped and uncapped 
mRNAs at either the first, second, or third nucleotide. Together, these results 
implicate a 5' to 3' exonuclease in the degradation of nonsense codon mRNAs 
in mammalian cells. 
Li and coworkers studied the length of the poly(A)-tail in nonsense and 
functional µ mRNAs. In experiments using RNase H digestion followed by 
northern blot analysis, they found that functional µ mRNA contains a shorter 
poly(A)-tail than nonsense µ mRNA. This result suggests that the degradation 
pathway of nonsense µ mRNA does not follow normal mRNA decay which is 
thought to be initiated by the shortening of the poly(A)-tail (reviewed in Ross, 
1995). It is possible that the degradation of nonsense µ mRNA follows a 
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pathway similar or identical to that of yeast pgk1 nonsense mRNA, in which the 
nonsense mRNA does not have its poly(A)-tail shortened before quickly 
decapping and degradation by a 5' to 3' exonuclease. Experiments have also 
been performed to determine if other steps in the degradation of higher 
eukaryotic nonsense mRNAs follow a pathway similar to that of yeast. 
Model 3 
To explain how a nonsense codon can trigger the reduction of nuclear 
mRNA, Chasin and coworkers have proposed the nuclear co-translational export 
model shown in Figure 4.2. This model explains how nonsense codons in a 
mRNA can be recognized by the translational machinery in the cytoplasm and 
still result in a nuclear decrease in the nonsense mRNA level (Urlaub et al., 
1989). In this model, ribosomes encounter nascent, not completely spliced RNA 
at the nuclear pore and begin the translation process (Figure 4.1 ). When a 
nonsense codon is encountered, the ribosomes activate the nonsense mRNA 
reduction pathway either at the surface or inside the nucleus (Figure 4.2). This 
could lead to the degradation of the mRNA or prevent further splicing, both of 
which would account for a drastic reduction in cytoplasmic nonsense mRNA 
levels. 
Model 4 
An additional model of nuclear degradation of nonsense mRNA has been 
Figure 4. Models for the recognition and degradation of mRNA containing 
nonsense codons. 1) Export of a normal mRNA using the translational-
translocation model. 2) Degradation of a nonsense mRNA during 
translational-translocation by putative nucleases either outside or inside 
the nucleus. 3) Cytoplasmic degradation of a nonsense mRNA. 4) 
Nuclear scanning model where nonsense codons are recognized in the 
exons of an mRNA which targets the mRNA for degradation. 
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proposed by Chasin and coworkers. In this model, which was termed the 
nuclear scanning model, a hypothesized nuclear scanner identifies a nonsense 
mRNA and targets it for degradation (Urlaub et al., 1989) (Figure 4.4). Because 
the only known complex that can identify codons in a mRNA is tRNA, 
cytoplasmic ribosomes and there associated factors, it is difficult to imagine how 
the scanning occurs in the nucleus without a translation-like process. Recently, 
this scanning model has been redefined to only effect completely spliced mRNA 
(Zhang and Maquat, 1996). Zhang and Maquat have used a site-directed 
mutagenesis approach to generate a nonsense codon. that spans two exons (is 
separated by an intron) in the triosephosphate isomerase (TPI) gene. In other 
words, the nonsense codon is generated by splicing two exons together and is, 
thus, only found in spliced mRNA. Although RT-PCR was used to determine 
differences in nuclear TPI RNA levels, which leads to problems quantitating 
exact differences in RNA levels, the evidence suggests that nuclear nonsense 
mRNA reduction occurs only on the completely spliced TPI mRNA and not on 
the TPI pre-mRNAs (Zhang and Maquat, 1996). These results suggest that if 
nuclear scanning occurs it would only affect completely spliced nonsense 
mRNAs and not nonsense pre-mRNAs. This hypothesis circumvents one of the 
difficulties of the nuclear scanning model which was to explain why pre-mRNAs 
that contain a nonsense codon within an intron are not targeted for nonsense 
mRNA reduction. These results, however, do not prove the existence of nuclear 
nonsense mRNA reduction. Once experiments are designed and carried out to 
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directly test the nuclear co-translational translocation and nuclear scanning 
models, these results may become clearer. 
Genes Involved in Nonsense mRNA Reduction 
Previously, researchers were only able to study the phenomenon of 
nonsense mRNA reduction, but recently through the use of genetic systems, 
researchers working with S. cerevisiae and C. elegans have identified a series of 
genes that are directly involved in the nonsense mRNA reduction process. In S. 
cerevisiae they are named UPF genes (.YQ-frameshift, once thought to be 
frameshifting enhancers) and in C. elegans they are called SMG (~uppressor of 
morphogenesis mutations gene) genes. UPF1, 2, 3 and SMG 2, 3, 5, and 7 
have been cloned. In any of the UPF mutants there is an increased steady state 
level of mRNAs with nonsense codons and unspliced pre-mRNAs that contain a 
nonsense codon within an intron (He et al., 1993). The best characterized of 
these genes, and the only one that will be discussed in detail is the yeast UPF1 
gene. By using genetic and molecular analysis, UPF1 was shown to be required 
in the nonsense mRNA reduction pathway (Peltz et al., 1990, 1993). The levels 
of nonsense mRNA return to that of the corresponding wild-type mRNA, 
indicating that the UPF1 gene is involved in the nonsense mRNA decay process 
but not in general mRNA decay. 
The UPF1 gene encodes a 109-kDa protein (Figure 5). The UPF1 protein 
(Upf1p) contains a number of motifs with interesting properties. The mcst 
Yeast UPF1 gene 1-3546 bp 
"<o' ~ ~ ¢:-0 ~~ 
I -u- urn_____ I 
M 3546 bp if 
Yeast UPF1 polypeptide (109 kDa) 
Zn Fingers 
consensus 
sequences 
Figure 5. Schematic representation of the S. cerevesiae UPF1 gene and gene product. 
· UPF1-D1 and UPF1-D4 are the locations of two missense mutations that lead to the production of a 
dominant-negative UPF1 gene product. 
w 
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thorough sequence analysis of the putative Upf1 p has been performed by 
Altamura and coworkers and is described here in detail (Altamura et al., 1992). 
Within the UPF1 ORF (from the N- to C- direction) there is a highly acidic region, 
a zn+2 finger motif, a NTP binding domain and a type 1 (superfamily 1) RNA 
helicase domain (Leeds et al., 1992; Altamura et al., 1992). It has been 
suggested that the acidic regions of DNA-binding transcriptional factors are 
required for their ability to act as transcriptional activators (reviewed in Struhl, 
1989). Upf1 p also contains conserved cysteine residues found in a number of 
zinc-finger DNA and RNA binding proteins (Burd and Dreyfuss, 1994). It is 
thought that these cysteine residues form structures that allow interaction with 
helices of nucleic acids. It is possible that this motif in Upf1 p could interact with 
ribosomal RNA (either double or single stranded) or with a nonsense mRNA. 
The elongation factor elF-2P also has a zinc-finger motif. When this motif is 
altered, the factor can no longer help the ribosome recognize the translational 
AUG start codon. This suggests that a zinc-finger motif could help recognition of 
a codon. It is therefore possible that the zinc-finger motif present in Upf1 p could 
be directly involved in the recognition of a stop codon. Upf1 p also contains two 
NTPase consensus motifs (Walker et al., 1982) that are the first and second 
motifs (motif I and II) of the RNA helicase region of RNA helicases of the 
superfamily I (Koonin, 1992). Many superfamily I putative RNA helicase genes 
such as SEN1 (DeMarini et al., 1992) and MOV-10 (Mooslehner et al., 1991) all 
contain a NTP binding domain and are thought to have NTP dependent helicase 
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activity. It has been proposed that the RNA helicase domain of Upf1 p could 
facilitate the degradation of a nonsense mRNA by unwinding secondary structure 
downstream of a nonsense codon thereby making the RNA accessible to 
nucleases (Peltz et al., 1993). 
Recently the functions of a number of these motifs have been confirmed 
(Czaplinski et al., 1995). Purified, epitope-tagged Upf1 p can bind to double 
stranded DNA or RNA. Upf1 p can be released from this substrate by the 
addition of ATP and in doing so, it unwinds the dsDNA or dsRNA; presumably by 
using its RNA helicase domain. Leeds and coworkers (1992) have shown that 
certain mutations in the RNA helicase domain of the UPF1 gene confer a 
dominant-negative effect upon cells transformed with the mutant upf1 (Leeds et 
al., 1992). These cells containing the wild-type UPF1 and the RNA helicase 
mutant upf1 act as if they are upf1-null. These data support the hypothesis that 
Upf1 p may be acting as a dimer and that the RNA helicase domain is critical for 
the function of Upf1 p. 
Experiments performed by Czaplinski and Peltz suggest an even more 
complex picture of Upf1 p function (personal communication). An upf1 mutant 
used in this study changed its growth on plates without leucine depending on the 
levels of nonsense Jeu2-1 mRNA (e.g. yeast that have a wild type UPF1 gene 
and a Jeu2-1 nonsense mutation do not grow in the absence of leucine, whereas 
yeast that have a upf1 null allele and a leu2-1 nonsense allele grow in the 
absence of leucine. In other words, the phenotype of a yeast cell with the leu2-1 
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allele and an upf1 mutation changes from Leu- to Leu+ because, in the absence 
of Upf1 p, nonsense leu2-1 mRNA is more stable and translational readthrough 
generates enough functional Leu2p to grow in the absence of leucine). Recent 
unpublished observations by Czaplinski and Peltz using various upf1 yeast 
challenge this conclusion and shed some light on how Upf1 p may be actually 
working. They have created a number of different upf1 mutants in the putative 
zinc-finger and RNA helicase regions of the UPF1 gene and tested the ability of 
the mutated Upf1 p to complement the function of wild-type UPF1 in vivo. Their 
results are shown in Table 2. 
Table 2. --Mutational analysis of UPF1 and its effects on a nonsense mRNA in vivoa 
Mutation 
Group 
A 
B 
c 
D 
Phenotype 
Nonsense leu2-1 mRNA 
levels 
Up 
Down 
Up 
Down 
Leu phenotype 
+ 
+ 
Specific Mutations Made 
in UPF1 
H94-R I H98-R I 
c122-s I C125-S I 
K436 to P, E, D, Q, or A 
C72-S I H11 O-R I 
RR793-KK 
DE572-AA I RR793-AA 
/TR800-AA 
C65-S I C84-S I 
C148-S 
aPhenotype indicates either high (up) or low (down) levels of the leu2-1 mRNA 
containing a nonsense codon while a + indicates growth, or - indicates lack of 
growth on drop-out medium. Specific mutations are indicated by their IUPC 
amino acid code. The wild-type residue and location of changes are indicated 
on the left before the arrow. The arrow(-) indicates the type of change that has 
been made. 
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These results demonstrate that Upf1 p is not only necessary for the decay of 
nonsense mRNAs, (Group A and C), but it may also be involved, either directly 
or indirectly, in modulating the recognition of the nonsense codon (Group A and 
D). 
Recently, UPF2/NMD2, whic.h is called NMD2 (for nonsense-mediated 
mRNA decay gene 2) has been cloned with the yeast two-hybrid system using 
the Upf1 p as "bait" (Cui et al., 1995; He and Jacobson, 1995). The way in which 
Upf2p was found implies that it interacts with Upf1 p. Additionally, dominant-
negative fragments of Upf2p expressed in the cytoplasm of yeast are able to 
interfere with the nonsense mRNA reduction pathway. However, the same 
Upf2p fragment located to the nucleus does not prevent nonsense mRNA 
degradation. This not only indicates that Upf2p interacts with Upf1 p and could 
be a component that recognizes a nonsense codon, but it also shows that the 
yeast nonsense mRNA reduction can occur in the cytoplasm. The identification 
of the yeast UPF3 gene could also help researchers that study nuclear nonsense 
mRNA reduction understand how this may occur. Upf3p contains a bi-partite 
yeast nuclear localization signal and, therefore, is thought to be present in the 
nucleus. The mammalian homologue of this gene (if it exists) would become a 
good candidate for a factor involved in nuclear nonsense mRNA reduction. 
As mentioned above, Parker's studies of yeast genes involved in general 
mRNA decay have indicated that the process involves 1) shortening of the 
poly(A)-tail, 2) decapping of the message and finally 3) 5' to 3' exonuclease 
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activity that degrades the mRNA. His studies of a mRNA containing a nonsense 
codon (pgk1) also found that the decay proceeds directly to the decapping step 
and then follows the normal decay pathway. His lab also studied whether the 
UPF1 gene played a role in the decapping process. In experiments using a 
yeast strain containing an UPF1 mutation, a mutation in the 5' to 3' exonuclease, 
and an mRNA with a nonsense codon, they found that the nonsense mRNA 
contained a shortened poly(A)-tail and eventually was decapped at a rate similar 
to a wild type mRNA. From this observation the authors concluded that UPF1 is 
involved directly or indirectly in the quick decapping of the nonsense mRNA. 
The intracellular location of Upf1 p is consistent with it being involved in 
nonsense codon recognition and/or decay. Upf1 p is predominantly found in the 
cytoplasm and has been shown to be associated with polysomes (Atkin et al., 
1995), and in this way, it could be involved in the recognition of a nonsense 
codon. Yeast lacking Upf1 p also have an increase in pre-mRNAs that contain a 
nonsense codon within an intron (He et al., 1993). Interestingly, not only is the 
pre-mRNA level increased in upf1 mutant yeast, but these pre-mRNAs are also 
associated with ribosomes in the cytoplasm. This indicates that nonsense 
mRNA reduction probably needs the translation process as well as the Upf1 p. 
Similarities of Nonsense mRNA Reduction Between The Yeast and Higher 
Eukaryotic Systems 
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The model systems for nonsense mRNA reduction in yeast and higher 
eukaryotic cells contain a number of similarities. First, translation is required for 
nonsense mRNA reduction. Compounds and RNA structures (cycloheximide 
and stem-loops, respectively), both of which inhibit ribosomal elongation can 
prevent nonsense mRNA reduction. Second, it appears that the poly(A)-tail of 
both yeast and mammalian nonsense mRNA (e.g. pgk1 and mouse µ) is not 
shortened before activation of nonsense mRNA reduction. This suggests that 
after the recognition of a nonsense codon (by a still unknown mechanism), the 
nonsense mRNA in yeast and mammalian cells might be degraded in a similar 
fashion. Third, not all nonsense codons can target an mRNA for nonsense 
mRNA reduction. The position of a nonsense codon within yeast or mammalian 
RNA determines whether a specific mRNA or pre-mRNA is targeted for 
nonsense mRNA reduction. 
Summary 
Significant effort has been put forward to study the effects of a nonsense 
codon on the stability of the afflicted mRNA (or pre-mRNA). Recently, the 
greatest advances have been made in the yeast S. cerevisiae. These systems 
have discovered possible cis-specific nonsense mRNA targeting elements, 
genes specifically involved in the nonsense mRNA reduction system ( UPF/NMD 
genes) and insights into the decay of nonsense mRNA after the nonsense codon 
has been recognized. Research of higher eukaryotic systems is still focused at 
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nonsense mRNA reduction phenomenon such as nuclear v.s. cytoplasmic 
nonsense mRNA reduction, the effects of a nonsense codon on pre-mRNA 
stability and splicing, and the position effect of nonsense codons. Until the 
system itself is identified and studied biochemically, the process of nonsen::;e 
mRNA reduction will remain an enigma. In order to understand the process of 
nonsense mRNA reduction in higher eukaryotic cells work needs to be done to 
identify the higher eukaryotic homologues of yeast nonsense mRNA reducing 
factors. 
The Hypothesis 
Nonsense codons found within mRNA frequently lead to a decreased 
steady state level of nonsense mRNA within an eukaryotic cell. This effect is 
found in simple (S. cerevisiae) and complex eukaryotes (vertebrate). Genes 
required for nonsense codon-mediated mRNA decay have been identified in S. 
cerevisiae and C. elegans through genetic screens. However, no mammalian 
nonsense mRNA reducing protein has yet been identified. Because of the 
general similarities between the nonsense mRNA reduction process in yeast and 
higher eukaryotes, and the observation that a large number of yeast genes are 
conserved in higher eukaryotic organisms (Tugendreich et al., 1994), I propose 
that nonsense mRNA reducing factors similar to those found in the yeast S. 
cerevisiae are present in mammalian cells and control levels of nonsense 
mRNAs. 
CHAPTER Ill 
MATERIALS AND METHODS 
Chemicals and Reagents 
General Chemicals and Reagents 
Ampicillin (Na Salt) and kanamycin from either Sigma Chemical (St. Louis, 
MO) or Boehringer Mannheim (lndianoplis, IN). L-canavanine from Sigma 
Chemicals; AGR501-X8(D) (Mix bead resin), BIS-acrylamide, gelatin, and Tween 
20 from BioRad (Richmond, VA). Yeast extract, Bacto-agar, Yeast extract w/o 
amino acids are from Difeo (Detroit, Ml). Agarose (ultra-pure), Geneticin (G-418 
Sulfate), cesium chloride (ultra-pure), di-thiothreiotol (DTI), LB-media base, 
Penicillin-Streptomycin (500 U/ml), L-Glutamine (200 mM), Glycerol (ultra pure), 
and RPMI 1640 powder from Gibco-BRL Life Technologies, Inc. (Gaithersburg, 
MD); dextran sulfate from Pharmacia (Uppsala, Sweden); fetal calf serum (FCS) 
from HyClone (Logan, UT); universal autoradiography enhancer chemicals (Part 
A and B) from DuPont NEN (Boston, MA); Triton X-100 from Serva (Heidelberg, 
Germany); ethyl alcohol (EtOH, 200 proof) from 
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paper Co. (Shelbyville, KY); Non-fat dehydrated milk from Carnation Food 
Products, Nestle Food Co. (Glendale, CA); scintillation liquid (Econo-Safe) from 
RPI (Mount Prospect, IL). All solutions were prepared in deionized water (dH20) 
filtered by a Millipore Milli-Q water filtering system (Bedford, MA). 
Radiochemicals 
[a-32P] dCTP (Cat# PB10205) 
Redivue [a-32P] dCTP (Cat# AA0005) 
[a-35S] dATP (Cat# SJ1304) 
Trans 35S-label (Cat# 51006) 
[y-32P] dATP (Cat# 35020) 
Amersham, Arlington Heights, IL 
Amersham, Arlington Heights, IL 
Amersham, Arlington Heights, IL 
ICN Biomedicals, Irvine, CA 
ICN Biomedicals, Irvine, CA 
DNA 5'-end labeling kit (Cat#702757) Boehringer Mannheim, 
Indianapolis, IN 
Enhanced Chemiluminescnce Kit Boehringer Mannheim, 
(Cat#1500694) Indianapolis, IN 
1-ethyl-3-(3-dimethylaminopropyl) Pierce Co., Rockford, IL 
carbodiimide/Diaminodipropylamine 
Immobilization kit (Cat#44899) 
Antigen Conjugation kit (Cat#77107) 
Nick-translation kit (Cat#18160-010) 
Pierce Co., Rockford, IL 
Gibco BRL, Gaithersburg, MD 
pGEM-T vector system I (Cat#A3600) Promega, Madison, WI 
Sequenase kit (2.0) (Cat#US70770) United States Biochemical, 
Cleveland, OH 
TNT in vitro translation kit (Cat#L4610) Promega, Madison, WI 
Wizard mini-prep kit (Cat#A7100) Promega, Madison, WI 
Qiagen plasmid isolation DNA 
kits (Cat#12143) 
Qiagen total RNA kit (Cat#74104) 
Antibodies 
Qiagen, Chatsworth, CA 
Qiagen, Chatsworth, CA 
Antibodies Used for lmmunofluroescence Analysis 
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Rabbit anti-VH81X 
FITC-labled goat anti-mouse µ 
(Cat#1021-01) 
Hartwell and Jack, unpublished; 
Loyola University, Maywood, IL 
Fisher Biotech, Pittsburgh, PA 
FITC-labled goat anti-rabbit lgG 
(Cat#9817SA) 
Gibco-BRL, Gaithersburg, MD 
Antibodies Used for Western Blot Analysis 
Rabbit anti-UPF1 peptide antiserum 
Horseradish peroxidase conjugated 
(HRP) affinity-purified goat anti-
rabbit lgG (Cat#170-6515) 
Affinity-purified goat anti-
MOPC 104E (mouseµ) 
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Allan Jacobson, University of 
Massachusetts Medical School, 
Worcester, MA 
BioRad, Irvine, CA 
Bornemann et al., 1995 
HRP conjugated rabbit anti-Goat lgG Fisher Biotech, Pittsburgh, PA 
Affinity purified rabbit anti-NORF1/pep1 This work 
Affinity purified rabbit anti-NORF1/pep2 This work 
Molecular Weight Standards 
1 Kb DNA ladder 
'A DNA!Hindlll fragments 
Rainbow protein marker 
Bacteriophage <t>X 17 4 DNA 
Gibco BRL, Gaithersburg, MD 
Gibco BRL, Gaithersburg, MD 
Amersham, Buckinghamshire, 
England 
Gibco BRL, Gaithersburg, MD 
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Enzymes 
Restriction endonucleases were obtained form Boehringer Mannheim 
Biochemicals (Indianapolis, IN), Gibco BRL Life Technologies, Inc. 
(Gaithersburg, MD) and New England BioLabs, Inc. (Beverly, MA); AmpliTaq 
DNA polymerase from Perkin Elmer Cetus (Norwalk, CT) and Taq polymerase 
and Superscript reverse transcriptase from Gibco-BRL Life Technologies, Inc. T4 
DNA ligase and Kienow fragment from either Pharmacia (Piscataway, NJ) or 
Promega (Madison, WI); RNasin and DNase I, from Promega (Madison, WI); 
RNase H from Pharmacia (Piscataway, NJ); RNase A (bovine pancreas) and 
lysozyme (chicken egg white) from Sigma Chemical Company (St. Louis, MO); 
DNA Sequenase (polymerase) version 2.0 from United States Biochemical 
(USS, Cleveland, OH); and Proteinase K from Boehringer Mannheim 
(Indianapolis, IN). 
Oligonucleotides 
Standard oligonucleotides were purchased from Promega Corp. and 
United States Biochemical or were synthesized by Bio-Synthesis (Lewisville, TX), 
Chander Raman, Gene Napolitano (Terrapin Technologies, South San 
Francisco, CA), or by the Macromolecular Core Facility at Loyola University 
(Maywood, IL). 
LAC primer: 17 mer 5'-TGTGGAATTGTGAGCGG-3' 
(Elledge et al., 1991 ), From Bio-Synthesis 
GAL primer: 17 mer 5' -ACTTI AACGTCAAGGAG-3' 
(Elledge et al., 1991), From Bio-Synthesis 
GAL-UP.Fow: 18 mer; 5'-TTCGGTTIGTATTACTTC-3' 
From Bio-Synthesis 
SP6 primer: 19 mer; 5'-GATTIAGGTGACACTATAG-3' 
From Promega 
T7 primer: 20 mer; 5'-TAATACGACTCACTATAGGG-3' 
From Promega 
M13 primer (-40, forward): 17 mer; 5'-GTTTTCCCAGTCACGAC-3' 
From USB 
M13 primer, backwards: 16 mer; 5'-TTCACACAGGAAACAG-3' 
From USB 
TRAPa primer#1: 14 mer; 5'-CACTAATTCCCATA-3' 
From Loyola Core Facility 
TRAPa primer #3: 14 mer; 5'-CTGTTIGATTGAAG-3' 
From Bio-Synthesis 
TRAPa primer #4: 16 mer; 5' -CTCCCCCGCTTGCTTC-3' 
From Bio-Synthesis 
TRAPa primer#5: 15 mer; 5'-GTTAAGTCCCAAGCTG-3' 
From Gene Napolitano 
TRAPa primer #6: 13 mer; 5' -GCAAGATGAAGATG-3' 
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From Gene Napolitano 
1RGF.hyb primer: 19 mer; 5'-CCTCAGGTTCTATTATGTC-3' 
From Loyola Core Facility 
2RGF.hyb primer: 16 mer; 5'-GGCATGTTTTCAGTGC-3' 
From Loyola Core Facility 
UPF1-01 .Forward primer: 15 mer; 5'-GGAAAACAGAAGCAG-3' 
From Bio-Synthesis 
UPF1-01 .Backward primer: 15 mer; 5'-CGGGTTAGACCCACG-3' 
From Bio-Synthesis 
2.0H35hom.forward primer: 26 mer; 
5'-GATGTTGACATGTGTTGGTGCTGGTG-3' 
From Loyola Core Facility 
2.0H35hom.backward primer: 26 mer; 
5'-CACCAGCACCAACACATGTCAACATC-3' 
From Loyola Core Facility 
SAM#3.Fow: 20 mer; 5'-GCTGATCCTTGTAGGCGACC-3' 
From Loyola Core Facility 
SAM#4.Bak: 20 mer; 5'-GGTCGCCTACAAGGATCAGC-3' 
From Loyola Core Facility 
SAM#5.Bak: 18 mer; 5'-CCTGGGACAGCTCCGGCT-3' 
From Loyola Core Facility 
SAM#6.Fow; 18 mer; 5'-GGACAGCTCGACGCGCAG-3' 
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From Loyola Core Facility 
SAM#7.bak: 18 mer; 5'-CTGCGCGTCGAGCTGTCC-3' 
From Bio-Synthesis 
SAM#8.bak: 20 mer; 5'-GCGTCTGCGTCTGGCTAGGA-3' 
From Bio-Synthesis 
SAM#9.bak: 19 mer; 5'-CAAGCAGCTCGGCCTCCTC-3' 
From Bio-Synthesis 
SAM#10.Fow: 17 mer; 5'-GCGGGCCAACGAGCACC-3' 
From Bio-Synthesis 
SAM#11. Fow: 19 mer; 5'-TCGGAGCACACACCAGCAC-3' 
From Bio-Synthesis 
SAM#12.Bak: 18 mer; 5'-CGACGAAAGCACCCAGGC-3' 
From Bio-Synthesis 
SAM#13.Fow: 16 mer; 5'-ACGCCAGAAGAACCGC-3' 
From Bio-Synthesis 
LAC2: 20 mer; 5'-TGAGAGAAGGGCTGTGACGC-3' 
From Chander Raman 
SAM3-2: 20 mer; 5'-GCATCATCACGCCCTACGAG-3' 
From Chander Raman 
SAM4-2: 20 mer; 5'-ATCAGGCTCAGTGGTCTTTG-3' 
From Chander Raman 
GALP3: 20 mer; 5'-CCCTGATAACTATGGCGATG-3' 
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From Chander Raman 
GALP3.rev: 20 mer; 5'-TACTGGTAGGCGTCCTCGTA-3' 
From Chander Raman 
SAM3.rev: 20 mer; 5'-GAAGATGTTGGATGGGAAGG-3' 
From Chander Raman 
SAM4.rev: 18 mer; 5'-CGAGGCTGGCCAAGATGC-3' 
From Chander Raman 
Gal-UP.Forward: 18 mer; 5'-TTCGGTTTGTATTACTTC-3' 
From Loyola Core Facility 
A.GT1 OGENE.F: forward primer: 27 mer; 
5'-CTTTTGAGCAAGTTCAGCCTGGTT AAG-3' 
From Gene Napolitano 
A.GT10GENE.B: backward primer: 24 mer; 
5'-GGCTTATGAGTA TTTCTTCCAGGG-3' 
From Gene Napolitano 
UPF1-5'-EcoRI primer: 29 mer; 
5'-CGAA TTCGAAA TGGTCGGTTCCGGTTCTC-3' 
From Bio-Synthesis 
UPF1-3'- BsaBI primer: 30 mer; 
5'-ATTGATCAGTATCCCAGTTCGCAI 111 ICG-3' 
From Bio-Synthesis 
SAM#3.Fow: 20 mer; 5'-GCTGATCCTTGTAGGCGACC-3' 
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From Loyola Core Facility 
SAM#4. Bak: 20 mer; 5' -GGTCGCCTACAAGGATCAGC-3' 
From Loyola Core Facility 
SAM#5.Bak: 18 mer; 5'-CCTGGGACAGCTCCGGCT-3' 
From Loyola Core Facility 
SAM#6.Fow; 18 mer; 5'-GGACAGCTCGACGCGCAG-3' 
From Loyola Core Facility 
Peptides 
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Peptides used in this study are of two forms. First, multiple antigenic 
peptide (MAPS) (Ponsette et al., 1988), or COCH-terminal branched peptides, 
were synthesized by Ingrid Haas (University of Heidelberg, Germany). Second, 
linear, non-branched peptides synthesized by Bassam Wakim (Loyola University 
Macromolecular Core Facility). 
UPF1#1; 16 mer; (GenBank #M76659:Codons 950 to 965) 
NH3-ARELQREEQKHELSKD - Poly-K 
UPF1#2; 16 mer; (GenBank #M76659:Codons 920 to 935) 
NH3-KSAFSQKQNRNEIDDR - Poly-K 
UPF1#3; 14 mer; (GenBank #M76659:Codons 635 to 648) 
NH3-EVQYRMNPYLSEFP - Poly-K 
NORF1-pep#1 (Lab name: SAM-PEP#1 ); 18 mer; (Codons 106 to 122) 
NHTEEDEEDTYYTKDLPIHAC-COOH 
NORF1-pep#2 (Lab name: SAM-PEP#2); 24 mer; (Codons 214 to 237) 
NH3-ASQSSLKDINWDSSQWQPLIQDRC-COOH 
Plasmids and DNA Probes 
Cloning Vectors and Plasmids 
50. 
Plasmid clones are indicated by name and by file number in the Chicago 
books in the laboratory of Dr. Hans-Martin Jack. 
pSP73 (plasmid clone: Chicago # 499) Promega, Madison, WI 
pUPF1 (plasmid clone: Chicago# 443) Dr. M. Culbertson (Leeds et al., 
1993) 
pUPF1-D1 (plasmid clone: 
Chicago # 490) 
pUPF1-D4 (plasmid clone: 
Chicago# 491) 
pH~-Apr-1-neo (plasmid clone: 
Chicago # 412) 
p73-UPF1~0.8 (plasmid clone: 
Chicago # 497) 
p73-UPF1/-5'3' (plasmid clone: 
Dr. M. Culbertson (Leeds et al., 
1993) 
Dr. M. Culbertson (Leeds et al., 
1993) 
From Ron Corley (Gunning et al., 
1987) 
This work 
This work 
Chicago# 561) 
pUPF1-5' end (plasmid clone: 
Chicago # 562) 
pUPF1/p-actin (plasmid clone: 
Chicago# 564) 
pUPF1-D1/p-actin (plasmid clone: 
Chicago # 609) 
pR-TRAPa (p5.1.1.X and p7.1.1.X) 
(plasmid clone: Chicago # 533 and 533) 
p2.0-Hindlll (plasmid clone: 
Chicago # 505) 
p6.4-EcoRI (plasmid clone: 
Chicago # 525) 
pNORF1 (p11.2 gene, 3.6-kb) 
(plasmid clone: Chicago # 579) 
pNORF1 (p15.1.1.1. gene, 5.5-kb) 
(plasmid clone: Chicago# 610) 
pR 13609 (plasmid clone: 
Chicago # 592) 
pH11830 (plasmid clone: 
Chicago # 593) 
pH11167 (plasmid clone: 
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This work 
This work 
This work 
This work 
This work 
This work 
This work 
This work 
Human EST sequencing project 
Boguski et al., 1993 
Human EST sequencing project 
Boguski et al., 1993 
Human EST sequencing project 
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Chicago# 594) Boguski et al., 1993 
pH15581 (plasmid clone: Human EST sequencing project 
Chicago# 595) Boguski et al., 1993 
pNORF1/7Z (pGem7Z+3.5kb NORF1) This work 
(plasmid clone: Chicago #599) 
p~-NORF1 antisense 
(plasmid clone: Chicago# 611) 
p~-NORF1 sense 
(plasmid clone: Chicago # 612) 
DNA Probes 
rabbit GAPDH (plasmid clone: 
Chicago # 265) 
yeast UPF1 
yeast UPF1 RNA helicase region 
yeast UPF1 5'-end region 
yeast CAN1 
mouse µ cDNA (plasmid clone: 
Chicago# 254) 
This work 
This work 
1.2-kb Hindlll fragment from pR-
GAPDH (Applequist et al., 1995) 
3.2-kb EcoRl/Xbal fragment from 
pUPF1 (a gift from M.Culbertson) 
1.3-kb Oral fragment from pUPF1 
1.4-kb EcoRl/Kpnl fragment from 
pUPF1 
1.3-kb Hindlll fragment from 
pTLC-1 (Broach et al., 1987) 
1.4-kb Apal/Smal 
human cDNA fragment R 13609 
human cDNA fragment H11830 
1.6-kb Hindlll/EcoRI or 
Hindlll!Notl fragment 
1.4-kb Hindlll/EcoRI or 
Hindlll!Notl fragment 
human cDNA fragment H 11167 1. 7-kb Hindll l/Notl fragment 
human cDNA fragment 11.2 3.5-kb Xhol fragment from 
p11.2.2 and p11.2.1 
human cDNA fragment 5' end of 1.3-kb Xhol/Sa/I fragment from 
NORF1 pNORF1/7Z 
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human cDNA fragment 3' end of 11.2 600-bp BstXl/Xhol fragment from 
NORF1 pNORF1/7Z 
Analysis of RNA 
Isolation of RNA from Mammalian Cells 
Solutions and Reagents 
guanidium isothiocyanate (GIT) 
homogenization buffer 
Mix 94.53 g guanidine 
isothiocyanate (4 M final), 1.67 
ml 3 M Na-acetate, (pH 6.0); and 
add dH20 to 200 ml. Add 8.35 
µI/ml ~-ME before each use. 
cesium chloride buffer 
DEPC-TE 
Total RNA Isolation 
o4 
Mix 95.97 g CsCI (5.7 M); 0.83 ml 
3 M Na-acetate, (pH 6.0); add 
dH20 to 100 ml, and sterile filter. 
Prepare TE using stock Tris-HCI, 
(pH 7.4); and 0.5 M EDTA using 
0.1% DEPC-dH20. 
Total RNA was isolated from cultured cells by either the GIT/cesium 
chloride method or by the Qiagen RNA preparation method (both described 
below). 
Guanidinium Thiocyanate/Cesium Chloride Method 
Total RNA was prepared from cultured cells with GIT followed by 
centrifugation through a cesium chloride (CsCI) solution (Chirgwin et al., 1979). 
Briefly, 1-2 X 107 cells were removed and washed with ice-cold sterile phosphate 
buffered saline solution (Dulbecco's PBS, Cat#21-031-LV, Gibco-BRL). The 
cells were transferred in 1 ml of PBS to a 15 ml-Falcon tube pelleted, decanted, 
and resuspended in residual liquid by tapping the tube vigorously. Cells were 
then resuspended in 2 ml of GIT homogenization buffer. The resulting cell 
homogenate was layered on 2 ml of CsCI solution in a clear 13 X 51 mm thin 
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wall/polymer open top ultracentrifuge tube (Nalgene UltraTubes, Nalge, 
Rochester, NY). The tubes were balanced with GIT homogenization buffer and 
centrifuged with 35,000 rpm for 18-20 hr at 20°C in a Beckman SW50.1 rotor and 
Beckman Preparative Ultracentrifuge (Model L8-70, Beckman, Palo Alto, CA). 
After centrifugation the supernatant was aspirated until the CsCI layer was 
reached. CsCI was removed by gentle pipetting. The bottom of the tube was cut 
off with a razor blade, and the clear RNA pellet (3-5 mm in diameter) was 
resuspended in 3 X 100 µI of ice-cold DEPC-TE and transferred to an 
autoclaved, chilled, 1.5 ml microcentrifuge tube. The RNA was precipitated 
overnight at -20°C after the addition of 1/10 volume of 3 M NaAc, (pH 5.2); and 
2.5 volume of ice-cold EtOH. The RNA was collected by centrifugation at full 
speed at 4°C for 2 hrs, washing with 70% EtOH, air-drying, and resuspended in 
DEPC-TE at concentration of 1-5 µg/µI. 
Qiagen Method 
The method was performed exactly as described by the manufacturer. All 
cell culture samples were disrupted by passing the GIT/cell resuspension 
repeatedly through a 20G1 115 gauge needle until foamy. The mixture was then 
processed as described in the RNeasy kit handbook. 
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Cytoplasmic RNA Isolation 
Cytoplasmic RNA was isolated by the Nonidet-P40/phenol method 
(modified from Favaloro et al., 1980). Briefly, 5 X106 cells were pelleted, washed 
once with ice-cold Oulbecco's PBS, transferred to a microcentrifuge tube and 
lysed for 30 minutes on ice in 200 µI of cold lysis buffer (from 5 Prime-3 Prime, 
Inc., Boulder, CO; 0.14 M NaCl, 1.5 mM MgCl2 , 0.5% Nonidet-p40, 10 mM Tris, 
(pH 8.6)) supplemented with 0.05 U/ml RNasin (Promega, Madison, WI). The 
nuclei and unlysed cells were removed by centrifugation at full speed in a 
microcentrifuge at 4°C for 30 seconds. 175 µI of the supernatant was transferred 
to a new microcentrifuge tube. RNA was then extracted twice with 300 µI of 
phenol/chisam (1+1) heated to 65°C and once with chisam at room temperature. 
RNA was precipitated with 1/10 volume NaAc and 2.5 volume ice-cold EtOH. 
The RNA was collected as described above and resuspended in 25 µI of OEPC-
TE. 
RNA Isolation from Yeast Cells 
Total RNA was isolated from yeast by the method of Elion and Warner, 
(1984). Briefly, 10 ml overnight cultures of yeast cells with an 00600 of 1-1.5 
were pelleted, washed with ice-cold dH20, pelleted again, and decanted. The 
pellet was resuspended in 200 µI of LET-1% SOS (10 mM Tris-HCI, (pH 7.4); 0.1 
M EOTA, 0.1 M LiCI, 1.0% SOS) and frozen at-70°C overnight. The yeast were 
thawed on ice, transferred to a cold micro-centrifuge tube, mixed with 120 µI of 
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autoclaved glass beads, and vortexed for 30 sec. 25 µI of phenol/chloroform 
(1+1) are added and vortexed again 4 X 30 seconds with the sample on ice 
between vortexings. 480 µI of LET-0.2% SOS (same as above only to a final 
concentration of 0.2% SOS) is added to the sample and mixed. The lysate is 
removed and extracted twice with 400 µI of TE equilibrated phenol, (pH 7.0); 
warmed to 65°C. Place the samples on ice for 5 minutes between each 
extraction. The aqueous phase is removed from the final extraction, precipitated 
at -70oC the addition of 1/10 volume of 3 M LiCI and 2.5 volume of EtOH. The 
precipitated RNA is collected by centrifugation at full speed for 1 hr at 4°C and 
the RNA is dissolved in 50 µI of DEPC-TE. The quantitation is performed as in 
section 2.14. 
Quantitation of RNA 
The concentration of RNA was determined by measuring the optical 
density (OD) at 260nm using the following equation: 
µg I µI RNA = 00260 X 40 X dilution factor. 
The purity of RNA was determined by comparing the ratio of the 
absorbance of RNA at 260nm to that at 280nm. Samples in the range of 1.8 to 
2.0 are considered relatively pure from protein contamination. 
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Northern Blot Analysis 
Solutions 
10 X MOPS 
5 X RNA loading buffer 
Gel overlay buffer 
Deionized formamide (dFA) 
Mix 41.9 g MOPS (sodium base), 
3.72 g sodium EDTA, 4.1 g 
sodium acetate, add 0.1 % 
DEPC-dH20 to 1 Land pH to 7.0 
with glacial acetic acid. 
12.5% Ficoll (Sigma) 
0.4% bromophenol blue 
1 X MOPS 
DEPC-dH20 to final 
percentages 
Mix 50 ml of 10 X MOPS, 89.3 ml 
formaldehyde (37% from Sigma), 
and add DEPC-dH20 to 500 ml. 
Formamide (Boehringer 
Mannheim) was deionized with 
5g per 100 ml AG 501-X8(0) 
mixed bead resins (Bio-Rad) by 
1 M sodium phosphate buffer 
(NaP, (pH 7.0)) 
Prehybridization solution 
Hybridization solution 
59 
stirring slowly at room 
temperature for 1 hour, filtered 
through a coarse Whatman filter 
disk and stored at -20°C in 
aliquots. 
200 ml 1 M NaH2P04 
600-700 ml 1 M Na2HP04 
to 1 L with dH20, (pH 7.0). 
Mix 2 ml dH20, 200 µ110% SOS, 
10 ml dFA, 5 ml 20 X SSC, 
2 ml 50 X Denhart's solution, 1 
ml 1 M sodium phosphate buffer, 
(pH 7.0); 0.25 mg/ml denatured 
sheared salmon sperm DNA 
(from 10 mg/ml stock solution). 
Mix 150 µ110% SOS, 7.5 ml dFA 
(50%), 3.75 ml 20 X SSC, 300 µI 
50 X Denhart's solution, 300 µI 1 
M sodium phosphate buffer, (pH 
Agarose Gel Solution 
Procedure 
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7.0); 3 ml 50% dextran sulphate, 
0.3 mg/ml denatured sheared 
salmon sperm DNA (from 10 
mg/ml stock solution). 
Mix 2.4 g agarose with 144.3 ml 
DEPC-dH20. Microwave the 
solution until the agarose is 
completely melted. Add 35.7 ml 
formaldehyde (37%), 20 ml 10 X 
MOPS, mix and pour. 
This procedure is that as described by Jack and Wabl (1988) and the 
hybridizations were performed as described by Meinkoth and Wahl (1984). 
Electrophoresis 
The appropriate amount of RNA (1-10 µg) was mixed with 10 µI of 
deionized formamide (dFA}, 3.5 µI of 37% formaldehyde, 2 µI of 10 X MOPS 
buffer, 2 µI of EtBr (1mg/ml), and filled with DEPC-dH20 to a final volume of 30 
µI. The mixture was heated to 65°C for 5 minutes and chilled on ice. 3 µI of 5 X 
RNA loading buffer was added to each sample and loaded into sample wells of a 
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formaldehyde agarose electrophoresis gel poured in a horizontal gel 
electrophoresis chamber (Model H3, BRL) submerged in overlay buffer. The left 
and right chambers were filled with 1 X MOPS buffer and electrophorised under 
constant voltage of about 40 V for overnight (-16 hours) until the bromophenol 
blue has migrated to the bottom of the gel. 
Transfer of RNA 
The RNA gel was photographed using an ultraviolet light transiluminator 
and a Polaroid camera, rinsed with dH20 and 1 O X SSC. Capillary transfer to a 
nitrocellulose membrane was performed overnight (BA85, 0.45 µm, Schleicher 
and Schuell, Inc., Keene, NH) in 10 X SSC (Figure 6). Standards as well as 18S 
and 28/26S RNA was labeled using a pencil. Filters were dried under a heat 
lamp for 20 minutes, baked under high vacuum at 80°C for 2 hrs. 
Hybridization 
Filters were prehybridized and hybridized with either an Omniblot system 
(ABN) or Hybaid brand hybridization oven according to the manufactures 
instructions. The prehybridization was performed in the prehybridization mix for 
over 1 hour at 42°C. The prehybridization was replace with the hybridization mix 
containing approximately 3 X 107 cpm of denatured 32P-labled probe and 500 µg 
of denatured sheared salmon sperm DNA. Hybridization was carried out for 12-
48 hrs at 42°C. After hybridization, the filters were washed once with 2 X SSC at 
Paper 
Towels--
250 g 
Weight 
Hybridization 
Membrane 
Gel 
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Glass Suspension 
Plate Capillary Wick 
Figure. 6 Schematic diagram of a nucleic acid capillary transfer 
apparatus. 
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room temperature to remove free radioactive probe and then several times with 
0.1 X SSC/0.1 % SOS for 20-30 minutes at 52-54°C. The membrane was 
washed until the background detected by a Geiger counter was considered low. 
The washed blots were wrapped in plastic wrap and radioactivity on the blot was 
determined with a Betagen Radioanalytic Imaging System (Betascope 603 Blot 
Analyzer, Betagen Corp., Mountain View, CA). The blots were then wrapped in 
plastic wrap and exposed to X-ray film (Kodak X-OMAT AR film, Eastman Kodak 
Company, Rochester, NY) flanked by one intensifying screen (Fisher Biotech, 
Pittsburgh, PA) for varying times at -70°C before processing by a X-ray film 
processor (Model QX-60A, Konica, Tokyo, Japan). 
The sizes of a RNA band was determined by measuring the distance 
between the loading well and the band and comparing it to that of known RNA 
molecular weight standards. The RNA size standard used was the RNA ladder 
and ribosomal RNAs. 
To control for RNA loading on each lane, northern blots were re-
hybridized with a 1.3-kb BamHl/EcoRI fragment of rabbit GAPDH (Applequist et 
al., 1995). 
RNase H Treatment of Total RNA 
RNase H treatment of total RNA was used to identify regions where 
RNA/DNA hybrids were formed. The procedure was performed as adapted from 
and described by Qian et al., 1993. 
Solutions 
10 X RNase H buffer 
RNase H mix 
Procedure 
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0.2 M HEPES, (pH 8.0); 
0.5 M KCI; 0.1 M MgCl2 
Mix 2.5 µI of 10 X RNase H 
buffer, 2.5 µI of 10 mM DTI, 1.2 
µI of RNase H (1 U/µI), and 8.8 µI 
of DEPC-dH20. 
Briefly, 10 µg of total RNA in 5 µI of dH20 or TE was mixed with the 
following; 2 µI of oligo-(dT) primer (0.5 µg/µI; Promega, Madison, WI) or with 0.2 
µg of a DNA oligonucleotide. This mixture was incubated for 30 minutes at 45°C. 
15 µI of the RNase H mix was added, incubated for 20 minutes at 37°C. The 
mixture was extracted once with chisam, and the RNA was precipitated at -20°C 
with 1/10 volume 3 M NaAc, (pH 5.2); and 2.5 volume of ice-cold EtOH. The 
RNA was collected by centrifugation for 1 hr at maximum speed at 4°C, and 
subjected to northern blot analysis as described in section Northern Blot 
Analysis. 
20 X SSC 
50 X Denhart's solution 
0.5 M EDTA 
2 M Tris-HCI, (pH 7.4) 
3 M Sodium acetate 
65· 
DNA Manipulations 
General Solutions 
Mix 525.9 g NaCl, 264.7 g Citric 
Acid, and add 3 L dH20. 
Mix 1 g polyvinylpyrrolidone, 1 g 
of BSA, 1 g of Ficol (DL-400), 
and add 100 ml of d H20. Store 
Whatman filtered aliquots at 
-20°C. 
Mix 186.1 gin 800 ml dH20, add 
NaOH (1 ON) until clear. Fill to 
1000 ml with dH20. 
Mix 12.114 g of Trisma-Base with 
90 ml of dH20. pH to 7.4 with 12 
M HCI. Fill to 100 ml with dH20. 
Mix 24.6 g of NaAc in 90 ml H20 
and pH to 5.2 by using glacial 
TE buffer 
acetic acid. Fill to 100 ml with 
dH20. 
Mix 5 ml of 1 M Tris-HCI, (pH 
8.0); 1 ml of 0.5 M EDTA, and 
add 500 ml of dH20. 
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Salmon Sperm DNA: Resuspend 1 g of salmon sperm DNA in 90 ml of 
dH20 and gently stir overnight. Sonicate the DNA solution on ice in 15 minute 
intervals. Test the average length of the DNA using TAE/agarose gel 
electrophoresis. Repeat the sonications until the average fragment length is 
between 1-3-kb and add SOS to 0.5% and proteinase K until 100 µg/ml. 
Incubate overnight at 42°C and then extract the DNA with TE equilibrated 
phenol, phenol:chisam (1 +1 ), and then with chisam until the interphase is clear. 
Collect the aqueous phase and precipitate the DNA with 1/10 volume of 3 M 
NaAc and 2.5 volumes of EtOH. Collect the precipitate by centrifugation, wash 
with 70% EtOH, and resuspend in 90 ml of dH20. Quantitate the DNA and dilute 
to obtain a stock concentration of 10 µg/µI, aliquot and freeze at -20°C. 
TE-saturated phenol/chisam: Melt phenol in 65°C waterbath. Add 8-
Hydroxy Qunoline (Sigma Cat #H-6878) to a final concentration of 1 mg/ml 
phenol. Extract the phenol once with equal volumes of 1 M Tris-HCI, (pH 8.0); 
and 3 to 5 times until the pH of the TE phase reaches 7-8. Mix 1 part TE-
equilibrated phenol with 1 part of chisam (chloroform/isoamyl alcohol at 25:1) 
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Amplification of Plasmid DNA 
Plasmid DNA Preparations 
Large preparations of plasmid DNA used for cloning, transfection and 
transformation were performed by the alkaline lysis as described by Sambrook 
and colleagues (1989) and also with a large scale plasmid kit from Qiagen as 
described by the Qiagen plasmid preparations manual (Qiagen Plasmid maxi kit, 
Cat#12162, Qiagen, Chatsworth, CA). Rapid, small scale plasmid preparations 
were performed as described by the Promega Magic minipreps kit (Cat#A7100, 
Promega, Madison, WI) according to the manufacturers instructions included 
with the kit. 
Solutions and Media 
LB-antibiotic media 
Lysis buffer 
2.5% LB 
5 mM Glucose 
100 µg/ml ampicillin, 15 µg/ml 
tetracycline, or 70 µg/ml 
kanamycin 
1% glucose 
10 mM EDTA, (pH 8.0) 
25 mM Tris-HCI, (pH 8.0) 
Lysozyme solution 
Alkali solution (prepare fresh) 
Potassium acetate, (pH 4.8) 
Proteinase K buffer 
Proteinase K stock 
RNase A buffer 
RNase A stock 
30 mg/ml of lysozyme in lysis 
buffer 
1% sos 
0.2% N NaOH 
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Mix 60 ml of 5 M KAc, 11.5 ml 
glacial acetic acid, and add 28.5 
ml dH20. 
50 mM Tris-HCI, (pH 8.0) 
10 mM CaCl2 (store -20°C) 
10 mg/ml of lyophilized 
proteinase K in proteinase K 
buffer (store -20°C) 
10 mM Tris-HCI, (pH 7.5) 
15 mM NaCl (store at -20°C) 
10 mg/ml of lyophilized RNase A 
in RNase A buffer (store -20°C) 
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Bacterial Strains 
Escherichia coli (E. colt) strains HB101, JM109, or DH5a are from the lab 
stocks of the lab of Dr. Jack. JM110 was obtained from New England BioLabs. 
All bacteria were made competent using a rubidium chloride/calcium chloride 
procedure (Sambrook et al., 1989). All bacteria containing plasmids were grown 
in either liquid culture or on agar plates in the presence of the appropriate 
antibiotic. In order to select for the presence of the DNA fragment disruption of 
the E. coli (3-galactosidase a-peptide gene present on some plasmids, they were 
propagated in JM109 or DH5a were grown on Luria Broth (LB) agar plates (1.5% 
Bacto-agar in LB-media, (pH 7.0)) supplemented with 100 µg/ml ampicillin, 40 
µg/ml X-Gal, and 5 mM IPTG. 
Small Scale Preparation of Plasmid DNA (Miniprep) 
A fresh, single colony was inoculated into 5 ml of LB-media+glucose 
containing the appropriate antibiotic. The cultures were shaken vigorously 
overnight at 37°C. 1.5-3 ml of the cultures were pelleted by centrifugation and 
the plasmids were isolated from the bacteria pellet with Magic mini prep kit 
(Promega, Madison, WI) according to the manufacturer's instructions. 
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Large Scale Preparation of Plasmid DNA 
Alkaline Lysis Method 
2.5 ml of an overnight culture was inoculated into 250 ml of LB-media 
+glucose medium containing appropriate antibiotic in a 1 L Erlenmeyer flask. 
The culture was shaken vigorously at 37°C until it reached an OD550 of 0.6-0.7. 
Bacteria were pelleted by centrifugation in a swinging bucket rotor in a Beckman 
table top centrifuge (Model GPR) at 3,200 rpm for 20 minutes at 4°C. The 
bacterial pellet was resuspended in 4 ml of lysis buffer. 1 ml of freshly prepared 
lysozyme was then added to the suspension. These cells were transferred to a 
50 ml high speed centrifuge tube and incubated for 5 minutes at room 
temperature and 5 minutes on ice. The bacteria were lysed by the addition of 12 
ml of alkali solution and subsequent incubation for 10 minutes on ice. Proteins 
were then precipitated by the addition of 9 ml of ice-cold potassium acetate 
solution for 20 minutes on ice. The solution was gently mixed, balanced, and 
then centrifuged in a Sorvall SS34 rotor at 12,000 rpm at 3°C for 30 minutes. 
The decanted solution was transferred into a new 50 ml tube and the DNA was 
precipitated with 1 volume of cold isopropanol for 20 minutes and collected by 
centrifugation in a Sorvall SS34 rotor at 15,000 rpm at 3°C for 30 minutes. The 
DNA pellet was partially dried by placing the tube in a Speed-Vac vacuum 
evaporator (Savant, Farmingdale, NY) and the pellet was resuspended in 2 ml 
TE. To eliminate the contaminating RNA the DNA was incubated with addition of 
71 
RNase A. 50 µI of RNase A was added and incubated at 37°C for 15-30 
minutes. To remove contaminating proteins 100 µI of 10% SOS was added 
followed by incubation with 40 µI of proteinase K at 42°C for 1 hour. The treated 
DNA in TE was extracted 3 times with phenol/chisam and once with chisam. 
DNA was precipitated with 1/10 volume of 3 M sodium acetate, (pH 5.2); and 2.5 
volume of ice-cold EtOH for 20 minutes to overnight at -20°C. DNA was pelleted 
a Sorval SS34 rotor with 12,000 rpm at 4°C. The DNA was washed with 70% 
ethanol, dried in a Speed-Vac vacuum evaporator, and dissolved in 250 µI of TE. 
1 µI of this DNA was quantitated by restriction enzyme digestion as described in 
section Quantitation of DNA. 
Qiagen Method 
Large scale plasmid isolation by the Qiagen method was carried out using 
100 ml bacteria cultures grown overnight in LB-media+glucose with antibiotics 
according to the manufacture's instructions (Cat#12162). 
'A Phage DNA Preparation 
'A Phage DNA preparation was carried out according to Sambrook et al., 
(1989). Briefly, eluted phage particles were titrated and infected into the 
appropriate strain at a pfu of 5 X 107 phage per 1010 E.coli cells. The cells were 
grown in 500 ml of LB-media+glucose containing 10 mM maltose and 10 mM 
MgS04 prewarmed to 37°C. Concomitant growth of bacteria and phages should 
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occur, which results in lysis and a clearing of the culture after 9 to 12 hours. To 
lyse residual bacteria, add 10 ml of chloroform to each flask and incubate for 10 
minutes at 37°C with shaking. The culture is cooled to room temperature and 
DNase I and RNase A are added to a final concentration of 1 µg/ml. The mixture 
is incubated for 30 minutes at room temperature. NaCl is slowly added to the 
culture to a final concentration of 1 M (29.2 g per 500 ml of culture). The NaCl is 
dissolved by gentle swirling of the flask. The culture is incubated for 1 hour on 
ice and residual debris are removed using a GSA rotor with 11,000 rpm for 1 O 
minutes at 4°C. Pool the supernatants in a clean flask and PEG 8000 is added 
to a final concentration of 10% w/v (i.e., 50 g per 500 ml of supernatant) and 
dissolve by slow stirring on a magnetic stirrer at room temperature. The phage 
particles are precipitated overnight on ice and pelleted by centrifugation in a 
GSA rotor with 11,000 rpm for 10 minutes at 4°C. Discard the supernatant 
thoroughly. Gently resuspend the pellet in 8 ml of phage buffer using a 
disposable plastic bulb pipette and extract the PEG from the suspension by 
adding an equal volume of chloroform and vortexing for 30 seconds followed by 
centrifugation in a Sorval SS34 rotor at 5000 rpm for 15 minutes at 4°C. 0.5 g of 
CsCI per ml of the phage solution is added and gently dissolved and layer onto 
CsCI step gradients prepared in a SW41 tube by adding the following CsCI 
solutions in phage buffer into the SW41 tube from the bottom up: 1. 7 g/ml of 
phage buffer, 1.5 g/ml, 1.45 g/ml and then on top the 0.5 g/ml solution containing 
the resuspended bacteriophage pellets also in phage buffer. The gradient is 

74 
dialysis tubing and quantitate it as described in section Quantitation of DNA 
before use. 
Enzyme Restriction of DNA 
0.5-1.0 µg of plasmid and phage DNA were digested with 2-5 U of 
restriction enzyme in a 20 µI reaction volume in buffers provided by the 
manufacturer under reaction conditions recommended by the manufacturer. 
Digested DNA was analyzed on 0.8%-1.2% agarose gel as described in section 
DNA Agarose Gel Electrophoresis, and DNA fragments were isolated as 
described in section DNA Band Isolation from Agarose Gels. 
DNA Agarose Gel Electrophoresis 
DNA fragments were separated in 0.8%-1.2% TAE/agarose gels as 
described by Sambrook et al, (1989). The gels were prepared as follows. 
Dissolve 1 g of agarose in 125 ml TAE buffer (40 mM Tris-HCI, (pH 8.0); 20 mM 
sodium acetate, 2 mM EDTA) by boiling in a microwave oven, cooled to 60°C 
and add 4 µI of ethidium bromide (EtBr) stock solution (10 mg/ml of dH20). Mix 
gently and pour into a horizontal gel casting tray (Wide Mini-Sub DNA 
electrophoresis Cell, BioRad, Richmond, CA). Allowed the gel to solidify at room 
temperature for 60 minutes and submerge it in the electrophoresis chamber 
(Wide Mini-Sub DNA electrophoresis Cell, BioRad, Richmond, CA) containing 1 
X TAE. Remove the comb before use. Add 1/5 volume of DNA loading buffer 
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(0.025% bromphenol blue, 2.5% Ficoll, 1 X TAE)to the DNA sample, heat for 5 
minutes at 65°C, chill on ice and load 20-25 µI on the gel. Separate the DNA 
with 40-70 V until the bromphenol blue dye front reaches about 2/3 of the way 
through the gel. 
Lambda (A.) DNA cleaved with restriction endonuclease Hindlll, ~X DNA 
cleaved with Haelll and/or a 1 kb DNA ladder (all from Gibco BRL) were run 
simultaneously to serve as DNA molecular weight standards. DNA bands were 
viewed under an ultraviolet light box and photographed on Polaroid 667 film with 
a Polaroid Camera (Model DS34, Polaroid Corp., Cambridge, MA). 
DNA Band Isolation from Agarose Gels 
Digested DNA was size fractionated by agarose gel electrophoresis. EtBr 
DNA fragments were visualized using ultraviolet light. The appropriate 
fragments were isolated with a razor blade or scalpel and extracted from the gel 
by one of the methods described below. 
Elu-T rap Method 
DNA was isolated from the agarose piece by electroelution using a an 
Elu-Trap apparatus (Schleicher and Schuell, Keen NH, Cat#46178) according to 
the manufacturer's instructions. Briefly, the agarose piece was placed in the 
elution cell and electroeluted from the agarose with 120 V for approximately 2-4 
hrs into a small elution chamber. The eluted DNA was removed from the 
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isolation chamber and precipitated with 1/10 volume of 3M NaAc and 2.5 volume 
EtOH overnight at -20°C. DNA was recovered by centrifugation and resuspend 
in TE to obtain approximately 1-2 µg DNA/µI. 
Sodium Iodide (Nal) Method (Super-Band isolation) 
The excised gel piece containing the DNA cut into small pieces and 
weighed. 2.5-3 volumes of 6 M Nal in dH20 was added to the tube with the 
minced agarose and DNA. The mixture was incubated at 45°C for 10 to 20 
minutes. The tubes are inverted to facilitate the dissolving of the agarose. 1 ml 
of Magic mini-prep resin (Promega, Madison, WI) was added to the melted 
agarose and incubated at room temperature for 15 minutes. The DNA fragments 
bound to the DNA binding resin were then processed according to the protocol 
provided by the manufacturer (Lit#TB117). 
Quantitation of DNA 
The concentrations of isolated DNA fragments, or plasmids, were 
estimated by comparing their EtBr-staining to that of DNA fragments of known 
amounts. Alternatively, optical densities at 260 and 280 nm were determined 
and the concentration wad calculated with the following equation: 
µg I µI DNA = OD260 X 50 X dilution factor. 
Pure DNA is expected to yield a OD2601280 of 1.8 to 2.0. 
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Dephosphorylation of DNA Fragments 
To prevent self-ligation of vector fragments a nucleotide 
dephosphorylation reaction was carried out as follows. Pipette into a autoclaved 
microcentrifuge tube: digested DNA 20-30 µI, 1 O X Calf Intestinal Phosphatase 
(CIP) buffer 5 µI, CIP enzyme 0.01 U/pmol DNA, and dH20 to 50 µI total 
volume. 
For 5'-overhangs, incubate the mixture at 37°C for 30 minutes, add 
another aliquot of diluted CIP, and incubate for another 30 minutes. For 3'-
overhangs or blunt ends, the reaction mixture is incubated at 37°C for 15 
minutes and then at 55°C for 15 minutes. Add another aliquot of CIP and 
incubate again at the same temperatures. 
Inactivate the CIP enzyme by addition of 20 µI of 500 mM EGTA, (pH 8.0); 
followed by heat inactivation at 65°C for 45 minutes. CIP treated DNA is 
prepared for use by one phenol, (pH 8.0); extraction, one chisam extraction and 
EtOH precipitation. Precipitated DNA is resuspended in 10 µI of TE and 
quantitated for use. 
Solutions 
10 X Ligation buffer 
Ligation of DNA Fragments 
300 mM Tris-HCI, (pH 
7.8); 100 mM MgCl2, 100 
1 0 X Kienow buffer 
10 X T3 polymerase buffer 
10 X dNTPs 
Sticky-End Ligations of DNA Fragments 
mM DTI, 5 mM ATP 
100 mM Tris-HCI, (pH 
7.5); 500 mM NaCl 
50mM on 
40 mM Tris-HCI, 6 mM 
MgCl2, 10 mM DTI, 10 
mM spermidine, 4 mM 
ATP, CTP, GTP, and UTP 
(pH 7 .2 at 37°C) 
0.125 mM of each dNTP 
78· 
A 5-10: 1 molar ratio of insert:vector DNA was used to obtain optimal 
ligation efficiency. Usually 0.1 µg of vector DNA was used in a 15 µI ligation 
reaction. One Weiss U of T4 DNA ligase (e.g. 1 Weiss unit is the amount of 
activity an enzyme can catalyze the ligation of greater than 95% of Lambda 
Hindlll fragments of 1 µg of DNA at 16°C in 20 minutes) (Pharmacia or Promega) 
was added to each ligation mixture and ligation reactions were carried out at 
15°C overnight (10-14 hrs). 
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Two-Step Ligations of DNA Fragments 
Two-Step ligation is a procedure to ligate two fragments that are 
compatible only at one of their free ends. 
Reaction 1. Ligation of compatible ends: 
GIP-treated vector 
DNA fragment 
10 X ligase buffer 
T 4 DNA ligase 
dH20 
0.5 µg 
5-10:1 excess over vector 
2 µI 
1 U (Weiss unit) 
to final volume of 20 µI 
Incubate overnight at 15°C and heat inactivate the ligase at 65°C for 10 
minutes. 
Reaction 2. Creation of compatible blunt ends. 
For 5' overhangs: 
DNA ligation mixture 
10 X Kienow buffer 
0.125 mM dNTPs 
100 mM OTT 
Kienow enzyme 
dH20 
20 µI 
3 µI 
3 µI 
1.5 µI 
1 U diluted in 1 X Kienow buffer 
to final volume of 30 µI 
Incubate at room temperature for 30 minutes. 
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For 3' overhangs: 
3' the 10 X Kienow buffer is replaced with T 4 DNA 
polymerase buffer and the Kienow enzyme is replaced with 
T4 DNA polymerase. Proceed as described for the Kienow 
reaction. 
Reaction 3. Ligation of the blunt ends: 
1. Ligation mixture 
10 X ligase buffer 10 µI 
50% PEG 10 µI 
100 mM OTT 1 µI 
T 4 DNA ligase 1 U (Weiss unit) 
dH20 to final volume of 100 µI 
2. Add 40 µI of the ligation mixture to the Klenowrr 4 DNA 
polymerase reaction 2 mix and incubate at 15°C 
overnight. 
Transform the ligation mixture into competent E. coli cells as described in 
Transformations of E. coli With Plasmid DNA using 50 ng of ligated DNA. 
Polymerase Chain Reaction (PCR) Amplification 
PCR was performed with purified plasmid DNA or with complete 'A phage 
particles. Either 1 ng of purified plasmid DNA or serial dilutions of 'A phage 
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particles (eluted 2-6 hours) were used, as a template. PCR was performed with 
the reagents and protocols as described below 
Solutions 
10 X PCR buffer 
10 X dNTPs (20 mM) 
Procedure 
Mix 1 ml of 1 M Tris-HCI (pH 8.3), 
5 ml of 1 M KCI, 250 µI of 1 M 
MgCl2 , 50 ml of 20% gelatin 
(BioRad), add dH20 to 10 ml 
final volume. Store at -20°C in 
small aliquots. 
Mix 10 µI of 100 mM dATP, 10 µI 
of 100 mM dCTP, 10 µI of 100 
mM dGTP, 10 µI of 100 mM 
dTTP, and add 500 µI of dH20. 
Store at -20°C in 50 µI aliquots. 
Pipette the following into a 0.5 ml autoclaved microcentrifuge tube: 
Template DNA (about 1-5 µI) X µI 
1 ng of purified plasmid DNA or 
10 fold serial dilutions of eluted 
phage particles (eluted 2-6 hours) 
10 X PCR buffer 3.5 µI 
10 X dNTPs 3.5 µI 
forward primer (50 pmol/ml) 
backward primer (50 pmol/ml) 
Taq polymerase (5U/µI) 
dH20 
1 µI 
1 µI 
0.2 µI (1 U) 
to 35 µI final volume 
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Overlay the mixture with 25 µI of mineral oil (Sigma, Cat# M-3516). Place 
the tubes in a thermal cycler (Perkin Elmer, Foster City , CA) and subject the 
tubes to the following reaction; 1 minutes at 95°C, 1 minutes at 68°C, 3 minutes 
at 72°C. The cycles were repeated 35 times, followed by a half hour at 4°C. 
Amplification products were analyzed and or purified on an agarose gel as 
described in DNA Agarose Gel Electrophoresis. Under certain conditions the 
annealing temperature of 68°C was lowered in order to allow primer annealing to 
the target DNA. 
Cloning of PCR Products 
Purified PCR products were cloned into the PCR cloning plasmid pGEM-T 
(Promega, Madison, WI) by the ligation methods described above and using the 
amounts of template as described by the manufacturer (Lit.#TB150). 
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Radio-labeling of DNA Probes 
Nick Translation 
Radioactive DNA probes were prepared by nick translation with a kit from 
Gibco-BRL according to the manufacturers instructions except that half of the 
volumes and a-32P dCTP label were used. The labeled DNA was separated 
from unincorporated a-32P dCTP nucleotides by gel chromatography on a G-50 
Sephadex (Fine) spin column according to the protocol supplied by the 
manufacturer (Boehringer Mannheim) (Cat#1273-973). The radioactivity in 1 ml 
of column eluate was measured in a liquid scintillation counter (window 0-1500, 
Packard, Downers Grove, IL). The specific activity was calculated using the 
following formula: 
cpm/µI x total eluate volume 
incorporation in cpm I µg DNA = 
µg input DNA. 
The average specific activities of nick translated probes using this protocol were 
0.5-1 X 108 cpm/µg DNA. 
5' End Labeling of oligonucleotides 
Oligonucleotides were phosphorylated with T4 polynucleotide kinase in 
the presence of 32P y-labeled dATP. The reaction was carried out as described 
below. 
100 pmol or 50 ng of 2 µI 
84 
oligonucleotide with free 5' ends 
10 X Kinase buffer "C" from 2 µI 
Boehringer Mannheim 
(500 mM Tris-HCI,, 100 mM 
MgCl2, 1 mM EDTA, 50 mM 
OTT, 1 mM spermidine, (pH 8.2 
at 25°C) 
32P a-dATP (ICN > 7000 4 µI 
Ci/mmol SA) 
dH20 11 µI 
T 4 poly-nucleotide Kinase 1 µI 
(1 OU/µI, Boehringer Mannheim) 
Incubate the mixture for 45 minutes at 37°C. After the reaction , fill to 50 
µI with dH20 and heat inactivate at 90°C for 5 minutes. Apply the reaction 
mixture to a G-25 Sephadex (Fine) spin column according to the protocol 
supplied by the manufacturer (Boehringer Mannheim) (Cat#1522990). The 
specific activity of the probe was calculated as described above. The average 
specific activities of labeled probes were between 1-2.4 X 109 cpm/µg 
oligonucleotide DNA. 
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DNA Sequencing 
DNA sequencing was performed on double stranded plasmid templates 
with the Sequenase 2.0 sequencing kit from USB (Sanger et al., 1977). Plasmid 
templates were denatured by addition of 200 mM EDTA and 200 mM NaOH, 
incubation at 65°C for 2 minutes. 1/10 volume 3 M NaAc and 2.5 volume EtOH 
is added and the DNA is precipitated overnight at -20°C. Denatured plasmid 
DNA is resuspended in 5 µI of dH20, 0.5 pmol sequencing primer, and 2 µI of 5 
X Sequenase Reaction Buffer is added and the volume is filled to 10 µI with 
dH20. The mixture is warmed to 65°C for 2 minutes, allowed to cool slowly to 
room temperature over a period of 30 minutes, and then chilled on ice. The 
Sequenase T7 DNA polymerase is diluted 1 :8 in enzyme dilution buffer. To the 
annealed DNA and primer add 1 µI OTT, 2 µI labeling nucleotide mixture, 2 µI 
diluted Sequenase enzyme and 0.5 µI of 35S a-dATP. The mixture is incubated 
at room temperature for 4 minutes. 3.5 µI of the sequencing reaction is added to 
4 vials each containing 2.5 µI of either di-dioxy (dd) ddGTP, ddATP, ddTIP, or 
ddCTP respectively. The reaction is incubated for 5 minutes at 37°C and 
stopped by the addition of 4 µI of stop buffer. These sequencing reactions can 
be stored at -20°C for up to 4 days. Before loading onto the pre-heated 
sequencing gel as described in chapter DNA Acrylamide Gel Electrophoresis 
(Sequencing Gels), heat the samples to 90°C for 2 min. 
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DNA Acrylamide Gel Electrophoresis (Sequencing Gels) 
Acrylamide gels for the separation of DNA subjected to Sanger dideoxy 
sequencing (Sanger et al., 1977) were prepared as described below. 
Reagents 
Acrylamide Stock Solution 
10 X TBE 
10% Ammonium persulfate (APS) 
Procedure 
Dissolve 40 g acrylamide and 
2 g bis-acrylamide in 100 ml of 
dH20 and sterile filter. 
Dissolve 284 g Trisma base, 165 
g boric Acid, 120 ml 0.5 M EDTA, 
(pH 8.0); in 3 L of dH20 
Dissolve 100 mg of ammonium 
persulfate in 1 ml dH20 
(can be used for up to 1 week) 
Clean 16 cm X 18 cm glass plates (Aladdin enterprise, San Francisco, 
CA) first with soap and hot water. Followed by dH20 and finally with EtOH. 
Wipe with lint-free cloth and assemble with 0.6 mm spacers. Tape the sides. and 
bottom of the glass plates and clamp together with large paper binding clamps 
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along each side. To prepare a 6% acrylamide denaturing urea gel, mix the 
following chemicals in a side-arm Erlenmeyer flask; 21 g Urea (Gibco-BRL), 7.25 
ml acrylamide stock, 5 ml 10 X TBE, and 20 ml dH20. Mix the reagents, degas 
for 1 O minutes, and add 400 µI of APS solution and 20 µI of TEMED (Sigma) with 
gentle swirling. Quickly pipette the mixture between the glass plates, insert the 
sharks tooth comb (Aladdin enterprise, San Francisco, CA) at the top of the gel, 
apply clamps near the top of the gel and allow polymerization to occur. Wrap the 
top of the polymerized gel in plastic wrap, apply 1 X TBE buffer to keep moist, 
and store overnight at room temperature. Carefully remove the comb and set up 
the glass plate in a electrophoresis apparatus (Aladdin enterprise, San 
Francisco, CA). Fill the top and bottom buffer tanks with 1 X TBE and insert the 
shark-tooth comb so that wells are formed. Prerun the gel with a constant 
voltage of 1000 V until the gel is warm and then increase the voltage to 1300-
1800 V until the temperature of the gel is approximately 50°C. Flush the wells 
with fresh 1 X TBE, heat the samples to 85°C for 2 minutes, and immediately 
apply the sample to the gel. Run the samples until the xylene cyanole FF green 
dye band has just run off the bottom of the gel. Remove the thin glass plate, lay 
on top of the gel a 3 mm Whatman paper soaked in 10% acetic acid/ 10% 
methanol and incubate for 10 minutes. Remove any free acid/methanol solution 
by gentle blotting and then remove the Whatman (Note: the gel will stick to the 
filter paper). Cover the gel side of the filter paper with plastic wrap, dry the gel 
for at least 30 minutes at 80°C, and expose the gel to autoradiography. 
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Southern Blot Analysis of DNA 
Solutions 
Lysis Solution 
Solution A 
Solution B 
Solution C 
Southern Hybridization Mix 
Mix 680 µI 1 M NaHC03 , 1.104 
ml Na2C03, 80 µI 0.5 M EDTA, 
0.2 g N-lauroyl sarcosine (Na 
salt), add dH20 to 40 ml and add 
12 mg of proteinase K. 
0.25 M HCI 
0.5 M NaOH 
1.5 M NaCl 
0.5 M Tris-HCI, (pH 7.4-7.5) 
3.0 M NaCl 
Mix 70 ml dH20, 20 ml 
50% Dextran sulphate, 10 ml 
10% sos 
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ONA Isolation 
Pellet 3 X 106 cells and wash once with ice-cold Dulbecco's PBS. 
Suspend the cell pellet and add 3 ml of lysis buffer, and using a 5 ml pipette, 
gently pipette the cell lysate up and down 2-3 times to lyse cells. Incubate the 
cell lysate at 37°C for 3-4 hr while periodically mixing the lysate. Transfer the 
lysate to a 50 ml conical tube extract with phenol (TE equilibrated, (pH 7.0)), 
chloroform, and isoamyl alcohol at a ratio of 25:24:1. Mix gently for 5-10 minutes 
and then separate the phases by centrifugation at 2370 rpm in a Beckman table-
top centrifuge. Repeat the extraction step one time. Extract once with 
chloroform:isoamyl alcohol alone (24:1) and transfer the aqueous phase into a 
sterile 25 ml Erlenmeyer flask with 0.2 volume 11 M ammonium acetate. Add 
2.5 volume 95% EtOH and mix the flask gently until DNA precipitates. Spool the 
DNA onto a Pasteur pipette and thoroughly wash the DNA in 70% EtOH. 
Dissolve the precipitated DNA at 37°C in 400 µI of dH20. Add 4 µI of RNase at 
10 mg/ml and incubate at 37°C for 30 minutes. Extract the aqueous mixture as 
above. Precipitate DNA in a microcentrifuge tube by the addition of 1/10th 
volume of 3 M NaAc and 2.5 volumes of EtOH, pellet, wash, and resuspend the 
DNA in 400-600 µI of TE and incubate at 4°C overnight. 
Restriction Digestion of DNA 
Digest approximately 10 µg of DNA in appropriate restriction enzyme 
buffer as described in section Enzyme Restriction of DNA. Extract the digested 
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ONA twice with equal volumes of phenol/chloroform (1+1) and once with 
chloroform. Precipate and wash the DNA as described above and resuspend in 
7.5 µI of 10 mM NaP04, (pH 6.8); in a volume suitable for application to 
TAE/agarose gel electrophoresis. Heat the sample at 37°C for >30 minutes, add 
5 X DNA loading buffer, heat to 65°C for 5 minutes, chill on ice. Apply the 
sample to a 0.7% TAE/agarose gel with 30 V for 16-18 hr in 1 X TAE. 
Transfer of DNA 
After completion of the electrophoresis soak the gel for 15 minutes in 
solution A, 30 minutes in solution B, and in solution C for 45 minutes. Transfer 
the DNA to Gene Screen Plus (DuPont, Boston, MA) as described for RNA and 
then dry the membrane for 30 minutes at 37°C. 
The filter is then prehybridized with the hybridization solution at 65°C and 
then hybridized at 65°C overnight in the same solution containing radiolabled 
probe boiled for 5 minutes with 100 µg of sheared salmon sperm DNA. The 
membrane is washed using high stringency conditions (68°C, 0.1 X SSC/0.1 % 
SOS) for 10 minutes until washing is sufficient. The blot is then dried and put to 
X-ray film at -70°C backed with a fluorographic enhancing screen. 
Bacterial Strains and Manipulations 
Preparation of Transformation Competent Bacterial Cells 
Solutions 
Solution A 
Solution B 
10 mM MOPS, (pH 6.5) 
10 mM RbCI 
10 mM MOPS, (pH 6.5) 
50 mM CaCI 
10 mM RbCI 
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Solutions A and B are filter-sterilized by passage through a 45 µm filter 
and stored at 4°C. 
Procedure 
The bacteria to be made competent are streaked from a frozen stock onto 
a LB-media plate. A single colony is inoculated into 5 ml of LB-media containing 
5 mM Glucose (LB-media+glucose) and shaken vigorously overnight at 37°C. 
100 ml of LB-media is innoculated with 2.5 ml of overnight culture. The culture is 
grown at 37°C until the 00600 is 0.13-0.15. The cells are centrifuged for 5 
minutes with 5,000 X g at 4°C in a sterile tube. The supernatant is decanted and 
the cells are resuspended in 50 ml of solution A. The cells are pelleted as 
described above. The cells are resuspended in 5 ml of solution B and then up to 
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50 ml with solution 8. The cells are incubated on ice for 30 minutes and then 
pelleted as described above. The supernatant is decanted and drained 
thoroughly. The cell pellet is gently resuspended in 4 ml of solution B. 1 ml of 
50% glycerol is added to the resuspended cells and 50 µI aliquots are frozen in 
small tubes at -70°C. 
Transformations of E. coli With Plasmid DNA 
25 µI of competent E. coli cells in a microcentrifuge tube and 50-500 ng of 
plasmid DNA, or 1-5 µI of ligation mixture were mixed gently and incubated on 
ice for 30 minutes. The mix was heat shocked in a 42°C water bath for 50 
seconds and placed on ice for 2 minutes. 1 ml of SOC medium (2% Bacto-
tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCI, 10 mM MgCl2 , 10 mM 
MgS04, 20 mM glucose) was added to the heat shocked cells, and the mixture 
was incubated at 37°C for 45-60 minutes. Aliquots of the transformation mix 
were plated on LB-media plates containing 100 µg/ml ampicillin, 15 µg/ml 
tetracycline or 70 µg/ml kanamycin. Transformants were screened as described 
in the following section. 
Screening of E. coli Containing Recombinant Plasmid Vectors 
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Blue/White Color Screening 
To screen transformed E.coli strains, JM109 and DH5a, for the presence 
of p-galactosidase activity, 50 µI of 2% X-Gal (Boehringer Mannheim, 
Indianapolis, IN, turns blue in the presence of p-galactosidase) and 100 µI of 
1 oo mM isopropylthio-p-D-Galactoside (IPTG) (Boheringer Mannheim, 
Indianapolis, IN, induces promoter activity and expression of p-galactosidase a-
peptide) were used. If the plasmid contains a DNA insert within the multiple 
cloning site, its presence will disrupt the a-peptide coding region and thus any 
a-peptide activity. To prepare media to detect p-galactoside activity within an E. 
coli strain containing a recombinant plasmid, the color inducing reagents were 
spread on 1.5% agar/LB-media plates containing an appropriate selective 
antibiotic (blue/white plates) for 30 minutes before transformed bacteria were 
plated. Recombinant plasmids are detected by their white color (lack of p-
galactosidase activity due to recombinant DNA within the coding region of the a-
peptide gene) while non-recombinant colonies (active p-galactosidase activity 
and active a-peptide) were blue. 
Bacterial Colony Lift 
To identify bacterial colonies that carry recombinant plasmids, the 
following protocol was adapted and modified from Buluwela et al., (1989). 
Briefly, LB-media plates containing bacterial colonies were cooled to 3°C before 
use. A nylon membrane (HyBond-N, 0.45 µm, X 82mm, Cat#RPH.82N, 
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Amersham, Arlington Heights, IL) was carefully laid onto the cold bacteria 
colonies and incubated for 2 minutes. To mark the orientation of the filter on the 
plate, filter and agar were punctured with a needle. The filter was removed and 
placed bacteria side up for 2 minutes on a Whatman filter soaked in denaturation 
solution (2 X SSC and 5% SOS). The filters were then placed on Whatman filter 
paper and microwaved on high power (100%) for 2-2.5 minutes. The filters were 
then soaked in 2 X SSC and the bacterial debris were gently rubbed off. The 
filters were prehybridized in a solution containing 0.5 M NaP04, (pH 7.0); 1% 
BSA (Boehringer Mannheim, Indianapolis, IN), 7% SDS, 1 mM EDTA at 65°C for 
at least 1 hour. 2 X 106 counts of denatured 32P-labeled DNA probe were added 
to the prehybridization mix and incubation was carried out overnight at 65°C. 
The filters were washed first with 2 X SSC at room temperature for 2-5 minutes 
and then with 0.1 X SSC/0.1 % SOS at 55°C until the filter that serves as a 
negative control (bacteria transformed with vector alone) is clear of radiation. 
The punctures in the filter were labeled with radioactive ink and the filters were 
autoradiographed overnight using an enhancing screen at -70°C. 
'A Phage Infections 
Phage Strains and Host Strains 
95 
'A phage particles either from a purified plaque or as a whole library were 
infected into host bacterial strain as described here. The host strain used with 
each type of phage is indicated in Table 3. 
Table 3. -- Bacteriophage and Host Strains Used 
Phage Vector Host Strain Excision Strain Reference 
EMBL4 c600hfl None Woodcock et al., 
1989 
'Agt10 LE392 None Sambrook et al., 
1989 
'A Zapll XL1-Blue MRF' SOLR Stratagene 
'A Zap Express XL 1-Blue MRF' XLOLR Stratagene 
'A Fixll XL 1-Blue-MRA None Stratagene 
Solutions 
Solutions used in phage resuspension, infection, and plating are 
described below. 
Phage buffer Dilute 5 ml of 5 M NaCl, 1 ml of 
1 M Tris-HCI, (pH 7.4); and 0.5 
ml of 1 M MgS04 in 25 ml of 
Top Agar 
Phage Manipulation Protocols 
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Autoclave 0.5 g of NaCl, 0.6 g of 
agarose, and 1 g of Bacto-
tryptone in 100 ml of dH20. 
After autoclaving and cooling to 
55°C add 5 ml of 1 M MgS04 . 
Phage particles either undiluted or diluted in phage buffer were added to 
the appropriate bacterial strain that was grown to an 00550 of 0.6-0.7 in LB-
media supplemented with 0.2% maltose and 50 mM MgS04. 100 µI of bacteria 
was used when the infection was plated on a 82 mm diameter plate and 300 µI if 
it was plated on a 137 mm diameter plate. Phage and bacteria were incubated 
together for 30 minutes at 37°C. Top agar warmed to 42°C (3 ml for a 82 mm 
plate and 7 ml for a 137 mm plate) was added to the bacteria/phage mixture 
inverted once and quickly spread on pre-warmed (37°C) plates. The plates were 
allowed to sit for 5 minutes at room temperature and then placed upside down at 
37°C to allow plaques to form. 
/..... Phage Screening and Plaque Purification 
LB-media plates containing lysogen plaques are screened for plaques 
containing the desired cDNA/DNA insert by using the following reagents and 
methods. 
Solutions 
Alkaline solution 
Neutralization solution 
3 X SSC/10% Dextran sulphate 
hyb solution 
6 X SSC/10% Dextran sulphate 
hyb solution 
2 X SSC/0.1 % SOS 
Mix 60 g NaOH, 262.9 g NaCl, 
and add 3 L of dH20. 
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Mix 181.7 g Tris-HCI, 525.9 g 
NaCl, and add 3 L of dH20. pH 
to 7.4 using 12 M HCI. 
Mix 150 ml 20 X SSC, 100 ml 50 
X Den hart's solution, 10 ml 10% 
SOS, 100 mg SS DNA 
(denatured), 100 g dextran 
sulphate and add dH20 to 1 L 
Mix 300 ml 20 X SSC, 100 ml 50 
X Den hart's solution, 10 ml 10 
% SOS, 100 mg SS DNA 
(denatured), 100 g dextran 
sulphate, and add dH20 to 1 L 
Mix 100 ml 20 X SSC, 10 ml 10 
% SOS, and add dH20 to 1 L 
1 X SSC/0.1% SOS 
0.1 X SSC/0.1% SOS 
Procedure 
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Mix 50 ml 20 X SSC, 10 ml 10% 
SOS, and add dH20 to 1 L 
Mix 5 ml 20 X SSC, 10 ml 10% 
SOS, and add dH20 to 1 L 
Cool plates containing plaques to 4°C. Overlay plaques with a 
nitrocellulose filter of the appropriate size (82 mm diameter, BA85 [0.45 µm, Cat# 
20440] or 132 mm diameter, BA 85 [0.45 µm, Cat# 20570] Schleicher and 
Schuell, Keene, NH) onto the plate until the filter is completely wet. Make 
alignment holes by puncturing the filter and agar plate with a needle. Lift filters 
from the plate with forceps and place plaque side up on a Whatman paper and 
dry for 5 minutes. Place the filters into alkaline solution for 1 minute and then 
transfer them into neutralization solution for 2 minutes. Remove the filters, dry 
them under a heat lamp, and then bake them at 80°C for 2 hrs. under high 
vacuum. Remove the filters and wet them in the appropriate hybridization 
solution without the dextran sulphate (either 3 X SSC mix for high stringency 
hybridization or 6 X SSC mix for low stringency hybridization). Remove the 
wetting solution and immerse the filters in the complete hybridization solution 
containing dextran sulphate for at least 1 hour at the appropriate hybridization 
temperature (64°C for high stringency [3 X SSC/10% dextran sulphate] or 55°C 
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for low stringency [6 X SSC/10% dextran sulphate]). Perform the hybridization 
overnight in the same solution and add 2 X 106 counts of denatured 32P-labeled 
DNA probe per ml. Wash the filters in the 2 X SSC/0.1 % SDS solution at 55-
580C for low stringency screen and with 1-0.1 X SSC/0.1 % SDS solution at 64-
680C for high stringency screen until the radiation on the negative control (filter 
with a lifted plaque or colony containing a known negative insert (e.g. GAPDH)) 
is minimal. Dry the filters, mark them with radioactive ink, cover them with plastic 
wrap, and expose them to X-ray film overnight against 1 enhancing screen at -
70°C. Positive plaques were picked by excising a small agar piece by using the 
large or small end of a pasture pipette and placing the agar plug in 1 ml of phage 
buffer. The above procedure was repeated with eluted phage until all plaques 
screened positive with the radiolabled probe. 
Plasmid excision from A YES phage by the ere/lox recombination system 
A.-YES phage particle eluted from a plaque-purified single plaque and 
were used to infect the E. coli strain BNN132. This bacteria strain contains the 
ere recombinase protein that is able to recognize its cognate recombination site 
(lox) within the A--YES phage DNA. The recombination process yields an 
ampicillin-resistant E. coli I yeast shuttle plasmid. The process of obtaining 
bacterial colonies containing the excised plasmid is described below. 
The E. coli strain BNN132 was grown to an OD550 of 0.6 in selective 
media (LB, 0.2% glucose, 70 µg/ml kanamycin) to select for the presence of the 
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ere gene present within a kanamycin containing transposon. A-YES phage 
particles are diluted in phage buffer and added to BNN132 at a ratio of 1 particle 
to every 3 bacteria (an 00550 of 0.2 contains 108 bacteria/ml). Incubate the 
phage and bacteria for 30 minutes at 30°C. Add 1 ml of selective media again, 
incubate the mixture for 1 hour at 37°C, and plate aliquots on LB-
media+ampicillin agar plates to select for the presence of the excised plasmid. 
Incubate the plates overnight at 37°C and analyze the colonies as described. 
Excision of Plasmid DNA from A Zapll pahge by helper phage 
Recombinant plasmids were excised from single cDNA phage clones 
isolated from Stratagene (La Jolla, CA) libraries A-Zap Express or A-Zap II. This 
was done exactly according to the Stratagene instruction manual (Cat#200253). 
Hybridization with DNA oligonucleotides 
Hybridization of nucleic acids supported on nitrocellulose membranes was 
performed as described by and adapted from M. Shulman, Univ. of Toronto. 
Solutions 
Hybridization mix Mix 50 ml 20 X SSC, 4 ml 1 M 
Na2P04 , (pH 7.0); 14 g SOS, 40 
ml 50 X Denhart's, and add 
dH20 to 200 ml final volume 
Wash solution 
Procedure 
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Mix 75 ml 20 X SSC, 100 ml 50 X 
Oenhart's, 25 g SOS, 12.5 ml 1 
M NaH2P04 , (pH 7.5); and add 
dH20 to 500 ml final volume at 
37°C 
Prehybridize Southern, northern or phage plaque blots on nitrocellulose at 
47°C for at least 1 hour. Add 32P-labeled probe (boiled 10 minutes then iced) 
directly to the prehybridization solution at a final concentration of 1 X 106 cpm/ml. 
Hybridize overnight at 47°C with gentle shaking. Wash the blot with the wash 
solution at 50°C for 10 minutes times until the negative control contains minimal 
background. Wash once with rinse solution (1 X SSC/1 % SOS) at 50°C for 5 
minutes and wrap the wet blot in plastic wrap and expose to film to test washing 
or dry the blot and put to film at -70°C with enhancing screen. Calculate the Tm 
of hybridization by the following equation: Add 2°C for each A or T and Add 4°C 
for each G or C. Hybridization should be at least 15-20°C below Tm· 
Mammalian Cell Culture Techniques 
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Growth of Cells 
All cell lines were grown in complete RPMI medium as described (Keyna 
et al., 1995). Breifly, all cell lines were maintained in RPMI 1640 medium 
supplemented with 10% (volume/volume) fetal calf serum (FCS, HyClone 
Laboratories), 4 mM L-Glutamine, 2.5 ml of penicillin-streptomycin solution (50 
U/ml), 0.05 mM ~-mercaptoethanol and 1 mM sodium pyruvate at 37°C or 30°C 
in a 5% COrhumidified incubator with copper lining (Model#B5060, Hereaus, 
South Plainfield, NJ). This medium is referred to as complete RPMI medium. 
Unless indicated otherwise, all cell culture reagents used were from Gibco-BRL. 
Cell Lines Used For This Work 
The cell lines used are described below. 
Table 4. -- Cell Lines Used 
Name Type Source 
FH I LOCB 81.13.13 B cell hybridoma Murine 
VXH I GAMO 12.8.10 B cell hybridoma Murine 
NYC B cell lymphoma Murine 
MORK B cell hybridoma Murine 
U-937 Monocytic Human 
Raji B lymphoma Human 
Jurkat T lymphoma Human 
He la Endothelial Human 
Reference 
Jack et al., 1989 
Jack et al., 1989 
Jack et al., 1992b 
Jack et al., 1992a 
ATCC # CRL 1593 
ATCC#CCL86 
ATCC # TIB152 
ATCC#CCL2 
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Table 4. cont. -- Cell Lines Used 
HA-VSMC Heart Muscle Cell Human ATCC # CRL-1999 
Gia Glioma Human Established from a 
grade 4 
neuroblastoma by 
LC. Erickson, Loyola 
University 
MC/CAR Plasmacytoma Human ATCC # CRL8083 
96-1 B cell hybridoma Rabbit Dr. Katherine Knight, 
unpublished 
Harvesting of Cells 
Cells were pelleted by centrifugation with 1100 rpm at 4°C for 5 minutes in 
a refrigerated table-top centrifuge (Silencer S-103 NA, , Rupp and Bowman, 
Tustin, CA). 
Freezing and Thawing of Cells 
To freeze cells, approximately 2.5 X 107 cells were pelleted, resuspended 
in 1.5 ml of RPMI freezing medium (RPMI 1640 supplemented with 30% FCS, 
15% DMSO, and 0.05 mM ~-ME), and transferred into a chilled cryogenic tube 
(Vangard CRYOS, Sumitomo Bakelite Co., Ltd., Japan). The frozen cells were 
kept at -70°C overnight and then transferred to liquid nitrogen for long-term 
storage. To thaw cells the frozen tubes were removed from liquid nitrogen and 
warmed in a 37°C water bath until most of the cells were thawed. The cells were 
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transferred to ice cold complete RPMI 1640 media, pelleted by centrifugation, 
and cultured in 15 ml of complete medium. 
Counting of Cells 
A aliquot of cells was removed from the flask and counted in a Neubauer 
hematocytometer chamber (Bright-Line, 0.1 mm, American Optical Co., Buffalo, 
NY). The cell number was determined by the following equation: Cells/ml = total 
number of cells in 1 of the 9 large counting fields X 2 X 104 . 
Transfection of Cells With Plasmid DNA 
All cell transfections were carried out by electroporation as described 
(Jack et al., 1992). 5 X 106 cells were collected and washed twice in ice-cold 
FCS-free RPMI medium and resuspended in 500 µI of the same medium. 5-20 
µg of DNA (in approximately 20 µI of TE) is added and mixed gently by pipetting. 
The cell suspension is subjected to one electric pulse of 330 µF, 285 volts at low 
conductivity on ice with a Cell Porator (BRL, Gaithersburg, MD). The 
electroporated cells were immediately transferred into 10 ml of complete RPMI 
medium/20% FCS and grown for 2 days. To isolate stable transfectants, the 
cells were diluted in complete RPMI containing 0.8 µg/ml G418 (Geneticin, 
Gibco-BRL) to a density of 5 X 104 cells/ml media. 100 µI of the diluted cells 
were plated per-well in 10, 96 well plates. Wells were screened under the 
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microscope for cell clones between days 7-10 and fed with RPMI containing 0.8 
µg/ml G418 at day 10. 
Protein Analysis 
Generation of Antisera Against Synthetic Peptides 
Peptides deduced from the aa sequence of a polypeptide were 
synthesized, coupled to a carrier protein, and rabbits were immunized with the 
peptide I carrier conjugate. Linear polypeptides were coupled to a carrier 
molecule and used as an immunogen as described below. Branched 
polypeptides (Figure 7) were used directly as an immunogen due to their natural 
ability to prime an immune response without a carrier molecule. 
Coupling of Non-branched Peptides to Carrier Molecules 
Because small linear peptides of 15-30 amino acid residues are poorly 
immunogenic, they were coupled to a large carrier protein (keyhole limpet 
hemocyanin [KLH] or bovine serum albumin [BSA]) using commercially available 
pre-activated KLH and BSA (Pierce Co., Rockford, IL). The chemical reaction 
that leads to a covalent association of peptide and carrier is outlined in Figure 8. 
The coupling between peptide and carrier was performed with a antigen-carrier 
coupling kit (Pierce Co., Rockford, IL) according to the manufacturer's 
instructions included with the kit. 
Peptide-Lys4-Tentacles 
Peptides Polylysine 
Scaffolding 
Figure 7. Schematic diagram of a multiple antigenic peptide. 
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Immunization 
Rabbits were either injected with carrier-coupled peptide or with branched 
peptides (antigen) as follows. The antigen is resuspended in PBS to a final 
concentration of 2 mg/ml and 1 ml of antigen is mixed with 500 µI of 0.9% NaCl 
and 1 ml of Complete Freund's Adjuvant (CFA). The emulsion is mixed using an 
emulsion mixer (5100 Mixer I Mill, Spex, Inc., Edison, NJ) for 5 minutes the 
mixture is put into a 3 ml syringe with a small spatula avoiding air bubbles 
whenever possible. Inject the whole mixture sub-dermal into the rabbits at 
different locations six times (by the rear legs, behind the neck and at their flanks) 
using a 20112 gauge needle. After 4-8 weeks boost the rabbits with the antigen in 
the following mixture: 100 mg antigen in PBS, 1 ml 0.9% NaCl, and 1 ml 
incomplete Freund's Adjuvant. If more boosting is required, repeat the 
procedure above. 
One week after the second boost, the rabbits are bled from a small cut on 
the ear (no more than 30 ml from a healthy rabbit). The blood is collected in a 30 
ml glass corex centrifuge tube and left at room temperature overnight (clotting 
occurs). Spin the mixture for 20 minutes at 2000 rpm in a table-top centrifuge 
and remove the cleared top layer of sera. Test the sera for antibody reactivity 
against the injected antigen. 
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Affinity Purification of Anti-peptide Antisera 
To isolate peptide specific antibodies from the antiserum, isolated rabbit 
serum was applied to a peptide matrix column (Pierce Co., Rockford, IL). Briefly, 
a pre-activated amine-containing agarose matrix was mixed with the peptide 
containing at least one COOH group. The mixture was treated with a 
carbodiimide catalyst in order to facilitate the formation of an amine bond 
between the amine-containing matrix and the COOH containing peptide (Figure 
9). The column is then washed of any free peptide. The prepared column is 
then incubated with rabbit sera allowing specific antibody-peptide interactions. 
Un-bound antibodys are washed from the column and then peptide-specific 
antibodies are released from the column by a 0.1 M Glycine (in dH20, (pH 2.5)). 
Solutions 
ELISA Analysis of Antisera 
color reaction solution 
ELISA substrate buffer 
Mix 10 mg Sigma 104 
Phosphatase Substrate [Cat#104-
0] in 10 ml of ELISA substrate 
buffer 
Mix 48.5 ml Diethanolamine, 400 
mg MgCl2+6H20, 100 mg NaN3, 
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and add 500 ml dH20, pH to 9.8 
with 12 M HCI. 
To determine the presence as well as the amount of specific antibodies, 
an ~nzyme linked immunoab_s.orbant assay ELISA assay was performed as 
described. 96 well plates (Falcon #3912-Test Ill) are first coated with target 
antigen at 10 µg/ml in PBS/0.1 % NaN3 overnight at 4 °C. The wells were washed 
twice with antigen incubated plate is washed twice with PBST solution (1 X PBS, 
0.05% Tween-20, 0.02% NaN3) and then blocked with 200 µI of PBS + 1 % BSA 
for 2 hr at 37°C or overnight at 4°C. After blocking, the wells were washed once 
with PBST, filled with serial dilutions of the antibodys solution and incubated for 2 
hr at 37°C. The wells were washed 5 X with the PSST. Then 50 µI of the 
secondary alkaline phosphatase antibody (diluted 1 :2000 in PBS + 0.1 % NaN3) 
is added and incubated for 2 hr at 37°C. The plates are washed 3 X with PBST 
100 µI of color reaction solution is added. Incubate for 30 minutes and read in 
ELISA reader at A.450 . 
lmmunofluorescence Analysis of Cytoplasmic Proteins (CIF) 
To detect cytoplasmic proteins, 1-5 X 104 cells in 200-300 µI of RPMI 
were centrifuged onto a glass slide at 1100 rpm for 2 minutes in a Shandon 
centrifuge (London, England). After briefly air-drying the pelleted cells, the slides 
112· 
(and the cells on them) were placed in EtOH for 5 minutes at room temperature 
and rehydrated in PBSF solution (1 X PBS, 0.1 % BSA, 0.1 % NaN3) for at least 
20 minutes. For direct CIF the slides were then incubated with 10 µI of diluted 
fluorescent-labeled antibodies for 10 minutes at room temperature (Burrows et 
al., 1981). For indirect CIF, the slides were first incubated with 10 µI of primary 
antibody, washed 3 X with PBSF, and then incubated with 10 µI of diluted 
fluorescent-labeled secondary antibody. The slides were washed 3 X with PBSF 
and the cells were mounted under a glass coverslip using Cytoseal 60 (Stephens 
Scientific, Riverdale, NJ). Mounted cells were examined under a fluorescence 
microscope (Leica Photofluorescence Microscope, Model LABOVERT FS, Leitz 
Wetzlar, Germany). 
lmmunoprecipitation of Metabolically Labeled Polypeptides 
Solutions and Reagents 
RPMI labeling medium Mix 500 ml methionine-free RPMI 
1640 (Gibco-BRL), 50 ml of 
dialyzed Fetal calf serum 
(HyClone), 10 ml of 200 mM L-
Glutamine (Gibco-BRL), 0.5 ml of 
1 M sodium pyruvate, 5 ml of 500 
U/ml Penicillin-Streptomycin 
10 X NET 
0.1 M (PMSF) 
1 X NET lysis buffer 
(Gibco-BRL), and 2.5 ml of 10 
mM ~-ME. 
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Mix 8.76 g NaCl, 1.86 g of 
sodium EDTA, 6.06 g Trisma 
base, 1 g NaN3, and add dH20 
to 100 ml. pH to 7.4 and store 
aliquots at -20°C. 
0.1 M in ethanol, store at -20°C 
Mix 10 ml of 10 X NET, 2.5 ml 
20% Triton X-100 in water, and 
add dH20 100 ml. Add 1 µI of 
0.1 M PMSF to every 100 µI of 
lysis buffer before use. Aliquot 
and store at -20°C. 
Washed 10 % Staphylococcus aureus S. aureus in PBS and NaN3 was 
prepared as described in 
Bornemann (pH.D. thesis). Cells 
were collected, washed 2 X in S. 
S. aureus wash buffer 
SOS sample buffer (1 X) 
aureus wash buffer and 
resuspended in the original 
volume of buffer. 
Mix 75 mg of methionine, 5 ml 
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0.5 M sodium EDTA, (pH 8.0); 
12.5 ml 2 M Tris-HCI, (pH 8.0); 1 
ml 10% NaN3 , 12.5 ml 20% Triton 
X-100, 25 ml 10% sodium DOC, 
5 ml 10% SOS, 62.5 ml 4 M 
NaCl, and add dH20 to 500 ml, 
pH to 8.3. Before each use add 
1-1.2 mg/ml Ovalbumin (Chicken 
Egg, Sigma, St Louis, MO) 
Mix 2.5 ml of 0.5 M Tris-HCI, (pH 
6.8); 2 g glycerol, 1 ml ~-ME, 200 
µI 0.2% bromphenol blue, 5 ml 
10% SOS, and add dH20 to 20 
ml. 
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Procedure 
Metabolic Labeling of Cells 
1-10 X 106 cells were starved for methionine for 1 hr in 1 ml RPMI labeling 
medium. 50 µCi/ml of Trans-[35S] label (1076 Ci/mmol, ICN) was added and 
cells were incubated for 60-180 minutes in 5% C02 at 37°C. Cells were washed 
in ice-cold PBS and lysed with ice-cold NET lysis buffer (250 µI/ 1-5 X 106 cells) 
and incubated on ice for 20 minutes. Nuclei and un-lysed cells were removed by 
microcentrifugation at 4°C for 5 minutes. The lysate was then transferred to a 
new microcentrifuge tube and placed on ice. 
lmmunoprecipitation 
Lysates were incubated for 4-16 hours at 4°C after the addition of the 
appropriate antisera or monoclonal antibody (approximately 5 µg antibody) to 
each 2 X 105 cells used (amount of the antibody may vary depending on the titer 
of the precipitating antibody used). In some cases where the primary antibody 
binds weakly or not at all to protein A, an appropriate secondary antibody was 
added which reacted with the first antibody and the incubation was carried out 
for 3 hrs at 4°C. Ab-Ag conjugates were precipitated by adding 100 ml of 
washed 10% S. aureus and incubated, the suspension was incubated for 30 
minutes in ice. S. aureus was pelleted in a microcentrifuge tube, washed 2-3 
times in S. aureus wash buffer and once with low salt washing buffer (50 mM 
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Tris-HCI, (pH 8.0)). S. arueus pellets were resuspended in 100 ml of 1 X SOS 
sample buffer, boiled for 3 minutes, and cooled in a water bath to room 
temperature. The S. aureus was pelleted and 50-75 ml of the blue solution was 
analyzed by SDS-polyacrylamide gel electrophoresis. 
Jn Vitro Translation of Proteins 
In vitro translation of proteins from RNA templates transcribed from cloned 
genes were performed with the TNT Coupled reticulocyte lysate system 
(Promega, Madison, WI) as recommended by the manufacturer. Briefly, 1-2 µg 
of linearized plasmid isolated from bacteria using magic mini-preps or from 
Qiagen was mixed with the following reagents; 
1-2 µg of linearized plasmid DNA X ~ti 
TNT rabbit reticulocyte lysate 12.5 µI 
TNT buffer 1 µI 
T7 DNA polymerase 0.5 µI 
35S-methionine, cystine (Trans-label) 2 µI 
10 mM amino acids (-methionine) 0.5 µI 
20 U of RNasin (RNase inhibitor from 0.5 µI 
Promega, Madison, WI) 
dH20 to 25 µI final volume 
The in vitro translation mixture is incubated at 30°C for 120 minutes. 5 µI 
of the reaction was mixed with 1 X Laemmli reducing SOS sample buffer (see 
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section SOS Polyacrylamide Gel Electrophoresis (SOS/PAGE)), incubated for 15 
minutes at 37°C. And analyzed by SOS-PAGE. Extra samples were frozen at -
70°C for later use. 
SOS Polyacrylamide Gel Electrophoresis (SOS/PAGE) 
Proteins were separated by molecular weight on a discontinuous SOS 
polyacrylamide gel system described by Laemmli, (1970). 
Reagents 
acrylamide solution 
8 X separating gel buffer (3M Tris) 
4 X stacking gel buffer (0.5 M Tris) 
10 % sos 
Mix 40 g of acrylamide (40%), 
1.07 g bis-acrylamide (1.07%), 
and add 100 ml of dH20. 
Mix 72.7 g of Trisma base, and 
add 200 ml of dH20. pH to 8.8 
with HCI. 
Mix 6.05 g of Trisma base, and 
add 100 ml of dH20. pH to 6.8. 
Mix 20 g of SOS with 200 ml of 
dH20. 
10% Ammonium persulfate (APS) 
TEMEO 
10 X Laemmli solution 
separating gel buffer 
1 X Laemmli sample buffer 
3 X Laemmli sample buffer 
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Mix 100 mg of APS with 1 ml of 
dH20. 
Stock solution from Sigma 
Mix 121.2 g of Trisma base, 577 
g glycine, 40 g SOS, and add 4 L 
of dH20. 
Mix 3.75 ml of 3 M Tris-HCI, (pH 
8.8); 0.3 ml 10% SOS, and add 
30 ml of dH20. 
Mix 2.5 ml of 0.5 M Tris-HCI, (pH 
6.8); 2 g 100% glycerol, 1 ml 13-
ME, 200 µI 0.2% BPB, 5 ml 10% 
SOS, and add 25 ml of dH20. 
Mix 7.5 ml of 0.5 M Tris-HCI, (pH 
6.8); 6 g 100% glycerol, 3 ml 13-
ME, 600 ml 0.2% bromphenol 
Electrophoresis 
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blue (BPB), 15 ml 10% SOS, and 
add 25 ml of dH20. 
16 X 18 cm glass plates were washed, dried, and assembled with 1.5 mm 
plastic spacers and plate clamps in a Hoefer vertical gel casting stand 
(Model#SE6015). The gel solution (7 .5 ml of acrylamide solution, 3. 75 ml 3 M 
Tris-HCI, (pH 8.8); 18.135 ml dH20) was prepared in a 100 ml vacuum 
Erlenmeyer flask and degassed the solution under vacuum for 10 minutes. 300 
µI of 10% SOS, 300 µI of 10% APS, and 15 µI of TEMEO are quickly added and 
mixed by gentle swirling. The solution is then poured between the glass plates 
and then overlaid with a few ml of butanol saturated with Tris-HCI, (pH 6.8). The 
gel is allowed to polymerize overnight at 3°C. The stacking gel (2.5 ml 0.5 M 
Tris-HCI, (pH 6.8); 875 µI monomer solution, 6.525 ml dH20) is degassed for 10 
minutes, and 100 µI of 10% SOS, 100 µI of 10% APS, and 6 µI of TEMEO are 
added, mixed, and pipetted on top of the separation gel that has been washed 
with dH20. A 1.6 mm multi-well comb is carefully inserted between the plates 
and the gel is allowed to polymerize for 20-30 minutes. The comb is removed 
while applying 1 X Laemmli buffer to the top of the gel. The wells are flushed 
and filled with 1 X Laemmli running buffer. The samples in Laemmli sample 
buffer are boiled for 4 minutes, placed in room temperature water and loaded 
into the wells. The samples are separated with a constant current of 30 mA for 1 
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gel until the BPS band has reached the bottom of the gel. The glass plates are 
disassembled and the gel is either used for a western transfer (section Transfer 
of Electrophoreticaly Separated Proteins to Nitrocellulose Filters) or is enhanced 
and dried for fluorography. SOS-PAGE was also performed using a mini-gel 
system (Cat#67320). with the same solutions as described above. 
Fluorography of Polyacrylamide Gels 
To shorten film exposure time in the detection of radiolabeled compounds 
in polyacrylamide gels. Incubate the gel in ENTENSIFY-Part A solution for 30 
minutes, then in ENTENSIFY-Part 8 (NEN Research Products, Boston, MA) for 
30 minutes. Rinse the gel in dH20, place the gel on Whatman filter paper, dry 
the gel for two hours at 80°C and place it to film at -70°C using one enhancing 
screen. 
Solutions 
Transfer buffer 
Western Blot Analysis 
Mix 12 g of Trisma base, 57.6 g 
glycine, 800 ml methanol, and 
add 4 L of dH20. 
10 X Ponceau S solution 2% Ponceau S dye 
Tris buffered saline 
Blotto 
antibody dilution solution 
Enhanced Chemiluminescence 
30% trichloroacetic acid 
30% sulfosalicylic acid 
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Mix 9.68 g of Trisma base, 
116.96 g NaCl, and add 4 L of 
dH20. pH to 7.5 with 12 M HCI. 
Mix 5 g of dry, non-fat milk and 
add 100 ml of TBS. 
Mix 500 mg of dry, non-fat milk 
and add 100 ml TBS 
EGL kit (Boehringer Mannheim) 
Transfer of Electrophoretically Separated Proteins to Nitrocellulose Filters 
Electrophoretically separated proteins were subjected to Western blot 
analysis (Beck-Engeser et al., 1987). Briefly, SOS gel was soaked for 10 
minutes in 100 ml of transfer buffer. 3 Whatman pieces cut to the size of the gel 
were wetted in transfer buffer placed on a semi-dry transfer apparatus (Model 
#FB-SDB-2020, Fisher Biotech, Pittsburgh, PA) followed by the gel. The 
following sandwich was assembled. The gel is followed by a sheet of 
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nitrocellulose (BA85, 0.45 µm, Schleicher and Schuell, Keene, NH) cut to the 
size of the gel. Above the nitrocellulose is placed 3 additional Whatman sheets 
wetted in transfer buffer. Air-bubbles between the sheets were removed by 
rolling the sandwich with a pipette. Proteins were then transferred with a 
constant current of 10 mA-per cubic cm of sandwich for 2-2.5 hrs. The sandwich 
is then disassembled and the transfer of the proteins to the nitrocellulose is 
confirmed by Ponceau S staining for 10 minutes. The filter is then destained in 
TBS. 
lmmunodetection of Transferred Proteins on a Nitrocellulose Filter 
The membrane is then destained and blocked in Blotto for greater than 1 
hr, rinsed with TBS 2 X 15 minutes and incubated with the primary antibody (in 
antibody dilution solution) overnight at 4°C. After removal of the primary 
antibody the membrane is washed twice with TBS + 0.1 % Tween 20 (BioRad, 
Cat# 170-6531) for 15 minutes and incubated with the secondary antibody (in 
antibody dilution solution) overnight at 4°C. Finally, the blots are washed twice 
with TBS for 15 minutes and subjected to enhanced chemiluminescence (ECL) 
as recommended by the manufacture (Boehringer Mannheim). Rainbow protein 
molecular weight marker were included to determine molecular masses of 
proteins and to control for protein transfer. 
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Yeast Strains. Growth and Manipulation 
Yeast Strains 
The Saccharomyces cerevisiae yeast strains used in this work are listed 
and discussed in Chapter 3. 
Media and Reagents 
YEPD (non-selective complete medium) 
yeast extract (Difeo) 
bacto-peptone (Difeo) 
dextrose 
dH20 
10 g 
20 g 
20g 
to 1 L final volume 
Autoclave aliquots. For growth on plates, add 25 g Bacto-agar per 
liter of YEPD. 
Selective media 
a) Drop-out medium (single selective or multiple selective medium) 
dextrose 20 g 
yeast nitrogen base w/o 6. 7 g 
amino acids 
appropriate 10 X drop-out 100 ml 
stock solution 
50 mM inositol 
dH20 
1 ml 
to 1 L final volume 
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Autoclave aliquots. For growth on plates, add 20 g Bacto-agar per 
liter of YEPD. 
1 O X drop-out stocks: The 10 X drop-out solution will not contain the amino 
acid for selection. For example ura3 yeast will be grown in media without uracil 
to select for the presence of a plasmid containing the URA3 gene. Add the 
following volumes of each amino acid supplement except the one that is being 
"dropped-out". 
Table 5. --Amino Acid Supplements Used in Yeast Drop-out Media 
Supplement Stock concentration 500 ml total 
adenine 5 mg/ml 20ml 
arginine 20 mg/ml 5ml 
histidine 20 mg/ml 5ml 
leucine 10 mg/ml 30 ml 
lysine 115 mg/ml 10 ml 
methionine 20 mg/ml 5ml 
threonine 60 mg/ml 25 ml 
tryptophane 10 mg/ml 10 ml 
uracil 2 mg/ml 50ml 
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Add 340 ml of dH20 to the indicated amounts of amino acids and in place 
of the "dropped-out" supplement add the same amount of dH20. Mix thoroughly, 
make 100 ml aliquots, autoclave, and label according to the "dropped-out" 
supplement (e.g. 10 X Ura-). 
b) Media supplemented with canavanine 
dextrose 
yeast nitrogen base 
arginine drop-out stock 
50 mM insitol 
Agar 
dH20 
20 g 
6.7 g 
100 ml 
1 ml 
20 g 
to 1 L final volume 
Autoclave the mixture and cool to 57°C. Add the appropriate amount of 
stock canavanine solution to the media or aliquot of media to make an arginine 
dropout plate with the desired amount of canavanine. The average amount of 
canavanine to select a can1 strain of yeast is 60 µg/ml. 
Drop-out induction medium (Used to induce the transcription of genes driven by 
the ga/1-10 promoter). 
Drop-out induction media 
glycerol (80% stock) 
10 X drop-out stock 
yeast nitrogen base w/o 
37 ml 
100 ml 
6.7 g 
amino acids 
50 mM inositol 
dH20 
1 ml 
to 1 L final volume 
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Autoclave the mixture and cool to 57°C before the addition of 10 ml of 
100% EtOH. For plates add 20 g of agar per L of plates. Store at 4°C. 
Introduction of Recombinant Plasmids Into Yeast 
Solutions and Reagents 
All yeast transformations described below were performed in the presence 
of carrier DNA (section DNA Manipulations and General Solutions) except that 
the average fragment length was approximately 2.0-0.7-kb. 
Transformation buffer Mix 2.4 g LiAc, 4 g PEG, (pH 
5.0; MW 3550); 1.543 g OTT, 
and 100 ml of dH20. Freeze 
aliquots at -20°C. 
For transformation, 50 µg of the DNA was boiled for 10 minutes and then 
put to ice. After this carrier was sufficiently cooled, 1 µg of the plasmid to be 
transformed was added. 
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Yeast Transformation 
Yeast were transformed by the method of Chen et al., (1992). Resuspend 
5 X 107 pelleted yeast cells in "One-step" transformation buffer. Mix the 
resuspended yeast with 1 µg of plasmid DNA and 50 µg of single-stranded 
carrier DNA (boiled salmon sperm) in a total volume of 100 µI. Incubated the mix 
at 45°C for 45 minutes and plate 10 µI and 90 µI of the suspensions directly onto 
selective medium and incubate the plates at 30°C for 3-4 days. Usually 20 µI 
and 80 µI were the plated cell volumes. The same protocol was used to 
transform DNA fragments into yeast. 
Yeast Mating 
The method used was adapted from a protocol by Rob Barrington (Dawes 
and Hardie, 1979). Yeast strains to be mated were grown on YEPD plates for 3 
days to obtain healthy yeast. These yeast were used in the protocol below. 
Generation of Diploid Yeast and Isolation of Yeast Spores 
Media 
Sporulation Plates 
KAc (1 % final) 10 g 
yeast extract (0.1 % final) 1 g 
dextrose (0.05% final) 0.5 g 
Procedure 
Bacto-agar (1.5% final) 
dH20 
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15 g 
to 1 L final volume 
Healthy yeast were picked from a YEPD plate using a toothpick. A 1 X 1 
X 1 mm patch of each yeast (one strain a and one strain a) was mixed together 
with 5 µI of sterile dH20 (patch mating). The mixed yeast were allowed to mate 
overnight at 30°C. The mixed yeast were streaked onto sporulation plates and 
incubated for 4-5 days at 25°C. Haploid spores were identified by suspension of 
a small amount of cells in a drop of water on a microscope slide and observed by 
light-field microscopy. The haploid tetrads will appear as clusters of four smetil 
spheres held within a barley discernible sphere. Spores were isolated by 
extraction in ether (Dawes and Hardie, 1979). Briefly, 5 small patches of 
sporulated yeast were picked and put into a microcentrifuge tube containing 100 
µI dH20. The yeast were resuspended by brief vortexing. 300 µI of Ether was 
added to the mixture and vortexed once for 30 sec. The mixture was centrifuged 
for 5 minutes and decanted. This extraction procedure was repeated twice. The 
small pellet of material obtained after the final extraction contains separated 
spores (almost invisible). These spores were then resuspended in 100 ml of 
dH20 and dilutions were plated onto the appropriate selective media to obtain 
haploid yeast of interest. 
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Replica Plating of Yeast 
Yeast to be replica plated are grown on appropriate media. This master 
plate containing the strain or strains of interest is printed onto a velveteen square 
placed over a circular Plexiglas block by applying gentle pressure across the 
whole plate. A copy of this impression is transferred to plates made with all the 
relevant selective media including a plate identical to the one used as the master 
plate (positive control). 
Storage of Yeast Strains 
Yeast were stored as frozen stocks as described by Ausbel et al., (1990). 
Yeast were grown to late-log or early-stationary phase in appropriate media. 700 
µI of the resuspenede culture was mixed with 300 µI of 50% glycerol and frozen 
at -70°C. Cells are revived by taking a fraction of cells from the frozen stock and 
plating on the appropriate media (usually YEPD). 
CHAPTER IV 
RESULTS 
Rationale. Hypothesis and Overall Experimental Approaches 
mRNAs containing nonsense codons (nonsense mRNA) encode 
truncated polypeptides that can interfere with the function of their corresponding 
full-length polypeptides. However, levels of most nonsense mRNAs are reduced 
in prokaryotes and eukaryotes when compared to that of the corresponding wild-
type mRNAs (reviewed in Brawerman and Belasco, 1993). Genes that encode 
proteins responsible for the selective reduction of nonsense mRNA have been 
identified only in lower eukaryotes (reviewed in Maquat, 1995). One example is 
UPF1, a group I RNA helicase that is required to rapidly degrade cytoplasmic 
nonsense mRNA (Leeds et al., 1991, 1992; He et al., 1993). Since the half-lives 
of cytoplasmic nonsense p-globin mRNA (Cheng and Maquat, 1993; Belgrader 
et al., 1994) and immunoglobulin µ mRNA (Li and Jack, unpublished 
observations) are decreased when compared to the corresponding wild-type 
mRNA, I hypothesized that mammalian cells contain a UPF1-like system that 
reduces levels of nonsense mRNA. To clone, or identify, a mammalian 
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gene required to reduce levels of nonsense mRNA, I chose the following 
approaches, all of which make use of the yeast UPF1 gene. 
• First approach 
Hybridize mammalian genomic and cDNA libraries with a yeast UPF1 
DNA probe. 
• Second approach 
Transfect a upf1 yeast strain with a mammalian cDNA expression library 
and rescue yeast transformants with a UPF1-positive phenotype. 
• Third approach 
Determine whether the expression of a dominant-negative form of yeast 
Upf1 p in a mammalian cell correlates with increased levels of nonsense 
mRNA. 
• Fourth approach 
Search translated mammalian DNA and protein databases with the yeast 
UPF1 amino acid sequence and determine whether identified genes are 
structural and functional homologues of yeast UPF1. 
Because only the fourth approach led to the isolation of a mammalian 
UPF1 homologue, I will describe and discuss this approach in detail. However, 
in the next three sections I will briefly review the results of the first three 
approaches. I will only discuss at length the data from the first approach, 
because it resulted in the isolation of a rabbit TRAPa cDNA that encodes a 
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protein thought to be involved in the translocation of nascent polypeptide chains 
across the ER membrane. 
Hybridize Mammalian Genomic and cDNA Libraries With a Yeast UPF1 DNA 
Probe. 
The strategy to clone a mammalian homologue of the S. cerevesiae UPF1 
gene by hybridization was carried out using a number of straightforward 
molecular biological techniques and approaches. First, the yeast UPF1 gene 
was used as a DNA probe to screen mammalian genomic DNA and cDNA 
libraries. To detect genes that have partial homology to UPF1, the hybridization 
was carried out under low stringency. Second, to determine whether the isolated 
genes are structurally homologous to the S. cerevisiae UPF1 gene the nucleic 
acid sequence of the clone was determined. This approach, however, did not 
result in the isolation of a DNA clone with homology to UPF1. Instead, I cloned a 
cDNA encoding rabbit TRAPa, a protein that may be involved in the 
translocation of cytoplasmic proteins into the lumen of the endoplasmic reticulum 
(ER). 
Isolation of a Rabbit Genomic Clone that Cross Hybridizes 
With the Yeast UPF1 DNA Probe 
To isolate a mammalian UPF1 homologue, I screened a human 
complementary DNA (cDNA) phage library (Elledge et al., 1991) and a genorr.ic 
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rabbit DNA phage library. The human library was chosen because a yeast 
expression plasmid containing the human cDNA insert can be easily excised 
from the phage and tested for its ability to complement a upf1 allele yeast strain. 
The rabbit genomic DNA phage library (in EMBL4) was chosen for the following 
reasons. First, each gene should be represented in the library at least once, and 
second, filters containing about 3 X 1 as lifted plaques were made available to me 
by Dr. Knight. The UPF1 probe used to screen the libraries was a 1.3 kb-Oral 
fragment (Figure 1 a.A). This DNA fragment contains the entire UPF1 RNA 
helicase region. Mutations in this region can lead to dominant-negative forms of 
UPF1 that, when transformed into wild-type UPF1 strains, abolish the function of 
the wild-type UPF1, that is, nonsense mRNA has the same turnover rate as the 
corresponding functional mRNA. Therefore, a mammalian UPF1 homologue 
may have conserved this important functional region, and thus, may contain 
enough nucleotide homologies that the human or rabbit homologue could be 
detected by using the UPF1 helicase probe. The flow-chart in Figure 11 shows 
the individual steps of the hybridization approach and summarizes the major 
results. When I screened filters that contained 2.5 X 1 as individual phage from 
the human Hela cell cDNA phage library or the rabbit genomic phage library, I 
identified 2 genomic rabbit phage clones (Figure 1a.B and Figure 11, box 2) and 
no Hela cDNA clones that hybridized with the UPF1 RNA helicase probe. To 
find the region of nucleotide homology within the two rabbit genomic phage 
clones and the UPF1 RNA helicase probe, I proceeded to isolate total 
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Figure 10. Schematic representation of the regions of the UPF1 gene used as probes in library and 
Southern blot analysis. (A) The bar represents the UPF1 ORF. The regions used as probes are shown 
below the UPF1 ORF. (B) Autoradiograph of rabbit genomic phage clones R1, and R5 after 1 round of 
plaque purification. Phage clones were hybridized with UPF1 RNA helicase probe using low stringency 
hybridization conditions as described in materials and methods. 
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1 
Screen the human cDNA and rabbit 
genomic phage librarys with the UPF1 
RNA helicase probe 
2 
Identified 2 overlapping rabbit genomic phage 
clones that hybridize to the Yeast 
UPF1 RNA helicase probe 
3 
Identified a 6.4-kb 
fragment from both 
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The 6.4-kb fragment does 
not hybridize with the Yeast 
UPF1 gene fragment 
phage clones 8 
Identify in the 6.4-kb 
that hybridize with fragment a 2.0-kb Hindlll (5' end) 
f 
5 
Probe a human and rabbit cDNA 
library with the 6.4-kb rabbit DNA 
fragment 
6 
No 
human 
clones 
identified 
7 
3000 
rabbit 
clones 
identified 
the Yeast UPF1 fragment fragment that hybridizes with 
RNA 1------~ the yeast UPF1 RNA 
helicase probe helciase probe 
9 
Subclone the 2.0-kb fragment 
and identify a 560-nt fragment. 
Subclone and sequence the 
560-nt fragment. 
11 
•A region of 61 nucleotides 
shows a 72% identity 
to part of the RNA helciase 
region of UPF1 
•25 nucleotides of a continous 
26 nuclotide stretch within 
the 61-nt region are found 
in UPF1 
10 
Screen a rabbit cDNA 
library with the 560-nt 
fragment. 
No clones identified 
Continued on Next Page 
Figure 11. Flow chart representing steps taken during the isolation of a 
rabbit genomic clone that cross hybridizes with the yeast UPF1 DNA 
probe and isolation of a rabbit cDNA. 
12 
Use 26-nt oligos in northern 
blot analysis 
13 
Hybridization with sense oligo 
does not detect yeast UFP1 
or any rabbit RNA species from 
total RNA 
15 
14 
Hybridization with antisense 
oligo detects yeast UPF1 and a 
rabbit RNA species from total 
RNAs 
Screen Human and Rabbit cDNA 
libraries with the 26-nt antisense 
16 
No positives 
from the 
Human cDNA 
library 
oligo 
18 
17 
Identify 2 positives 
clones from the 
rabbit cDNA library 
Mapping of the 2 positive 
clones indicates that they are 
identical. Sequence analysis of a 
cDNA insert revealed that it encodes 
the rabbit homologue of the 
canine TRAPa gene. 
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phage DNA and map the regions of the 2 clones. The results demonstrated that 
although the two rabbit genomic clones are slightly different, they contain DNA 
restriction sites at similar sites throughout their insert regions. I conclude that 
these two genomic phage clones are overlapping. I also carried out low 
stringency Southern blot analysis on the same restriction enzyme mapped DNA. 
I was able to detect a 6.4-kb EcoRI fragment in both clones which hybridized 
with the UPF1 RNA helicase probe under low stringency conditions (Figure 11, 
box 3). I conclude that the 6.4-kb EcoRI fragment contains a region of 
nucleotide homology between the UPF1 probe and the fragment of rabbit 
genomic DNA. To determine if the rabbit genomic fragment also contains 
nucleotide homology to the 5'-end of the yeast UPF1 gene I used the 5' end of 
the UPF1 gene as a probe on the same Southern blot using low stringency 
conditions. From this Southern I conclude that the insert region of the rabbit 
genomic phage clone does not specifically hybridize to the 5' end of the UPF1 
gene (Figure 11, box 4). 
I used the 6.4-kb EcoRI fragment as a probe to isolate a cDNA fragment 
from a human or rabbit cDNA library (Figure 11, box 5). Unfortunately, I was not 
able to identify any human cDNA clones (Figure 11, box 6). However, by 
screening the rabbit cDNA library I was able to identify approximately 3000 
hybridizing phage plaques (Figure 11, box 7). It is possible that the hybridization 
of most phage clones is due to regions within the 6.4-kb probe that have no 
homology to the yeast UPF1 RNA helicase probe. To generate a smaller probe 
that hybridizes to the UPF1 RNA helicase probe, I subcloned the 6.4-kb EcoRI 
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fragment into a plasmid vector, digested the vector with restriction enzymes and 
determined by Southern blot analyses which of the rabbit fragments hybridized 
to the UPF1 RNA helicase probe (Figure 11, box 8) (data not shown). A 2.0-kb 
Hindlll DNA fragment was identified, isolated and subcloned into a plasmid 
vector. Southern blot analysis of restriction digestion of the 2.0-kb Hindlll 
fragment identified a 0.56-kb EcoRl!Pstl fragment that still hybridized with the 
UPF1 RNA helicase probe (Figure 11, box 9). The EcoRI site comes from the 
vector and the Pstl site is located within the 2.0-kb Hindlll fragment about 500-bp 
downstream of the vector SP6 site. I, therefore, predicted that if I sequence the 
plasmid that contains the 2.0-kb Hindlll fragment with a SP6 primer, I would be 
able to find the region of nucleotide identity between the UPF1 RNA helicase 
probe and the rabbit genomic DNA fragment. 832 nucleotides of the 2.0-kb 
insert were sequenced and confirmed the presence of a Pstl site 560-nt 
downstream of the SP6 site of the vector. When I searched the GenBank 
nucleic acid sequence database with the 832-nt rabbit sequence using the 
FASTA program (GCG Program Manual, 1994), I found that 72% of a 61-bp 
region (underlined position 399-460, Figure 12) of the 832-nt sequence are 
identical to the corresponding region in UPF1 (Figure 13). Within the 61-nt 
region of identity, there is a 26-nt region of 96% identity to UPF1 
(position 399-424 of the rabbit genomic fragment, position 2051-2077 of 
UPF1, Figure 14) (Figure 11, box 11 ). Additional analysis of the rabbit sequenr.e 
revealed the presence of a putative splice donor and splice 
20h35ssr.Txt Length: ~ February 3, 1995 
HindIII 
AAGCTTATCGATTTCGAACCCGGGGTACCGAATTCTCCTATCCCATGCAT 
GTGACTTCTAATATAATTATCAAATGTAGGACAGTGATACTGGACTTCAG 
GTGTTACTTAAATCCCATCAGTTTTCCCACTTGTATTCTTTTTCAGACCC 
AAGATCCTACACTGCGTTTGTCATTTCTCCCTGGTTTCCTGTAATCTGTG 
AGAGTTCCTAGGCCTCCCAGTCACTCCCCGTCTTTTATGATCTTAGTACT 
TTGACAGAATATTGGGCATTTTTTTTGGACCATGTCCTCAGGTTCTATTA 
TGTCTTTTTATTTTTTTTGTGATTGAAGAGAATTTTTGCATTTGTGGCGA 
GAAACAAATGATACAGTGTCCTTGGTGCAGGGTGTAAAGGGTTCTGTGA,T 
GTTGACATGTGTTGGTGCTGGTGACGTTAAQT.TTGAT.cACTTGGT'.rG~ 
TG1'.12AGQTTTGGACTCTAAAGCTGCTGCCCCTCCCTTTGCAGTTGGTAGA 
TATCTTGGGGGCATGTTTTCAGTGCAAATATGACTCCTCTCACATGTTCA 
TGTACTGATTTCAGCNTCGCTCGGTGGGGCTTGTCTGCAGCACTGAGGAG 
TTCCCTTTCCCTTCATTACCCTTGTTGAGTGGAGTCTTCTCAAGGAGGAG 
CTGTCCTTNNCCCGCATTTNTTTGCTTCTTAGCTCATCTCTGACTATGGA 
TATGGATTCAAGGGTACTTGCATNTTTCTNTNNGTCCACACCTACTACTT 
TCATGGTTTATTTNCTCAGATTGTGCAATTGTTGATCACGAGGAGCTCCT 
TCAGTTTGCCTCCTGTTTTCTTTCTAAAAGCC 
Figure 12. Partial nucleotide sequence of the 2.0-kb Hindi II fragment 
of the genomic rabbit clone R5. The Pstl restriction site is indicated 
in bold and the Hindlll cloning site is underlined. The region with 
nucleotide identity to the UPF1 probe is underlined. The identity was 
determined with a FASTA analysis using the 832-nt sequence. 
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Yscupfl. Gb_Pl 
phage clone #5 
SCORES Initl: 80 Initn: 80 Opt: 107 
72.1% identity in 61 bp overlap 
i~ TCVGAGDK Yscupf AGCAGAAATTCTCAATAAGGCAGATGTCGT TGTTGCACATGTGTTGGTGCTGGTGATAA 11111 111111111TIT11111111 RGF TCCTTGGTGCAGGGTGTAAAGGGTTCTGT TGTTG-ACATGTGTTGGTGCTGGTGACGT polyT--NCAGG T C V G A G D V 
R L ..... ~ Yscupf GCGCTTAGA-CACTAAATTTAGGACTGTGTT TTGATGAAAGTACTCAAGCTTCTGAGC 
11 I I I I 111 11 111 I I I I 
RGF TAACTTTGATCACTTGGTTGAGGTGTGAGGT TGGACTCTAAAGCTGCTGCCCCTCCCTT 
N F CAGGTGAG 
Figure 13. Original printout of the result of a FAST A analysis using 832 
nucleotides of the 2.0-kb Hindi II fragment of rabbit clone RS. Yscupf is part 
of the S. cerevesiae UPF1 DNA sequence and RGF (rabbit genomic 
fragment) is part of the sequence of DNA shown in Figure 12. Underlined are 
the putative splice donor and acceptor sites found within the rabbit genomic 
fragment flanking the region of identity. The splice consensus sequences are 
shown below the underlined region (reviewed in Genes IV, Lewin, 1994). 
The putative amino acid sequence encoded by the rabbit genomic DNA and 
UPF1 is shown above and below the respective nucleotide sequences. The 
aa changed in the D1 dominant- negative form of UPF1 is in bold and 
underlined. The region with 72% identity is shown betwee~ the arrows. 
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20h3prim.For 
Gb_Pl:Yscupfl 
LOCUS YSCUPFl 3546 bp ds-DNA PLN 12-MAY-1992 
DEFINITION Saccharomyces cerevisiae zinc finger protein (UPFl) gene, 
complete eds. 
ACCESSION M76659 
KEYWORDS UPFl gene; zinc-finger protein. 
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SOURCE Saccharomyces cerevisiae (strain GRF88) (library: Ycp50) DNA. 
SCORES 
20h3pr 
Initl: 80 Initn: 80 Opt: 92 
96.3% identity in 27 bp overlap 
10 20 
ATGTTG-ACATGTGTTGGTGCTGGTGA 
111111 11111111111111111111 
Yscupf AGCAGAAATTCTCAATAAGGCAGATGTCGTATGTTGCACATGTGTTGGTGCTGGTGATAA 
2030 2040 2050 2060 2070 2080 
Yscupf GCGCTTAGACACTAAATTTAGGACTGTGTTAATTGATGAAAGTACTCAAGCTTCTGAGCC 
2090 2100 2110 2120 2130 2140 
Figure 14. Origional printout of the result of a FAST A analysis using the 
26-nt sequence (nt position 399-424 in Figure 12). Yscupf is the 
S. cerevesiae UPF1 DNA sequence and 20h3pr is the sequence of the 
26 bp oligonucleotide used to perform the analysis. 
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acceptor site (Lewin, Genes IV, 1995). Between the putative splice sites, one of 
the possible ribosomal reading frames could translate a putative protein 
encoding amino acids identical to those of UPF1 (Figure 13). I conclude from 
these results that the cloned region of rabbit genomic DNA could contain an 
exon of a gene that is the rabbit homologue of the yeast UPF1 gene, or a least a 
rabbit RNA helicase. Translation of an mRNA encoded by this region could lead 
to the production of a protein that has Upf1 p like functions or RNA helicase 
activity. 
Isolation of a Rabbit cDNA 
To avoid extensive sequencing and exon/intron mapping of my genomic 
clone, I attempted to isolate a cDNA clone by screening appropriate libraries with 
a 26-nt oligomer that is identical to the 26-nt region (Figure 14). A 26-nt oligomer 
complimentary to the putative coding region of the rabbit genomic fragment was 
synthesized (26-nt antisense oligo) and used as a probe to determine if a RNA 
species can be detected in total spleenic RNA. When I performed northern blot 
analysis of total rabbit RNA from various tissues using the 26-nt antisense oligo 
as a probe, I detected a 1.3-kb band in total spleen RNA and a 3.6-kb band in 
yeast RNA with the 26-nt antisense oligo (Figure 11, box 14). The 3.5-kb band is 
very likely UPF1 mRNA because a UPF1 probe detects a band of the same size 
(data not shown). I screened 2.5 X 105 phage from a rabbit spleen cDNA library 
(a gift from Dr. Chander Raman) and from a human Hela cDNA library with the 
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26-nt antisense oligo (Figure 11, box 15). I identified two rabbit cDNA clones 
that hybridized with the 26-nt antisense oligo (Figure 11, box 17) but no phage 
clones were identified from the human cDNA library (Figure 11, box 16). cDNA 
inserts from the two rabbit phage clones were rescued from the page particles by 
using PCR and a primer set p.gt1 O.fow0.gt1 O.bac) that flanks the cDNA insert. 
Agarose gel electrophoresis of the PCR product from each phage clone revealed 
a product of 1.2-kb (data not shown). I predicted that if the 1.2-kb PCR product 
actually contains regions of nucleotide identity with the UPF1 gene it should be 
able to hybridize with a UPF1 RNA helicase probe. The PCR products were, 
therefore, subjected to Southern blot analysis under low stringency conditions 
using the UPF1 RNA helicase region probe. The results demonstrated that all 
PCR products as well as the original rabbit genomic phage clone are able to 
hybridize with the UPF1 RNA helicase probe while a DNA fragment amplified by 
PCR from a rabbit GAPDH cDNA or A--phage clones did not hybridize (data not 
shown). To determine whether the clones were identical, A- DNA was digested 
with various restriction enzymes. The results revealed the presence of identical 
restriction enzyme sites within both 1.2-kb inserts (Figure 11, box 18; data not 
shown). DNA sequencing of both clones was performed and revealed that their 
sequences are identical. The nt sequence of the 861 bp ORF of the two rabbit 
cDNA inserts differ by only one nucleotide (a wobble base leading to no aa 
change) and encodes for 286 aa (34.5-kDa). However, a poly(A)-addition signal 
sequence could not be located and comparison of the TRAPa sequence with the 
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putative RNA helicase region of UPF1 revealed that TRAPa does not contain a 
helicase domain. FASTA and TFASTA analysis (GCG Program Manual, 1994) 
showed that the rabbit sequence has a high degree of nucleotide and amino acid 
identity to that of the canine translocon-associated protein alpha (TRAPa) gene 
(GenBank accession #X51367; Figure 11, box 18) (Figure 15) a gene product 
found to be associated with the translocon and associated proteins (Figure 16) 
(Hartmann et al., 1993). 
The ORF has 89% and 94% identities to the canine TRAPa gene at the nt 
and aa level, respectively (Figure 15). The deduced aa sequences of both rabbit 
and canine TRAPa share conserved hydrophobic as well as acidic aa regions 
(Figure 15). Therefore, I conclude that I have isolated a full-length cDNA clone 
encoding rabbit TRAPa. Finally, part of the 26-nt antisense oligo sequence us~d 
to screen the rabbit cDNA library was located within the rabbit sequence 
(underlined and bolded in Figure 15), however, the sequence was translated in a 
reading frame that was different from that of yeast UPF1 (compare aa sequence 
250-255 in Figure 13 with aa sequence 551-555 in Figure 15). These results 
indicate that I have isolated a rabbit cDNA with a very high degree of nucleotide 
and amino acid identity to that of the canine TRAPa gene. Therefore, I conclude 
that I have cloned the rabbit homologue of the canine TRAPa gene whose gene 
product might be important for translocating nascent polypeptide chains from the 
cytoplasm across the ER membrane. 
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Figure 15. Comparison of nt and deduced aa sequences of rabbit and canine 
TRAPa. The nt sequence of rabbit TRAPa (rTRAPa) was determined as described 
(Sanger et al., 1977) from two cloned cDNA inserts. The nt sequence of canine 
TRAPa (cTRAPa) was retrieved from the GenBank database (accession no. 
X51367). In the alignments, a period indicates nt identity and a star a break in the 
nt sequence. The aa sequence predicted from the nt sequence of rTRAPa is 
shown above the codons in the single letter IUPC format, whereas only canine aa 
residues that are different from that of the rabbit aa sequence are shown below the 
canine nt sequence. The putative hydrophobic leader and transmembrane regions 
are underlined and the translational start and termination codons are double 
underlined. Acidic(-) and basic(+) aa residues are indicated and stretches of 
acidic aa residues, which are shared by rabbit and canine TRAPa. 
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Figure 16. Schematic representation of the translocon proteins o:, p, y, and 8. Putative disulfide bonds, 
carbohydrate moities, and charged residues are indicated. Adapted from Hartmann et al., 1993. 
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Characterization of the Rabbit TRAP a cDNA 
I carried out experiments in various mammalian cells to analyze the 
expression of TRAPa on the mRNA level in various mammalian cells (see Table 
4). I analyzed total RNA from a rabbit (B cell hybridoma, 96-1), mouse (B cell 
lymphoma, NYC) and the human (T cell line, Jurkat) by northern blot analysis 
using high stringency conditions and the complete rabbit TRAPa cDNA clone as 
a probe. Figure 17.A shows the results from this experiment. In rabbit lanes I 
detected bands of 1.3, 2.8 and 3.7 kb (lane 2), in mouse 1.3, and 2.8 kb (lane 6), 
and in human lanes bands of 1.3, 3.7, and 2.7 kb in size (lane 4). From these 
results, I assume that the 1.3-kb band most probably represents TRAPa mRNA 
because its size corresponds very well with that of my rabbit TRAPa cDNA 
clone. Because I detect in the rabbit, human, and mouse cells very slmilgr 
bands with the rabbit TRAPa probe, this gene is very likely conserved during 
evolution. This is further supported by the fact that TRAPa of other species such 
as human and trout (Hartmann and Prehn, 1994) are very similar to the canine 
and rabbit TRAPa. 
To determine if the mRNA species larger than 1.3-kb are TRAPa mRNA 
precursors, I carried out northern blot analysis on the same cell lines using RNA 
isolated from the cytoplasm where only completely spliced TRAPa mRNAs 
should be present. Figure 17 .A shows the results from this experiment. After 
probing the blot with the complete rabbit TRAPa gene, I was able to detect the 
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same bands in both total and cytoplasmic RNA from rabbit, mouse and human 
tissues (Figure 17 .A, lanes 1, 5, and 3 respectively). The purity of the 
cytoplasmic RNA was confirmed by absence of rRNA precursors (35S) in the 
EtBr stained gel (Figure 17.B). I conclude from these results that it is unlikely 
that the bands larger than 1.3-kb are TRAPa pre-mRNAs. Instead, they could 
represent alternatively spliced forms of TRAPa mRNAs or transcripts encoded 
by genes that are different from TRAPa but contain stretches of nucleotide 
identity to the TRAPa cDNA probe. 
TRAPa mRNA Expression In B Lymphoid Lines Representing a B and Plasma 
Cell 
Although TRAPa is not required in vitro for translocating nascent peptides 
across the ER membrane (Migliaccio et al., 1992), its close proximity to the 
translocon suggests a role in this process (Mathes et al., 1994). If TRAPa is 
involved in the translocation process of nascent polypeptide chains into the ER 
lumen, I would predict that TRAPa is expressed at higher levels in a cell with an 
extensive network of ER, which is characteristic for secretory cells. To test the 
idea, I analyzed TRAPa mRNA levels in antibody-producing cell lines that differ 
in their amount of ER and immunoglobulin secretion rate. I found that the 
antibody-secreting hybridoma cell NYCH, which represents a secretory plasma 
cell with an abundant network of ER (Jack et al., 1992), expressed 2-3 X times 
more TRAPa mRNA (1.3-kb) than the B lymphoma line NYC, which represents 
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a mature B cell with a less developed ER network (Jack et al., 1992) (Figure 18). 
Although it remains to be shown that TRAPa is required for polypeptide 
translocation across the ER membrane in vivo, our findings support the idea that 
it may play an important role in protein translocation. Whether the 2.8-kb 
species of RNA in mouse (2.8- and 3.7-kb in rabbit) play a role in producing 
TRAPa protein that aids in protein translocation is unknown. 
Conclusion 
The work above describes my attempt to clone the mammalian 
homologue of the S. cerevesiae UPF1 gene using low-stringency hybridization. 
When an expressed gene (cDNA) was finally isolated, I found that the rabbit 
cloned encoded a homologue of the canine TRAPa (Figure 15). The exact 
function of the canine TRAPa gene is not known. It is known to be a protein 
found to span the membrane of the endoplasmic reticulum (ER) (Wiedmann et 
al., 1987). Though its function is not known, it is possible (as deduced from its 
location) that it is involved with the process of protein translocation across the 
ER membrane (Prehn et al., 1990). It is in close proximity with three other 
proteins called TRAP ~' y and 8 and are thought to be part of the translocon 
(Hartmann et al., 1993), a group of proteins found at the site of protein 
translocation. So far there is evidence for and against the participation of 
TRAPa in the translocation of proteins with leader sequences across the 
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membrane of the ER. Cross linking experiments have identified TRAPa as a 
protein residing in the vicinity of the signal sequence of a polypeptide chain 
during the TRAPa-dependent targeting event (Wiedmann et al., 1987). 
Additionally, lgG or Fab fragments directed against the cytoplasmically exposed 
carboxy terminus of TRAPa block translocation of a secretory protein (Hartmann 
et al., 1989). Conversely, by using microsomal membranes made from TRAPa 
depleted detergent extracts of canine pancreas show that the depletion of 
TRAPa had no effect on the translocation of a secretory precursor (Migliaccio et 
al., 1992). However, so far no molecular analysis of TRAPa at the mRNA level 
have been investigated. If TRAPa is involved in the translocation process of 
nascent polypeptide chains, one prediction would be that TRAPa is expressed at 
higher levels in a cell with a secretory phenotype (an extensive network of ER). 
To test this hypothesis I analyzed TRAPa mRNA levels in antibody-producing 
cell lines that differ in the amount of their ER and potential to secrete antibodies 
(Jack et al., 1989). I found that the antibody secreting B cell hybridoma, (NYCH) 
which represents a secretory plasma cell with extensive ER produces 5 times 
more 1.3-kb TRAPa mRNA than its parent B cell line (NYC) (Figure 18). 
Although it remains to be shown that TRAPa is directly required for 
polypeptide translocation across the ER membrane in vivo, my findings support 
the idea that it may be important in protein translocation. The above conclusion 
is, however, based on mRNA expression analysis. First of all, the increase in 
1.3-kb mRNA levels have not been confirmed on the protein level using an 
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antibody against the TRAPa protein. Second, although there was a 5 fold 
increase in 1.3-kb mRNA level, there was no difference in 2.8-kb mRNA level. It 
appears that this mRNA is not under the same type of control as that of the 1.3-
kb species. This could be due to differential transcription rate or to different 
mRNA stability between the two cell types. Finally, it is not clear whether TRAPa 
protein is indeed transcribed from the 1.3-kb transcript. The 1.3-kb transcript 
could also be encoded by a cross-hybridizing gene. In this case, TRAPa would 
be encoded for by the 2.8-kb or 3.4-kb transcript. 
As mentioned above there is evidence for and against TRAPa's role in the 
translocation of nascent polypeptide chains into the lumen of the ER. The 
evidence described here indicates that when a cell secretes more proteins 
(immunoglobulin in this case) it makes more 1.3-kb TRAPa mRNA. Based on 
the assumption that the 1.3-kb TRAPa mRNA encodes the TRAPa protein, it is 
tempting to speculate that as a cell increases the size of its ER (and thus its 
secretion potential), it increases TRAPa production to facilitate the translocation 
process of secreted proteins. As mentioned above, TRAPa may not be essential 
for protein translocation. However, it could, together with essential proteins, 
serve as a translocation enhancer. 
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Transfect an upf1 Null Yeast Strain With a Mammalian cDNA Expression Library 
and Rescue Yeast Transformants With a UPF1-Positive Phenotype. 
Mammalian homologues of the yeast S. cerevisiae genes can be isolated 
by complementation of a mutant yeast strain with a candidate mammalian gene 
or a mammalian expression library. This process has a number of steps. First, 
the identification or generation of a strain that doesnt express the gene of 
interest (mutant allele) and changes its phenotype, for which one can select, 
depending on the presence or absence of the gene of interest. Second, the 
mutant yeast is then transformed with a cDNA library generated from the 
organism from which the homologue will be cloned. Third, yeast transformants 
are selected, or screened, for a positive phenotype. Fourth, the introduced gene 
is isolated from the yeast and analyzed for structural (sequence) and functional 
homology (antisense expression in mammalian cells). This approach is only 
successful if the mammalian gene product replaces the function of the absent 
yeast protein. 
The first goal was to generate a UPF1 mutant yeast strain (upf1) that 
changes its phenotype depending on the presence or absence of Upf1p, e.g. 
doesn't grow in the absence of an essential nutrient. For example, when the 
HIS4 gene contains a nonsense codon the mRNA is usually degraded and the 
yeast is unable to grow in the absence of histidine (Leeds et al., 1992), however, 
when the UPF1 gene is absent from this yeast cell the mRNA becomes stable 
leading to an increase in his4 mRNA levels and, due to a subsequent ribosomal 
read-through of the nonsense codon, an increase in the level of His4p. Although 
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this selection scheme is useful to isolate upf1 mutant yeast strains, it might be 
difficult to use it for isolating a mammalian homologue. This is because the 
complementation of a upf1 mutant would render a His+ cell His-, which would 
require the replica-plating of thousands of transformants on His- and His+ plates. 
The selection system I have devised uses negative selection marker in S. 
cerevisiae, the CAN1 gene product. The CAN1 gene encodes arginine permase, 
a outer transmembrane protein that transports the amino acid arginine. The 
CAN1 gene product can also import the toxic arginine analogue canavanine. 
Canavanine is able to act as a chain terminator during protein translation and 
leads to the death of the yeast cell. As expected, cells that have a functional 
CAN1 gene are sensitive to medium containing canavanine and cannot grow 
whereas can1 yeast (CanR) are able to grow in canavanine (reviewed by 
Rosenthal, 1977). My selection system employs the CAN1 gene to select for 
upf1 mutant yeast cells that have been complemented with a mammalian UPF1 
homologue. I proposed to generate a yeast strain containing a can1 gene with a 
nonsense codon (canavanine resistance) and a defective UPF1 gene. If the loss 
of UPF1 leads to an increase in nonsense can1 mRNA and if there is enough 
translation read-through, more Can1 p should be synthesized, leading to a 
canavanine sensitive phenotype. Or in other words, the yeast cells should not 
grow in the presence of canavanine (Figure 19). The complementation of this 
sensitive strain with a mammalian UPF1 homologue would then lead to the 
Inactivate UPF1 in yeast containing 
a can 1 gene with a nonsense 
codon (nonsense can1 mRNA) 
Test whether yeast is 
If So/ sensitive to canavanine 
, ~Not 
Stop Approach 
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'-.... Transform Cans, upf1 yeast with 
mammalian cDNA yeast expression 
library and plate transfectants on 
plates supplemented with canavanine 
Transformants that complement the/ 
upf1 defect will degrade the can1 
nonsense mRNA and survive 
/ 
Rescue the complementing 
cDNA for further analysis 
Figure 19. Schematic diagram of the complementation approach to 
isolate a mammalian UPF1 homologue by complementation of a UPF1-
yeast strain. Can1R, grows in canavanine, Can5 , doesn't grow in 
canavanine, UPF1-, UPF1 is deleted. 
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degradation of the nonsense can1 mRNA and thus, to decreased Can1p levels. 
Consequently, yeast cells that have been complemented with a functional UPF1 
homologue, should grow in the presence of canavanine (Figure 19). In this way 
only yeast receiving a mammalian homologue of the UPF1 gene would grow and 
these cells could easily be isolated for study. Because I was unable to generate 
a suitable upf1, can1 nonsense, yeast strain, I will only briefly discuss this 
approach in the following sections. 
Creation of a Selectable Yeast Strain That Changes Its CAN1 Phenotype 
Depending on the Presence of Upf1 p 
To carry out this approach I obtained yeast strains that contain can1 
genes with different nonsense codons (Ono et al., 1983) and a UPF1 mutant 
strain (Table 6) (Leeds et al., 1991). These strains were tested and have the 
correct phenotypes (data not shown). One important part of the UPF1 positive 
selection system is that the levels of can1 nonsense mRNAs are decreased in 
the presence of the Upf1 p. Because at the beginning of these experiments I 
didn't have an antibody against the Upf1 p, I performed northern blot analysis and 
found that nonsense can1 mRNA levels in the three strains Ono 279, 280, and 
284, were approximately 50% lower when compared to the steady state level of 
functional CAN1 mRNA in the parent strain Ono26 (data not shown). From 
these results I conclude that the presence of an UPF1 mRNA correlates 
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Table 6. Yeast Strains 
Strain Genotype Source 
Ono 26 MA Ta leu2-1, 112 metB-1 B.I. Ono 
Ono 280 MATa leu2-1, 112 can1-204 metB-1 B.I. Ono 
Ono 284 MATa leu2-1, 112 can1-202 metB-1 B.I. Ono 
PLY154- MATa upf1-D1 ura3-52 trp1-D1 rpb1-1 his4-38 This work 
ura3::his4 leu2-1 ura3::HIS4 
PLY154 MAT a upf1-tl 1 ura3-52trp1-tl1 rpb1-1 his4-38 M. Culbertson 
leu2-1 
Y06-15C MATa ade2-1 arol-1 can1-100 leu2-2 ilv1-2 B.I. Ono 
his4-166 lys2-101 metB-1 
SL988-11A MAT a leu2-1 Jys2-1his3-tl1 ura3-52 trp1 S. Liebman 
with a decrease in the steady state level of can1 mRNA containing a nonsense 
codon when compared to the parent strain. This result raises the possibility that 
upon elimination of the UPF1 gene in the can1 nonsense codon yeast strains, 
the level of can1 nonsense mRNA will increase and that this increase combined 
with possible ribosomal read-through of the nonser.ise codon will lead to the 
production of enough Can1 p to change the phenotype of the UPF1 mutant strain 
from canavanine resistant to canavanine sensitive. 
The following briefly describes the steps involved in the generation of a 
suitable yeast strain that can be used to select for the presence of a mammalian 
UPF1 homologue (Figure 20). First, I inactivated the URA3 gene by insertion of 
a selectable marker. This will allow selection of transformants containing URA3 
upf1- Strain 
I KO 
' URA3 Make Diploids 
and Sporulate 
DJ A+a 
Ono strains containing a can 1 gene 
with a nonsense codon 
/ 
Select for presence of His+ (50% are UPF1-) 
~ 
Screen Ura3- yeast by replica plating to Ura- plates 
Select for Upf1- yeast colonies 
by plating on leu- plates 
/I\ 
Confirm absence of Upf1 gene by 
northern blot analysis 
~ Study Further f 
Test upf1 (Upf1-), ura3 (Ura3-) yeast for canavanine sensitive. If yeast are only 
canavanine sensitive, it indicates that the absence of UPF1 may be de-suppressing 
the can1 nonsense mRNA leading to the production of CAN1 protein and thus, 
canavanine sensitivity. Confirm this effect by UPF1 transformation and 
complementation. If both canavanine sensitive and canavanine resistant yeast exist 
it indicates that the absence of upf1 cannot de-suppress the can1 nonsense mRNA 
and the yeast cannot be used to identify a UPF1 mammalian homologue by 
complementation. 
Figure 20. Flow chart to generate a suitable yeast strain to isolate a 
mammalian UPF1 homolgue by complementation. 
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plasmids (data not shown). To generate a upf1, ura3, nonsense can1 strain 
which will finally be used as the recipient for the mammalian cDNA library, I used 
a mating and sporulation approach. To do this the appropriate yeast strains 
(PL Y154 ura3::HIS4, with Ono 26, 280, 284) were mated, sporulated, and 
selected for the presence or absence of appropriate markers according to the 
protocol described in materials and methods. To select for the presence of the 
upf1 gene disrupted by an insertion of the HIS4 gene, the haploid segregates 
were screened for the ability to grow in His- media. Because the can1 nonsense 
codon strains (Ono 26, 280, 284) all contain a wild-type HIS4 gene, I expected 
that only 50% of the His+ yeast would contain a disrupted UPF1 gene. To 
identify the yeast with a disrupted UPF1 gene I replica-plated the His+ yeast 
colonies on plates without leucine. Because the haploid segregates contain 
either a UPF1-suppressable (leu2-1) or UPF1-non-suppressable (leu2-1, 112) 
allele of the leu2 gene, only cells that do not have UPF1 and contain the 
suppressible allele of leu2 can grow in the absence of leucine. The Leu+ yeast 
colonies were then replica plated onto Ura- plates to obtain yeast that are 
auxotrophic for the library selection marker (URA3). To confirm the absence of a 
functional UPF1 gene, RNA from these yeast colonies was subjected to northern 
blot analysis using a UPF1 probe (Figure 21). The results demonstrate that the 
Ura-, His+, Leu+ yeast colonies do not express UPF1 mRNA when compared to 
the parent Ono strains. These yeast colonies will contain either a wild-type or 
nonsense codon CAN1 allele (to be discussed below) (Figure 20). 
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Figure 21. Northern blot of total yeast RNA using a UPF1 probe. 5 µg of total RNA from HIS+, URA+, LEU+ yeast 
colonies was subjected to northern blot analysis using a complete UPF1 probe. Filters were exposed for 2 days at -70°C 
using one enhancing screen. Ono 279, 280, 284 contain a nonsense can 1 mRNA and Ono 26 contains a functional 
CAN1 gene and serves as a positive control for hybridization. Sizes (in kb) of molecular size markers are indicated on 
the right of the blots. EtBr staining (not shown) verified that about the same amount of RNA was loaded in all lanes. --l. (j) 
--l. 
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To test whether the upf1 mutant yeast is able to suppress a can1 
nonsense codon allele and change the phenotype of the yeast from canavanine 
resistant to canavanine sensitive, I determined the sensitivity of the yeast 
colonies to canavanine. Briefly, yeast were grown overnight in liquid cultures 
and counted according to the optical density. Ten-fold dilutions of cells were 
spotted onto plates containing increasing levels of canavanine from 0 µg/ml to 
150 µg/ml. All the parent strains used to create the new haploid crosses were 
also plated on these plates to control for a wild type CAN1 or a nonsense can1 
gene. Each cross of the upf1 null strain with Ono 280 as well as Ono 284, both 
of which contain nonsense can1 genes, yielded colonies that are completely 
resistant to canavanine, or that are completely sensitive to canavanine (Figure 
22). This suggests that all yeast colonies received a CAN1 allele from either the 
upf1 parent (PLY154 ura3::H/S4, CAN1), or from the Ono strains (Ono nonsense 
strains, can1). Further, I conclude that the absence of Upf1p does not lead to 
the suppression of the can1 nonsense codon mRNA in Ono 280 and Ono284. 
Thus, none of the crossed yeast strains, although some of them contain a 
nonsense can1, and each of them upf1, are suitable for the selection of a 
functional UPF1 gene or mammalian homologue. 
Conclusion 
I have shown here that the presence of a UPF1 gene correlates with the 
PLY 167 (UPF1- I Can1 +) 
Ono 26 (UPF1+ I Can1+) 
Ono 26 (UPF1- I Can1 +) 
Ono 280 (UPF1 +I Can1-) 
Ono 280 (UPF1- I Can1-) 
Ono 284 (UPF1+ I Can1-) 
Ono 284 (UPF1- I Can1-) 
0 20 40 60 80 100 120 140 160 
Canavanine concentration µg/ml 
Figure 22. Growth of various yeast strains on canavanine . Bars represent the degree of growth of 
various mutant UPF1+1-, CAN1+1-yeast strains on canavanine plates. 
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0) 
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decreased steady state level of a can1 mRNA containing a nonsense codon. 
Unfortunately when the UPF1 gene is absent, the phenotype of the mutant yeast 
cells does not change from canavanine resistant to canavanine sensitive. 
Because this change does not occur, it is not possible to use these yeast strains 
as recipients for a mammalian cDNA library to select for cDNA clones that 
complement the upf1 defect. Two explanations might be that levels of can1 
nonsense mRNA do not significantly increase in upf1 cells or that an increase in 
Can1p is not enough to confer canavanine sensitivity. 
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Determine Whether the Expression of a Dominant-Negative Form of Yeast Upf1 p 
In a Mammalian Cell Correlates With Increased Levels of Nonsense mRNA 
Overall Approach and Rational 
The use of dominant-negative genetic systems has become widespread in 
identifying the function of a gene in lower eukaryotic and mammalian organisms. 
This technique involves the expression of a truncated or mutant form of a gene 
whose product can interfere with the normal function of its corresponding wild 
type gene. The mutant gene is thought to interfere by competing for interacting 
molecules, thereby inhibiting the ability of the wild type gene product to carry out 
its intended function, or by interacting directly with the wild type gene product 
and, thereby, eliminating its function. Alternatively, a truncated or wild-type 
polypeptide could gain a function, which interferes with other physiological 
processes within a cell. 
It is possible that dominant-negative forms of Upf1 p (Upf1-D1 p ), which 
have been identified in yeast cells, could also act dominant-negative in a higher 
eukaryotic cell. If mammalian cells contain a UPF1-Like protein, I expect that the 
expression of yeast Upf1-D1 p in a mammalian cell could result in increased 
levels of nonsense mRNA (Figure 23). If this is the case, it would be the first 
evidence that a UPF-Like system exists in mammalian cells. 
bla 
UPF1-D1 
p~-actin 5, '''·;m 3' Mouse Hybridoma VXH 
-A...._ r::-caplntron j 
p:!~~~~r~~-vf ..... j ------ Measure UPF1-D1 mRNA, µ nonsense mRNA, 
• and Upf1-D1p levels in 
stable transfectants 3' Stable 
poly(A) Transfectants 
Figure 23. Strategy to identify a UPF1-like system in a mammalian cell by expression of a dominant-
negative form of UPF1. The Schematic representation of the cloning of UPF1-D1 into the expression 
vector pHp-APr-1-neo and subsequent transfection into the mouse B cell hybridoma VXH. Structure of the 
nonsenseµ mRNA in VXH is shown in the cell. The exons are indicated by boxes (VH variable; C, 
constant) and the length of translation products by lines below the mRNA. The position of the nonsense 
codon at the end of the VH exon is represented by the X. 
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CJ) 
m 
167 
Generation of a Mammalian UPF1-D1 Expression Vector 
To determine if a dominant-negative form of the yeast Upf1 p can block the 
function of a putative mammalian factor that controls nonsense mRNA levels, I 
obtained a dominant-negative UPF1 mutant gene. This gene called UPF1-D1, 
contains a missense mutation within the RNA helicase region (Gly556Asp). Wild 
type yeast transformed with this mutant UPF1-D1 behave as if they lack the 
UPF1 gene, that is, they grow in the absence of leucine, although they still 
contain a nonsense leu2-1 mRNA (see page 34 for explanation). From these 
results it was determined that this UPF1 mutant acts in a dominant-negative 
fashion on the wild type UPF1 expressed within the same cell (Leeds et al., 
1992). To carry out this approach, I cloned the UPF1 and UPF1-D1 genes into a 
mammalian expression vector as described in Figure 24. To confirm that the 
UPF1-D1 construct was not altered during the cloning procedure, I confirmed the 
01 mutation by DNA sequencing and performed western blot analysis on in vitro 
transcribed-translated products generated from an UPF1-D1 plasmid. I was able 
to detect the 01 mutation after the swapping of the 01 fragment (Figure 25) and 
a radiolabeled band of the same size produced from in vitro transcribed-
translated UPF1 and UPF1-D1 plasmids (Figure 26). This indicates that the 
cloning of UPF1 and UPF1-D1 did not alter the ORF. 
1 
2 
3 
4 
Eco47111 
Eco47111 
3' UTR 
BamHI 
' 
To remove the 3' UTR, partially digest p73+UPF1 with Eco47111, 
isolate the 8.9-kb fragment and completely restriction digest the 
fragment with BamHI. Blunt the ends of the fragment and ligate the 
product. 
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PCR amplify the 5' ORF using a 
chimeric 5' end primer that adds a 
EcoRI site immediately upstream 
of the A TG translation start site. 
EcoRI l!!I BsaBI 
Digest p73+UPF1/-3'UTR with / 
EcoRI and BsaBI and remove 
the 5' UTR fragment. Replace 
the missing region of ORF with 
the new PCR product 
Isolate the DNA fragment containing 
the UPF1-D1 mutation on a BstXl/Nrul 
fragment from the plasmid pUPF1-D1 
BstXI !!!!!!!I Nrul 
Digest p73+UPF1/-5'3' with 
BstXI and Nrul and remove / 
a region of the ORF. Replace 
the missing region with the 
UPF1-D1 mutant fragment 
• 
Remove UPF1 and UPF1-D1 on a 
Sall/Xbal fragment and ligate into 
pHb-APr-1-neo prepared with 
Sall/BamHI using a two step ligation. 
Figure 24. Schematic representation of the steps taken to clone UPF1 and 
UPF-01 ORF into the mammalian expression vector pH~-APr-1-neo. The 
restriction enzyme sites used are listed and a Sall and Xbal sites are 
represented by a (S) and (X) respectively. 
UP Fl ATGTCGTATGTTGCACATGTGTTG~TGCTGGTGATAAGCGCTT 
UPFl-Dl ATGTCGTATGTTGCACATGTGTTGATGCTGGTGATAAGCGCTT 
UPFl-Dl 
swap sequence ATGTCGTATGTTGCACATGTGTTGATGCTGGTGATAAGCGCTT 
Figure 25. Partial sequences of the wild-type UPF1 and 
corresponding sequences in a dominanat-negaitive form of UPF1 
(01). The UPF1 and UPF1-D1 sequence are described in Leeds et 
al., 1991; UPF1-D1 swap sequence was deduced by sequencing 
p73+UPF1-01/-5'3' with the primer UPF1 .bak. 
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Figure 26. Western blot analysis of yeast cell lysates and UPF1 IVTL products. (A) Various amounts of 
total yeast lysate (as indicated) and (B) 5 or 10 µI of whole UPF1 or UPF1-D1 IVTL product were 
separated on a reducing 10% SDS/PAG. The gel was transferred to nitrocellulose and incubated with anti-
UPF1 rabbit antisera (from Jacobson) at 1 :200. The rabbit anti-UPF1 antibodies were detected using a 
HRP-labled goat anti-rabbit lgG (1:7000) followed by ECL detection. The total yeast lysate western was 
exposed for 5 minutes to film and the UPF1 IVTL western was exposed for 30 minutes. 
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Expression of UPF1 and UPF1-D1 in Mouse B cells 
Containing a Nonsense mRNA 
171 
To test whether either the wild-type UPF1 or the dominant-negative UPF1 
interfere with a putative mammalian UPF1 homologue, I individually transfected 
the UPF1 or UPF1-01 expression vectors into a mouse B cell hybridoma that 
contains a nonsense codon within the second exon of the lg µ heavy chain 
mRNA (indicated with an X Figure 23) (VXH, Jack et al., 1989). VXH cells stably 
transfected with the UPF1, UPF1-01, as well as an empty vector were screened 
by northern blot analysis for their ability to express the UPF1 or UPF1-01 mRNA. 
Northern blots revealed the same size band in VXH transfected cells and yeast 
cells (Figure 27, lanes 1-7 and 10-15). From this I concluded that my transfected 
UPF1 and UPF1-D1 genes can be transcribed into mRNA. The same northern 
blot was also subjected to probing with a mouse µ cDNA probe as well as a 
GAPDH probe to control for total RNA loading. The levels of hybridization of 
these probes were quantitated using Betascope blot analysis. After 
normalization for RNA loading I found that the level of µ nonsense mRNA was 
unchanged in cells transfected with the UPF1-D1 expression vector when 
compared to the negative control (VXH with vector alone) (Table 7). To test 
whether the UPF1 and UPF1-01 mRNAs can be translated, I performed weste:-n 
blot analysis of the transfected cells. I found that I could also detect a protein of 
the same molecular weight in my UPF1-01 expressing cells (Figure 27, lanes 2, 
4, and 14; and Figure 28 1-3) using an anti-UPF1 antibody (gift from A. 
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Figure 27. Northern blot analysis of VXH cells stably transfected with UPF1-D1 
expression vector and vector alone. 1 Oµg of total RNA from VXH (lab 
nomenclature: GAMO 12.8.10) stably transfected with UPF1-D1 (lanes 2, 3, 4, 5, 
6, 7, 11, 12, 13, 14, 15) and vector alone (~-actin) transfectants (lanes 8, and 16) 
as well as the VXH parent cell line FH (lab nomenclature: LOCB 83.13.13.1) 
(lanes 9, and 17) were subjected to northern blot analysis as described in 
materials and methods and first, probed with a mouse µ cDNA, and second, a 
UPF1 probe. RNA from yeast Y06-15C in lanes 1, and 10 served as a positive 
control for UPF1 hybridization. To control for RNA loading, the blot was finally 
hybridized with a rabbit GAPDH cDNA probe (data not shown). 
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Table 7. --Quantitation of Northern Blot Analysis in Figure 27a 
Hybridomas RNA µ pre-µ GAP DH rel [µ] rel [pre-µ] %µ % pre-µ 
loaded [µ/GAP DH] [pre-µ/GADPH] %VXH %VXH 
[CPM] [CPM] [CPM] 
FH Blot A 5 µg 455.5 6.3 8.2 55.5 0.77 2000% 154% 
VXH/p-actin (#4) 5 µg 21.2 3.9 8.0 2.7 0.50 100% 100% 
VXH/UPF1-D1 (#2) 5 µg 12.7 4.3 9.3 1.3 0.46 48% 92% 
VXH/UPF1-D1 (#3) 5 µg 21.5 6.7 10.4 2.0 0.64 74% 128% 
VXH/UPF1-D1 (#7) 5 µg 16.3 4.1 14.7 1.1 0.28 40% 56% 
VXH/UPF1-D1 (#10) 5 µg 24.8 5.1 10.2 2.4 0.50 88% 100% 
VXH/UPF1-D1 (#11) 5 µg 23.6 6.5 11.2 2.9 0.58 107% 116% 
VXH/UPF1-01 (#13) 5 µg 13.5 5.5 16.0 0.8 0.34 29% 68% 
FH Blot B 5 µg 245.5 5.7 7.8 31.5 0.73 1350% 160% 
VXH/p-actin (#4) 5 µg 11.9 2.4 6.4 2.3 0.45 100% 100% 
VXH/UPF1-D1 (#15) 5 µg 10.5 6.6 8.6 1.1 0.77 48% 171% 
VXH/UPF1-D1 (#16) 5 µg 13.4 8.7 10.5 0.9 0.82 39% 182% 
VHX/UPF1-D1 (#17) 5 µg 9.8 4.0 12.8 0.5 0.31 21% 68% 
VXH/UPF1-D1 (#19) 5 µg 22.2 7.7 13.9 0.9 0.55 40% 122% 
VXH/UPF1-D1 (#20) 5 µg 20.7 7.8 10.9 1.4 0.71 61% 157% 
aRadioactivity of respective bands in each Northern blot (CPM) was determined by using a betascope blot analyzer. 
Relative steady-state level of respective RNA was calculated by dividing CPM of µ by that of GAPDH in the same lane. 
% [µ] is the percent of[µ] relative to that of untransfected hybridoma FH by setting FH (cells containing the same µgene 
as VXH cells except that the stop codon TAG reverted to AAG) value equal to 100%. 
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Figure 28. Western blot of protein lysates of VXH cells stably 
transfected with a UPF1 or UPF1-D1 expression vector. Protein from 8 
X 105 cells was separated by reducing SOS/PAGE, transferred, and 
probed using an rabbit anti-UPF1 peptide antiserum (1 :200). The 
antibody-antigen complex was detected using a HRP labled-goat anti-
lgG antiserum (1:10,000) followed by ECL detection. The bands were 
detected by fluorography using a 5 minute exposure. Lanes 1-3, UPF1-
D1 transfected cells; lane 4, UPF1 transfectants. Lane 5, untransfected 
VXH and lane 6, total yeast lysate. Bands detected within the 
bracketed region are mouse y2b heavy chains that cross react with the 
goat anti-rabbit lgG secondary antibody. 
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Jacobson). It is possible that the yeast Upf1 p or Upf1-D1 p folded at 37°C are 
unable to act in a dominant-negative fashion. Therefore, I repeated the northern 
blot analysis with cells that were grown at 30°C, a temperature at which yeast 
cells are normally cultured in the lab. Northern blot analysis of these 
transfectants revealed the same results as obtained with cells grown at 37°C 
(data not shown). From these results, I conclude that the amount of Upf1-D1 p, 
or wild-type Upf1 p that is synthesized in stable VXH transfectants does not result 
in a decrease of nonsense µ mRNA. 
Conclusions 
If mammalian cells contain a UPF1-Like protein, I expected that the 
expression of yeast Upf1-D1p in a mammalian cell could result in increased 
levels of nonsense mRNA. If this is the case, it would be the first evidence that a 
UPF-Like system exists in mammalian cells. To test this hypothesis, cells 
containing a µ nonsense codon-containing mRNA were transfected with a 
construct designed to promote high level expression of Upf1-D1p, a dominant-
negative form of Upf1p. Stable transfectants expressed the UPF1-D1 mRNA 
and low levels of Upf1-D1 p. No change in nonsense µ mRNA was observed. 
This result could be due to a number of reasons. First, the level of Upf1-D1 p 
produced was not high enough to interfere with the mammalian nonsense mRNA 
reduction system. Second, the levels of Upf1-D1p were sufficient to have a 
presumed effect but a UPF-Like system does not exist in mammalian cells. 
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Search Mammalian DNA Databases With the Yeast UPF1 Amino Acid Seguence 
and Determine Whether Identified Genes are Structural and Functional 
Homologues of Yeast UPF1. 
To identify human or other mammalian homologues of genes that have 
been previously cloned in lower organisms, one could compare the cloned 
sequence to mammalian nucleic acid and protein databases. If a human gene 
fragment is found, it could then be used to isolate the complete gene from a DNA 
library. A complete gene could then be sequenced and tested for its function as 
discussed below. 
Using the XREFdb to Search for Mammalian Homologues of the Yeast UPF1 
Gene 
Recently a number of new search programs and databases have been 
developed for researchers who want to find a human, rat, or mouse homologue 
of genes cloned from lower eukaryotic organisms. One such search program is 
the XREFdb program (Basset et al., 1995) which is accessible via the world wide 
web (http://www.ncbi.nlm.nih.gov/XREFdb/). The XREFdb provides BLAST 
similarity searches (TBLASTX; Altschul et al., 1990) with an amino acid 
sequence provided by the user. XREFdb searches databases that contain 
Expressed Sequence Tags (EST) (Boguski et al., 1993) and Sequence Tagged 
Sites (STS} (Green et al., 1989) of cloned DNA and cDNA fragments. The query 
sequence submitted to the XREFdb is compared once a month with the rapidly 
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and ever expanding database of DNA sequences generated from the human and 
mouse genome projects and a report of the identified genes is sent to the user 
who submitted the search. 
To identify mammalian homologues of the S. cerevisiae gene UPF1, I 
submitted the Upf1 p sequence (SwissProt accession #P30771) to the XREFdb 
for the first time in September 1995. In both September and October 1995, 
XREFdb E-mail reports were sent to me with no significant matches. In 
November 1995, a XREFdb report was received that contained a number of 
alignments between amino acid sequences deduced from human EST cDNAs 
clones and the Upf1 p. 
Analysis of Clones Whose Sequence Matched That of UPF1 
The original data report that was sent in November, 1995, by the XREFdb 
is shown in Figure 29. When I located the regions that matched with the EST 
sequences in the UPF1 sequence, I found that all EST sequences aligned with 
the RNA helicase region of the Upf1 p (Figure 30). Further analysis of the 
alignments revealed three subsets of matched sequences. The first subset 
contains the first two genes identified in the XREFdb report (GenBank accession 
#F06433 and #R13609). These two human EST cDNAs, which were derived 
independently from same library (a human fetal brain cDNA library constructed 
by Benito Soares, M. Fatima Bonaldo, Hillier, L., The WashU-Merck EST Project, 
unpublished, 1995) share a large amount of identical amino acid residues 
(Figure 29). This suggests that they originated from the same transcript. 
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Figure 29. XREFdb announcement that my UPF1 query sequence has been 
matched to a number of recently sequenced human cDNA EST clones. Sbjct 
indicates the marked EST sequence; query, the submitted UPF1 sequence; 
positives, the number of identical and similar amino acid matches between the 
indicated sbjct and query. 
EST Similarity Search Report: (TBLASTN vs. human/mouse/rat dbEST subset) 
Gene name(s): NAM7/UPF1 Searched: 28 Oct 95 
GenBank Mapped? 
New? NCBI_ID: Accession: P value: N: Matrix: Hiscore: (Probe #) 
New 122095 F06433 4.le-38 2 BLOSUM62 183 Yes(#l65)* 
Organism: 
Library: 
source: 
E-mail: 
Phone: 
H.sapiens 
normalized infant brain cDNA 
Genethon 
genexpress@genethon.fr 
33169472800 FAX: 33160778698 
Score = 183 (83.9 bits), Expect 4.le-38, Sum P(2) 4.le-38 
Identities= 37/68 (54%), Positives= 43/68 (63%), Frame= +2 
Query: 624 LISLGHVPIRLEVQYRMNPYLSEFPSNMFYEGSLQNGVTIEQRTVPNSKFPWPIRGIPMM 
L+ LG P RL+VQYRM+ LS FPSN+FYEGSLQNGVT R F WP PM 
Sbjct: 146 LVXLGIRPXRLQVQYRMHSALSAFPSNIFYEGSLQNGVTAADRVKXGFDFQWPQPDKPMF 
Query: 684 FWANYGRE 691 
F+ G+E 
Sbjct: 326 FYVTQGQE 349 
Score 174 (79.8 bits), Expect= 4.le-38, Sum P(2) = 4.le-38 
Identities = 32/47 (68%), Positives = 40/47 (85%), Frame = +3 
Query: 
Sbjct: 
576 QASEPECLIPIVKGAKQV!LVGDHQQLGPVILERKAADAGLKQSLFE 622 
Q +EPEC++P+V G KQ+ILVGDH QLGPV++ +!CAA AGL QSLFE 
3 QXTEPECMVPVVLGGKQLILVGDHCQLGPVVMCKKAAKAGLSQSLFE 143 
New 184188 Rl3609 4.6e-30 2 BLOSUM62 165 
Organism: 
Library: 
Source: 
E-mail: 
Phone: 
H.sapiens 
Soares inf ant brain lNIB 
Wilson RK 
est@watson.wustl.edu 
314 286 1800 FAX: 314 286 1810 
Score= 165 (75.7 bits), Expect 4.7e-30, Sum P(2) = 4.7e-30 
Identities= 33/52 (63%), Positives= 37/52 (71\), Frame= +2 
No 
Query: 624 LISLGHVPIRLEVQYRMNPYLSEFPSNMFYEGSLQNGVTIEQRTVPNSKFPW 675 
L+ LG PIRL+VQYRM+P LS FPSN+FYEGSLQNGVT R F W 
Sbjct: 143 LVVLGIRPIRLQVQYRMHPALSAFPSNIFYEGSLQNGVTAADRVKXGFDFQW 298 
Score 133 (61.0 bits), Expect = 4.6e-30, Sum P(2) = 4.6e-30 
Identities= 24/37 (64%), Positives= 32/37 (86%), Frame= +l 
Query: 
Sbjct: 
578 SEPECLIPIVKGAKQVILVGDHQQLGPVILERKAADA 614 
+EP C++P+V GAKQ+ILVGDH QLGPV++ +!CAA A 
7 TEPXCMVPVVLGAKQLILVGDHCQLGPVVMCKKAAKA 117 
New 271744 Rll830 2.2e-ll 3 BLOSUM62 
Organism: H.sapiens 
Library: Soares infant brain lNIB 
83 
Score= 83 (38.l bits), Expect= 2.2e-ll, Sum P(3) = 2.2e-ll 
Identities• 17/27 (62\), Positives= 22/27 (81%), Frame= +2 
Query: 
Sbjct: 
758 EVASVDAFQGREKDYIILSCVRANEQQ 784 
EV +VDAFQGR+KD +I++ VRAN Q 
167 EVDTVDAFQGRQKDCVIVTXVRANSIQ 247 
Score • 71 (32.6 bits), Expect = 2.2e-ll, Sum P(3) = 2.2e-ll 
Identities= 15/23 (65%), Positives= 19/23 (82\), Frame• +3 
Query: 
Sbjct: 
793 RRLNVGLTRAKYGLVILGNPRSL 815 
+RLNV +TRAKY L ILG+ R+L 
276 QRLNVTITRAKYSLFILGHLRAL 344 
No 
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683 
325 
sum p( 3 ) = 2.2e-11 
wll• (S4 t), Frame = +2 
• 12/22 
118 
sum p(2) = 3.Je-ll 
w11. l 
-. 31/62 (SH)• Frame = + 
No 
LVGDHQQLGPVILERKAADAGLKQSLFERLI 625 
VGD +QL p ++ KA + G QS+ R 
I 
++i~VGDPKQLPPTVISMKAQEYGYDQSMMARFC 18 6 
= 3.Je-11 
Frame = +l 
114 No 
VGDHQQLGPVILERKAADAGLKQSLFERLISL 627 
ILVGD +OL P ++ KA + G QS+ R L 
LVGDPKQLPPTVISMKAQEYGYDQSMMARFCRL 224 
= 6.3e-ll 
(72lr), Frame = +3 
: EST clones and their names used in the lab. 
Insert Size in kb 
(approximate) 
1.5 
1.3 
1.6 
Lab Designation 
Clone 1 / SAM1 
Clone 2 I SAM2 
Clone 3 I SAM3 
r-.* 
- . 
N/A Clone 4 I SAM4 
181 
1 
Putative zn+2 
fingers 448 RNA Helicase Region 
r---ros433 I 
I R136o9 I 
Ct111l67~1 
I A15581 I 
CH11830-=i 
804 971 
Figure 30. Schematic representation of the yeast UPF1 protein and alignments with the 
putative translation products deduced from from cDNA EST clones identifed by the XREFdb 
and shown in Figure 29. Amino acid residues in UPF1 that border the RNA Helicase region are 
indicated. 
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I, therefore, decided to obtain the clone that was the most accessible (GenBank 
accession #R13609). The second subset contained only clone H11830 
(GenBank accession #H11830). The third and final subset contained clones 
H15581 and H11176 (GenBank accession #H15581, #H11167). These two 
human EST cDNAs overlap completely. Therefore, only clone H11167 was used 
in all subsequent experiments. The human EST cDNA clones mentioned above 
were requested and upon arrival, all four clones were renamed (Table 8). The 
insert size of clones 1, 2, and 3 was determined by restriction enzyme digestion. 
Even though the GenBank sequence of each clone was between 250 and 400 nt 
long, the actual insert size of the clones was between 1.3-kb and 1.6-kb in 
length. Clone 1 (R13609) had an insert size of approximately 1.5 kb. To verify 
the identity of clone 1, both ends of this clone were sequenced. The 5' 
sequence of clone 1 could be aligned with the published GenBank sequence of 
clone 1 (#R 13609) (Figure 31 ). The 3' end of the clone contained nucleotides 
compatible to the oligomer used to generate the first strand cDNA synthesis 
during the cDNA library construction (data not shown). Therefore, my clone 1 
contains a 1.5-kb insert whose 5' sequence is identical to that published in 
Gen Bank file #R 13609. Next, I isolated the 1. 5-kb insert from the plasmid and 
used it as a probe in northern blot analysis of total human RNA. Inserts were 
also prepared from clones 2 and 3 (Gen Bank clones #H 11830 and #H 11167, 
respectively) and used as probes for northern blot analysis. However, the 
sequences of inserts 2 and 3 were not confirmed by DNA sequencing. The 
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R 13609 = Sequence obtained from Gen Bank file #R 13609 
SEA = Sequence by SEA 
Rl3609 CCAGGCACCGAGCCGNAGTGCATGGTTCCCGTGGTCCTCGGGGCCAAGC 
111111 
SEA CCAAGC 
Rl3609 AGCTGATCCTTG-AGGCGACCACTGCCAGCTGGGCCCAGTGGTGATGTGC 
111111111111 11111111111111111 11111111 I 1111111 11 
SEA AGCTGATCCTTGTAGGCGACCACTGCCAGCAGGGCCCAGTGGTGATG-GC 
Rl3609 AAGAAGGCGGCCAAGGCGGNCTGTCACAGT-CGCTCTTCGAGNCCTGGTG 
111111111111111 111 1111111111 I I 
SEA AAGAAGGCGGCCAAG-CGG-CTGTCACAGTCCG-T 
Rl3609 TGCTGGGCATCCGGCCCATCCGCCTGCAGGTCCAGTACCGGATGCACCC 
Rl3609 AATGGTGTCACTGCAGCGGATCGTGTGAAGAAGGGATTTGATTTCCAGT 
Rl3609 CAAGAGGGAGATTTGCCAGTTTGGGGCAACTTCTTACCTTGAACAGGGA 
Rl3609 CC 
Figure 31. Alignment of nucleotide sequences from the 5' end of clone 1 (SEA) 
and GenBank clone #R13609. Sequence of the 5' end of clone R13609 was 
obtained by double stranded sequencing of plasmid containing insert of clone 1 
by the Sanger didioxy method (Sanger et al., 1977) using primer M13.back 
primer. Alignment errors may be due to errors in the automated sequencing of 
the EST clone or by incorrect reading of data by (SEA). 
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results from these three northern are shown in Figure 32. Northern blot analysis 
using clone 1 revealed in human cells, two bands of 3.6 and 5.5 kb, whereas 
probing blots with both clones 2 and 3 revealed in human cells bands of 8.0 and 
11.0 kb in size. Interestingly, in mouse cells, clone 1 detected a weak band of 
4.5 kb in size and clone 2 detected a weak band of 10.8 kb. Whether or not 
these bands represent murine homologues of human clone 1 and 2 remains to 
be seen. From these experiments, I conclude that clone 1 might represent a 
homologue of the yeast UPF1 gene because the size of the transcripts (3.7- and 
5.5-kb) are closest in size to those encoded by UPF1 (3.2-kb). 
Isolation of a Human cDNA Clone Using a Clone 1 Probe 
To isolate a full length human cDNA representing the human clone 1 
cDNA fragment (R13609), I screened approximately 2.5 X 105 individual plaques 
of a human oligo-d(T)-primed cDNA library prepared from Hela cell RNA 
(Elledge et al., 1991) with the isolated 1.5-kb fragment of clone 1 under high 
stringency conditions. Seven hybridizing phage clones were identified, plaque 
purified, and used to infect an E. coli strain able to excise a yeast/E. coli shuttle 
vector from the phage DNA. The shuttle vector can be used to express the 
cDNA from an inducible promoter in yeast cells (Figure 33). Plasmids could be 
excised from seven (clone numbers 8.1.1/2, 11.1.1/2, 11.2.1/2, 13.1.1/2, 
15.1.1/2, 21.1.1/2, 22.1.1/2) of seven clones and the size of their cDNA inserts 
was determined by restriction digestion (Appendix Figure 1.A). Six of the seven 
9.4- :,; * 
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5.5 ...... 
4.4- .. 
3.6 ....... 
2.4-
1.4-
1 2 3 
R13609 
(clone 1) 
4 5 6 
H11830 
(clone 2) 
7 8 
...-11.0 
.... 8.0 
H11167 
(clone 4) 
Figure 32. Northern blot analysis of human and mouse RNA using 
probes isolated from human cDNA EST clones. Indicated amounts 
of total RNA were subjected to northern blot analysis using the 
probes called clone 1 (R13609), 2 (H11830) and 3 (H11167). 
Arrows indicate the position and size of RNA bands detected in 
human cells. An asterisk indicates faint bands detected in mouse 
cells that are 11.0-kb band with the H11830 probe (lane 4) and a 
4.6-kb band with the R13609 probe (lane 1). 
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Excision of ampicillin resistant 
p YES plasmid after infection of 
A, YES phage into ere recombinase 
producing bacteria strain 
poly(A) 
Human 
cDNA 
~ 
A.YES 
cDNA 
Transform the plasmid into yeast under inducing conditions 
(2% galactose) to test if the cDNA product can complement a 
defective yeast gene. 
Figure 33. Schematic diagram of pYES plasmid excision from phage A-YES and subsquent test of 
human cDNA for complementing ability. 
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clones contained detectable inserts. One clone (clone 11.2.1/2) contained an 
insert of 3.6-kb (called clone 3.6)., whereas the other clones contained smaller 
inserts (Appendix Figure 1.A, 1.C). Restriction mapping revealed that three of 
the clones with smaller inserts (21.1.1, 8.1.1, 13.1.1) overlapped with the insert 
of clone 3.6 (Appendix Figure 1.B, 1.0). These clones were not examined 
further. 
When I sequenced the 3' end of clone 3.6, I found that the nucleotide 
sequence was identical to that of the original clone 1 (GenBank clone #R13609) 
(data not shown). When I used the 3.6-kb insert as a probe in a northern blot 
analysis of human total Hela RNA, I detected bands of 5.5- and 3.6-kb (Figure 
34). Because the original 1.5-kb clone 1 probe also detected 3.6-kb and 5.5-kb 
bands in Hela RNA (Figure 32), I conclude that I have cloned a 3.6-kb cDNA 
that very likely represents a full length cDNA of the original 1.5-kb clone 1 probe. 
Sequence Analysis 
The insert of the 3.6-kb clone (clone 3.6) was sequenced by Sanger 
dideoxy chain termination method (Sanger et al., 1977) and primer-walking 
(Slightam et al., 1994) with the ABI Cycle Sequencing kit from Perkin Elmer 
(Branchburg, NJ) and an ABI automated DNA sequencer. The sequence of 
clone 3.6 was 3602 bp in length and contains the poly(A)-signal sequence 
AATAAA and from nucleotide 176 to nucleotide 3529 a 3354-bp open reading 
frame (ORF) that could encode a 123-kDa polypeptide (Figure 35). The first 
amino (N)-terminal ATG codon of clone 3.6 is very likely the true translational 
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Figure 34. Northern blot analysis of total and cytoplasmic RNA using 
the 3.6 clone probe. (A) Northern blot of 5 µg of total RNA from the 
mouse B cell hybridoma FH (Lane 1) and human endothelial cell line 
HeLa (lane 2). Blot was exposed to film 2 days at -70°C with one 
enhancing screen. (8) Northern blot of 10 µg of cytoplasmic (C, lane 
3) and total (T, lane 4) HeLa RNA. Blot was exposed to film 3 days at 
-70°C with one enhancing screen. 
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Figure 35. Nucleotide and predicted amino acid sequence of the human NORF1 
gene. 
gcggcggctcggcactgttacctctcggtccggctggcgccgcgggcggtttggtcctttccgggcgcgcgggggcgaca 80 
gcggcagcgacccgaggcctgcggcctaggcctcagcgcggcggcgggctcgagtgcagcgcggaaccggcccgagggcc 160 
ctacccggaggcaccatgagcgtggaggcgtacgggcccagctcgcagactctcactttcctggacacggaggaggccga 240 
M S V E A Y G P S S Q T L T F L D T E E A E 22 
gctgcttggcgccgacacacagggctccgagttcgagttcaccgactttactcttcctagccagacgcagacgccccccg 320 
L L G A D T Q G S E F E F T D F T L P S Q T Q T P P 48 
gcggccccggcggcccgggcggtggcggcgcgggaagcccgggcggcgcgggcgccggcgctgcggcgggacagctcgac 400 
G G P G G P G G G G A G S P G G A G A G A A A G Q L D 75 
gcgcaggttgggcccgaaggcatcctgcagaacggggctgtggacgacagtgtagccaagaccagccagttgttggctga 480 
A Q V G P E G I L Q N G A V D D S V A K T S Q L L A E 102 
gttgaacttcgaggaagatgaagaagacacctattacacgaaggacctccccatacacgcctgcagttactgtggaatac 560 
L N F E E D E E D T Y Y T K D L P I H A C S Y C G I 128 
acgatcctgcctgcgtggtttactgtaataccagcaagaagtggttctgcaacggacgtggaaatacttctggcagccac 640 
H D P A C V V Y C N T S K K W F C N G R G N T S G S H 155 
attgtaaatcaccttgtgagggcaaaatgcaaagaggtgaccctgcacaaggacgggcccctgggggagacagtcctgga 720 
I V N H L V R A K C K E V T L H K D G P L G E T V L E 182 
gtgctacaactgcggctgtcgcaacgtcttcctcctcggcttcatcccggccaaagctgactcagtggtggtgctgctgt 800 
C Y N C G C R N V F L L G F I P A K A D S V V V L L 208 
gcaggcagccctgtgccagccagagcagcctcaaggacatcaactgggacagctcgcagtggcagccgctgatccaggac 880 
C R Q P C A S Q S S L K D I N W D S S Q W Q P L I Q D 235 
cgctgcttcctgtcctggctggtcaagatcccctccgagcaggagcagctgcgggcacgccagatcacggcacagcagat 960 
R C F L S W L V K I P S E Q E Q L R A R Q I T A Q Q I 262 
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caacaagctggaggagctgtggaaggaaaacccttctgccacgctggaggacctggagaagccgggggtggacgaggagc 1040 
N K L E E L W K E N P S A T L E D L E K P G V D E E 288 
cgcagcatgtcctcctgcggtacgaggacgcctaccagtaccagaacatattcgggcccctggtcaagctggaggccgac 1120 
P Q H V L L R Y E D A Y Q Y Q N I F G P L V K L E A D 315 
tacgacaagaagctgaaggagtcccagactcaagataacatcactgtcaggtgggacctgggccttaacaagaagagaat 1200 
y D K K L K E S Q T Q D N I T V R W D L G L N K K R I 342 
cgcctacttcactttgcccaagactgactctgacatgcggctcatgcagggggatgagatatgcctgcggtacaaagggg 1280 
A Y F T L P K T D S D M R L M Q G D E I C L R Y K G 368 
accttgcgcccctgtggaaagggatcggccacgtcatcaaggtccctgataattatggcgatgagatcgccattgagctg 1360 
D L A P L W K G I G H V I K V P D N Y G D E I A I E L 395 
cggagcagcgtgggtgcacctgtggaggtgactcacaacttccaggtggattttgtgtggaagtcgacctcctttgacag 1440 
R S S V G A P V E V T H N F Q V D F V W K S T S F D R 422 
gatgcagagcgcattgaaaacgtttgccgtggatgagacctcggtgtctggctacatctaccacaagctgttgggccacg 1520 
M Q S A L K T F A V D E T S V S G Y I Y H K L L G H 448 
aggtggaggacgtaatcaccaagtgccagctgcccaagcgcttcacggcgcagggcctccccgacctcaaccactcccag 1600 
E V E D V I T K C Q L P K R F T A Q G L P D L N H S Q 475 
gtttatgccgtgaagactgtgctgcaaagaccactgagcctgatccagggcccgccaggcacggggaagacggtgacgtc 1680 
V y A V K T V L Q R P L S L I Q G P P G T G K T V T S 502 
ggccaccatcgtctaccacctggcccggcaaggcaacgggccggtgctggtgtgtgctccgagcaacatcgccgtggacc 1760 
A T I V Y H L A R Q G N G P V L V C A P S N I A V D 528 
agctaacggagaagatccaccagacggggctaaaggtcgtgcgcctctgcgccaagagccgtgaggccatcgactccccg 1840 
Q L T E K I H Q T G L K V V R L C A K S R E A I D S P 555 
gtgtcttttctggccctgcacaaccagatcaggaacatggacagcatgcctgagctgcagaagctgcagcagctgaaaga 1920 
V S F L A L H N Q I R N M D S M P E L Q K L Q Q L K D 582 
cgagactggggagctgtcgtctgccgacgagaagcggtaccgggccttgaagcgcaccgcagagagagagctgctgatga 2000 
E T G E L S S A D E K R Y R A L K R T A E R E L L M 608 
acgcagatgtcatctgctgcacatgtgtgggcgccggtgacccgaggctggccaagatgcagttccgctccattttaatc 2080 
N A D V I C C T C V G A G D P R L A K M Q F R S I L I 635 
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tggtgctgggcatccggcccatccgcctgcaggtccagtaccggatgcaccctgcactcagcgccttcccatccaacatc 
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ttctacgagggctccctccagaatggtgtcactgcagcggatcgtgtgaagaagggatttgacttccagtggccccaacc 
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cgataaaccgatgttcttctacgtgacccagggccaagaggagattgccagctcgggcacctcctacctgaacaggaccg 
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tacgagggccagcgctcctacctggtgcagtacatgcagttcagcggctccctgcacaccaagctctaccaggaagtgga 
Y E G Q R S Y L V Q Y M Q F S G S L H T K L Y Q E V E 
gatcgccagtgtggacgcctttcagggacgcgagaaggacttcatcatcctgtcctgtgtgcgggccaacgagcaccaag 
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gcattggctttttaaatgaccccaggcgtctgaacgtggccctgaccagagcaaggtatggcgtcatcattgtgggcaac 
G I G F L N D P R R L N V A L T R A R Y G V I I V G N 
ccgaaggcactatcaaagcagccgctctggaaccacctgctgaactactataaggagcagaaggtgctggtggaggggcc 
P K A L S K Q P L W N H L L N Y Y K E Q K V L V E G P 
gctcaacaacctgcgtgagagcctcatgcagttcagcaagccacggaagctggtcaacactatcaacccgggagcccgct 
L N N L R E S L M Q F S K P R K L V N T I N P G A R 
tcatgaccacagccatgtatgatgcccgggaggccatcatcccaggctccgtctatgatcggagcagccagggccggcct 
F M T T A M Y D A R E A I I P G S V Y D R S S Q G R P 
tccagcatgtacttccagacccatgaccagattggcatgatcagtgccggccctagccacgtggctgccatgaacattcc 
S S M Y F Q T H D Q I G M I S A G P S H V A A M N I P 
catccccttcaacctggtcatgccacccatgccaccgcctggctattttggacaagccaacgggcctgctgcagggcgag 
I P F N L V M P P M P P P G Y F G Q A N G P A A G R 
gcaccccgaaaggcaagactggtcgtgggggacgccagaagaaccgctttgggcttcctggacccagccagactaacctc 
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cccaacagccaagccagccaggatgtggcgtcacagcccttctctcagggcgccctgacgcagggctacatctccatgag 
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tcccagtattaaaaggtggcggcggaagagctaagcaacgtggcttagtccatcagcatcttattctgggtaataaaaaa 
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initiation codon, because it is flanked by sequences that predict strong 
translational initiation (Kozak, 1994) and is preceded by an in-frame TAG stop 
codon from nucleotide positions 107 to 109. As mentioned above, clone 3.6 
could encode a protein of approximately 123-kDa. To determine if this is the 
case, in vitro transcription-translation (IVTL) was performed using a linearized 
NORF1 cDNA plasmid preceded by a T7 polymerase promoter. When 
radiolabeled IVTL products were subjected to SOS/PAGE, I detected a band with 
an apparent molecular mass of 130 kDa (Figure 36). This result indicates that 
the ORF of the 3.6-kb NORF1 clone (clone 3.6) can be translated into a protein 
product of approximately 130-kDa. This corresponds well with the calculated 
molecular mass of 123 kDa. The difference between predicted and apparent 
molecular weight might be due to the fact that acidic polypeptides run aberrantly 
in SOS polyacrylamide gels (Koshland, 1985; Bornemann et al., 1995). 
Comparison of NORF1 Polypeptide Sequence to Sequences in Databases 
When the translated non-redundant GenBank, PDB, SwissProt, and PIR 
databases (release date: July 22, 1996) was searched with the deduced amino 
acid sequence of clone 3.6 using the BLAST program (Altschul et al., 1990), the 
results revealed that the human protein showed the highest degree of homology 
to yeast UPF1 (Leeds et al., 1991 ), which is also known as NAM7 (Altamura et 
al., 1992). First, 71% of the human coding sequence from codon 121 to codon 
kDa 
-200 
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-69 
-46 
Figure 36. In vitro transcription-translation (IVTL) of UPF1 and 
NORF1 RNA transcribed from plasmid DNA. 5 µg of linearized 
plasmid was subjected to in vitro transcription-translation in the 
presence of 35S-labeled methionine and cystine using the TnT 
coupled transcription-translation kit (Promega, WI) as suggested by 
the manufacturer. 10 µI of reaction product was separated by 10% 
SOS/PAGE and subjected to flurography for 16 hours. 
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918 is 60% identical and 74% similar to the corresponding UPF1 (NAM7) coding 
sequence from codons 60 to 856. Second, both proteins contain at their amino 
(N)-terminal ends an acidic stretch followed by a cysteine-rich region and in their 
middle parts, an RNA helicase region (Figure 37.B). 
The RNA helicase region of the human polypeptide from codons 489 to 
875 is 63% identical and 85% similar to that of Upf1 p (codons 427 to 811) and 
contains in the same order all seven RNA helicase motifs that are found in Upf1 p 
(Altamura et al., 1992; Leeds et al., 1992), and other group I RNA helicases 
(Koonin, 1992). Remarkably, the distances between six of the seven RNA 
helicase consensus motifs are preserved between the human protein and yeast 
Upf1 p and the distances between domains lb and II differ only by two amino acid 
residues (Figure 37.B). The BLAST search revealed also that all seven RNA 
helicase consensus motifs in the human protein are very similar to that of other 
putative eukaryotic group I RNA helicases (Koonin, 1992) such as S. cerevisiae 
SEN1, mouse MOV-10, the putative S. pombe UPF1 homologue, the human and 
mouse µ switch region binding proteins SMBP-2, a putative human DNA 
helicase, and an insulin enhancer binding protein (Figure 37, Table 9). Thus, I 
conclude that the human 3.6-kb cDNA clone encodes a putative group I RNA 
helicase. 
In contrast to the seven RNA helicase motifs, which are present in all 
group I RNA helicases, a cysteine-rich region is found only in the human protein 
and Upf1 p but not in other members of the group I RNA helicase family. The 
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Figure 37. Sequence comparison of human NORF1 and yeast UPF1. (A) Partial 
complementary nucleotide and entire deduced amino acid sequences of human 
NORF1 and comparison with the S. cerevisiae UPF1 amino acid sequence 
(SwissProt accession # P30771 ). The numbers at the right indicate nucleotide 
and amino acid positions. Untranslated regions are shown in lowercase and 
translated regions in uppercase letters. Arrows indicate the region of the NORF1 
nucleotide sequence that was omitted from the figure and can be retrieved from 
GenBank file #U59323. The start and stop codons of NORF1 are in bold and the 
in-frame stop codon upstream of the ATG as well as the poly(A)-addition signal 
site are underlined and italicized. The glycine/praline-rich regions and the 
serine/glutamine (SQ) and serine/glutamine/proline (SQP) repeats are 
underlined. The deduced amino acid sequences of NORF1 and UPF1 (in single 
letter IUPC code) are shown below the partial nucleotide sequence. In the 
alignments (top, NORF1 and bottom, UPF1 ), a period indicates an identical 
amino acid residue and a forward slash a gap of one amino acid introduced for 
optimal alignments. Charged amino acids at the N-terminal ends are indicated 
by + and -. The cysteine-rich putative zinc finger motifs are underlined in bold, a 
putative tyrosine phosphorylation site is boxed and the seven group I RNA 
helicase motifs (I, lb, II-VI) are indicated by gray-shaded boxes. (B) Domain 
maps of human NORF1 and yeast UPF1. The domains are indicated by boxes. 
Numbers between and below the domains and at the ends indicate amino acid 
distances, and numbers in the boxes the net charge of the domain. "PG", 
praline/glycine-rich; "SQP" serine/glutamine and serine/glutamine/proline 
repeats. 
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Table 9. --Alignment of Consensus Motifs Shared Between Human NORF1 and Other Eukaryotic Members of the RNA 
Helicase Superfamily I. 
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cysteine-rich region in the human protein extends from codons 123 to 213 
(Figure 37.A) and is 63% identical and 90% similar to that of Upf1 p (residues 62 
to 152). The cysteine-rich region in both the human and Upf1 p is preceded by 
an acidic stretch of 47 and 55 amino acids, respectively, with a net charge of -9. 
Two motifs within the cysteine-rich region of the human protein (starting at codon 
123 and codon 183, respectively), as well as Upf1 p (starting at codon 62 and 
122, respectively), can be written as CysX2CysXnCysX3Cys (X represents any 
amino acid and n is 6 for the first and 26 for the second motif). The distances 
between the two motifs are preserved in both the human protein and Upf1 p and 
the distances between their cysteine-rich and RNA helicase regions differ only by 
one amino acid residue (Figure 37.A and B). Alternatively, starting with the first 
cysteine at codon 122, or 62 in Upf1 p, another putative zinc finger motif can be 
written as CysX2CysX26HisX3His. All three motifs can be partially aligned with the 
zinc finger/knuckle motif CysX2_5CysX4_12Cys/HisX2_4Cys/His, which is found in 
some zinc finger DNA binding proteins as well as in polypeptides that interact 
with RNA (Burd and Dreyfuss, 1994 ). 
Because the human protein exhibits the highest degree of homology to 
the group I RNA helicase Upf1p (Figure 37.A) and contains a very similar overall 
polypeptide domain structure as Upf1p (Figure 37.B), I conclude that the human 
protein, which I named NORF1 (nonsense mRNA reducing factor 1 ), is a putative 
group I RNA helicase and the first mammalian structural homologue of yeast 
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Upf1 p, a yeast protein responsible for reducing nonsense mRNA levels (Leeds et 
al., 1991). 
Compared to Upf1 p, NORF1 has 63 and 83 more amino acids on its N-
and carboxy (C) -terminal ends, respectively. These extra tails contain motifs 
that are absent from yeast Upf1 p, such as an additional acidic stretch of 34 
amino acids with a net charge of -9 followed by three repeats of a 
praline/glycine-rich motif (PGGXG) at the N-terminal tail. This glycine-rich region 
could be involved in RNA binding (Burd and Dryfuss, 1994). There are also 
multiple SQP and SQ repeats at the C-terminal tail (Figure 37.B) but a structural 
or functional role for this motif has not been determined. 
Expression of NORF1 
If NORF1 is involved in degrading nonsense mRNA, I would expect that it 
is expressed in every tissue, because any cell can potentially generate nonsense 
mRNA, for example via imprecise pre-mRNA splicing. Northern blot analysis 
was performed using total RNA from several human cell lines representing 
various human tissues and probed with the human 3.6-kb NORF1 probe. A 
predominant -5.5-kb and a minor -3.7-kb transcript in all samples (Figure 38), 
suggesting that NORF1 is expressed in many tissues. 
The size of the 3. 7-kb transcripts corresponds very well with the size of 
the 3.6-kb cDNA clone and, therefore, could represent mature NORF1 mRNA. 
The 5.6-kb mRNA might represent an incompletely spliced precursor of the 
mature 3.7-kb NORF1 mRNA. If this is true, I would expect that levels of the 5.6-
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Figure 38. Northern blot analysis of NORF1 mRNA in human cell lines. (A) 
5 µg of total RNA was subjected to northern blot analysis and hybridized 
with the complete human clone 3.6 probe. The blot was subjected to 
flurography for 2 days. RNA size markers are indicated in kilobases (kb) on 
the left and the position of the 18S and 28S RNA and the two NORF1 
transcripts on the right. (B) Photograph of the ethidium bromide stained gel. 
The arrows point to the hybridizing bands at 5.5 and 3.6 kb. 
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kb transcript would be lower in both total and cytoplasmic total RNA preparations 
when compared to the signal of the 3.7-kb band. However, as detected by 
northern blot analysis, levels of the 5.6-kb transcripts are higher in both total and 
cytoplasmic RNA preparations than levels of the 3.6-kb transcript (compare in 
Figure 34 lane 4 with lane 3). Therefore, it seems more likely that the two 
transcripts represent mature mRNA that was generated from a common pre-
mRNA by either differential splicing or differential usage of polyadenylation sites. 
To isolate a cDNA clone that might represent the 5.5-kb transcript, I screened a 
human Jurkat A.-phage cDNA library with a 5' probe of clone 3.6 (Xhol-Sa/I 
fragment in Figure 39). I identified 22 clones; eight of these clones were plaque 
purified and plasmids were excised from plaque-purified phage. Restriction 
enzyme digestion of plasmids prepared from the 8 clones (3.1.1.1/2, 3.2.1.1/2, 
9.1.1.1/2, 15.1.1.1/2, 17.1.1.1/2, 19.1.1.1/2, 21.1.1.1/2, 27.1.1.1/2) identified 
inserts of different sizes (Appendix Figure 2). The largest insert (clone 15.1.1/2) 
was 5.5-kb in length. This clone, whose size corresponds very well with that of 
the 5.5-kb transcript, was named clone 5.5 and used for further analyses. 
Restriction mapping analysis (Appendix Figure 3.A, 3.8) and partial DNA 
sequencing of clone 5.5 revealed that clone 3.6 overlaps with clone 5.5 . For 
example, I identified in clone 5.5 all restriction enzyme sites that were found in 
clone 3.6 (Figure 39). Moreover, I verified in clone 5.5 sequences of clone 3.6 
that contain the translational start and stop sites and the polyadenylation signal 
site AATAAA (Figure 39). I also detected at the 3' end of clone 5.5 a second 
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3.6 / CGAGGGCCCTACCCGGAGGCACCATGAGCGT CAGTATTAAAAGGTG-/ /-GGTAATAAAAA 
5.5 / CGAGGGCCCTACCCGGAGGCACCATGAGCGT CAGTATTAAAAGGTG-/ /-GGTAATAAAAA TATTAATAAACAGTTTTG 
M S Q Y * 
Figure. 39. Schematic representation and partial sequence alignment of the human NORF1 clones 3.6 and 5.5. 
ORFs are indicated by black boxes, untranslated regions by white and gray-shaded boxes, and poly(A) addition 
signal sites by black circles. Sequenced regions are underlined. Restriction cutting sites are X, Xhol; B; BstXI; S, 
Sall; E, Eco47111; D, Oral. Relative size of the two clones can be seen by comparison to the scale above. 
Sequenced regions of each gene are shown by blunt end bars below each gene. Key regions of the NORF1 gene 
nucleotide sequence identical between the two clones are shown below each gene except for the additional poly(A) 
addition signal site in clone 5.5. 
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classical polyadenylation signal site (AATAAA). I, therefore, propose that both 
the 3.7-kb and 5.5-kb transcript contain the same ORF and differ in their 3' 
untranslated region. Thus, the two transcripts might have been generated from 
the same pre-mRNA by differential polyadenylation signal site usage. However, 
I cannot completely exclude that clone 3.6 represents a truncated cDNA 
fragment of the 5.6-kb transcript. It may be possible that the 3.6-kb transcript is 
encoded by a gene that is different from NORF1 but shares with NORF1 some 
DNA sequence identity. 
Expression of NORF1 Protein 
To determine if a NORF1-like protein of about 130-kDa is present within 
human cells, I generated a rabbit antiserum reactive against peptides deduced 
from hydrophilic regions of the putative ORF of NORF1 (underlined in Figure 40). 
The synthesized peptides (NORF1/pep#1 and #2) were coupled to keyhole 
limpet hemocyanin (KLH) and used to immunize rabbits. The antibodies vvere 
affinity-purified from serum on the respective NORF1-peptide columns and used 
in western blot analysis. The affinity purified anti-NORF1-pep#1 antibodies 
stained on a western blot the radiolabeled 130-kDa protein that was in vitro 
translated from a clone 3.6 template (Figure 41). This antibody also detected a 
130-kDa protein in both mouse (lane 3) and human cells (lane 4). This suggests 
that the ORF of NORF1 can be translated in vitro, and in vivo, into a 130-kDa 
polypeptide. It is not known if the anti-NORF1-pep#1 antibodies detect yeast 
Upf1 p but it is unlikely that it would do so as the peptide epitope used to 
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Figure40. Hydrophobicity plot of NORF1 used to design NORF1 peptides.· The 
plot was generated by submitting the polypeptide sequence below the 
hydrophobicity plot to the ExPASy molecular biology server at 
http://expasy.hcuge.ch/www/ tools.html. The bracket in the plot represents the 
region of NORF1 residues used as an immunogen. The exact residues are 
shown below the plot and are in bold and underlined. 
ProtSoale output ~or user sequence 
3 
Hpholo. / Kyte Doolittle 
1 I 
-\ -'-~ 
2 
Q> 
'-g 0 
U> 
- 1 ~ Jr--1--;f ··-'I ·-l--+--J·-----
- 2 !--·-------·--------! .. ··---- ...... _ .................. - ...... ____ __ 
-
3 
I 
1 1~0pep1 1~0 1 I 50 200 250 
Position 
10 20 30 40 50 60 
MSVEAYGPSS QTLTFLDTEE AELLGADTQG SEFEFTDFTL PSQTQTPPGG PGGPGGGGAG 
80 90 100 110 120 130 
AGQLDAQVGP EGILQNGAVD DSVAKTSQLL AELNFEEDEE DTYYTKDLPI liACSYCGIHD 
150 160 170 180 190 200 
KKWFCNGRGN TSGSHIVNHL VRAKCKEVTL HKDGPLGETV LECYNCGCRN VFLLGFIPAK 
220 230 240 250 
QPCASQSS~K DINWDSSOWQ ~LIQDRCFLS WLVKIPSEQE 
70 
SPGGAGAGAA 
140 
PACVVYCNTS 
210 
ADSVVVLLCR 
N 
0 
en 
__J __J 
~ ~ 
T""" T""" 0 0 
LL LL T""" f'... T""" f'... 
0:: 0:: I C'? I C'? 
kDa 0 0 ~ en x en I I z z ::J > ::J 
200-
.--
97- ,~ ~i~l?' 
';',< 
--
,·~~~"-~> ' 
69 -
• 46- ~,, 
1 2 3 4 5 6 
anti-NORF1 pre-immune 
Figure 41. In vitro transcription-translation (IVTL) and western blot 
analysis of IVTL products and cellular lysates. Western blot analysis of 
IVTL products (lane 2), and analysis of cell extracts from mouse VXH 
(lanes 3 and 5) and human U-937 cells (lanes 4 and 6 ) with rabbit anti-
NORF1-pep#1 peptide antibodies (lanes 2-4) and preimmune serum 
(lanes 5 and 6). Whole IVTL reaction product (lane 1) (5 µI) was 
detected by fluorography for 4 days. Molecular mass protein standards 
are indicated in kilodaltons (kDa) on the left. 
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generate the anti-NORF1-pep#1 antibodies is not found within the predicted 
UPF1 polypeptide. Based on these data, I conclude that I have cloned a human 
cDNA (NORF1) that exhibits a large degree of amino acid identity to that of yeast 
Upf1 p, a group 1 RNA helicase required for nonsense codon-mediated mRNA 
degradation. It also suggests that both human and mouse cells express the 
NORF1 protein. 
Functional Analysis of NORF1 
NORF1 Complementation of an upf1 Null Yeast Strain 
To determine if NORF1 is capable of reducing nonsense mRNA levels in 
a upf1 null (upf1) yeast strain, I transformed the yeast strain PL Y154 ura3::1-f/S4 
(PL Y154) with a plasmid that contains the complete ORF of NORF1 cDNA under 
the control of the inducible ga/1-10 promoter. PL Y154 cells contain a nonsense 
LEU2 allele (leu2-1), which encodes a nonsense leu2-1 mRNA. Because Upf1p 
is absent from PL Y154 cells, nonsense leu2-1 mRNA becomes more stable and 
a low degree of translational readthrough can generate enough Leu2p to support 
the growth of PL Y154 cells in the absence of leucine. If NORF1 can replace the 
function of Upf1 p in yeast, leu2-1 mRNA should rapidly be degraded and the 
transformants will not grow in the absence of leucine. Six transformants were 
isolated and tested for their inability to grow in the absence and presence of 
leucine. The growth of these transformants was compared to yeast cells 
transformed with a control plasmid lacking an insert (pYes 2.0, lnvitrogen). 
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Figure 42 shows the results from these experiments. Yeast containing either the 
NORF1 cDNA (a-d) or the control plasmid (e-h) were both able to grow in the 
absence of uracil (indicating the presence of the transformed plasmid), the 
presence of galactose (which induces expression of the NORF1 cDNA), and in 
the absence of leucine, indicating that levels of nonsense /eu2-1 mRNA have not 
been decreased. Therefore, I conclude that the presence of the NORF1 cDNA 
under inducing conditions is not able to replace the function of Upf1 p, that is, to 
induce the degradation of nonsense mRNA. 
Leeds and co-workers (1992) were able to determine that mutations in the 
RNA helicase region of the UPF1 gene led to a dominant-negative effect in yeast 
cells containing a wild type copy of the UPF1 gene. Based on these 
observations, it may be possible NORF1 rather blocks Upf1 p leading to a UPF1-
minus (upf1) phenotype. To test this idea, yeast cells containing a wild type 
UPF1 gene were transformed with the plasmid containing the complete NORF1 
ORF or with a control plasmid that does not contain the NORF1 ORF. If NORF1 
acts in a dominant-negative fashion, it will interfere with Upf1 p and prevent the 
degradation of the nonsense mRNA transcribed from the /eu2-1 gene, which will 
change the phenotype of the transformed yeast cell from Leu- to Leu+. 
Transformants were generated and grown in the absence of uracil (which selects 
for the presence of the transformed plasmid library) and the presence of 
galactose (which induces the expression of the NORF1). However, when replica 
plated on plates with or without leucine, none of the cells transformed with the 
NORF1 (Figure 43 a-d) or control plasmid (e-h) grew on plates 
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Figure 42. Complementation of a UPF1 null (upf1) yeast strain with the NORF1 
cDNA. The yeast strain PL Y154 ura3::HIS4 was transformed with the galactose 
inducible NORF1 cDNA yeast shuttle plasmid (11.2.2) or with the galactose 
inducible yeast shuttle plasmid pYes 2.0 with no insert. Transformants were 
patched onto plates lacking uracil (Ura-) and replica plated to the indicated 
plates. The plasmid used to transform the yeast is shown above the plate and 
the composition of the plate medium is shown below the plate. Whether cell 
growth was observed is noted in parentheses after the medium. 
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Figure 43. Dominant-negative test of a UPF1 null (upf1) yeast strain with the 
NORF1 cDNA. The yeast strain SL988-11A was transformed with the galactose 
inducible NORF1 cDNA yeast shuttle plasmid (11.2.2) or with the galactose 
inducible yeast shuttle plasmid pYes 2.0 with no insert. Transformants were 
patched onto plates lacking uracil (Ura-) and replica plated to the indicated 
plates. The plasmid used to transform the yeast is shown above the plate and 
the composition of the plate medium is shown below the plate. Whether cell 
growth was observed is noted in parentheses after the medium. 
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supplemented with leucine. From this result I conclude that NORF1 does not 
block the function of Upf1 p in yeast cells. But in fact, more control experiments 
need to be done to confirm the expression of NORF1 protein in the yeast cells 
grown under inducing conditions. 
In summary, NORF1 when expressed in yeast cells does not replace nor 
block the function of Upf1 p. However, it is possible that in both the 
complementation and dominant-negative approaches NORF1 was expressed at 
levels that were not high enough to replace Upf1 p or to act dominant-negative. 
Alternatively, NORF1 might not replace the function of Upf1 p in yeast cells, 
because it cannot interact with another protein that is required to induce the 
degradation of nonsense mRNA. 
NORF1 Antisense RNA Expression in Mammalian Cells 
To determine if the NORF1 protein controls nonsense mRNA levels in a 
mammalian cell, I stably expressed NORF1 antisense transcripts from a 
transfected NORF1 cDNA in mouse B cells containing a immunoglobulin µ 
mRNA with a nonsense codon (Jack and Wabl, 1989) (Figure 44). If NORF1 is 
involved in the regulation of nonsense mRNA, downregulation of NORF1 
synthesis by antisense NORF1 transcripts should result in an increase in µ 
mRNA levels. 
NORF1 
p B-actin 5' 3• Mouse Hybridoma VXH 
Q__ r:-Cap ) lntron . 
pHBAPr- \J ./'11.3' ,,l/ 
NORF1 K I t{. --------
bla Stable Transfectants 
Figure 44. Schematic representation of the antisense orientation cloning of NORF1 into the expression 
vector pHp-APr-1-neo and subsequent transfection into the mouse B cell hybridoma VXH. The complete 
NORF1 ORF was excised on a Xhol/Hindlll fragment and cloned into the vector prepared with Hindlll/BamHI. 
The pHp-APr-1-neo contains a p-actin promoter (P), a 5' UTR intron, a SV40 poly(A) addition site, an ampicillin 
resistance gene (bla), and a neomycin/G418 resistance gene (neo). Structure of the nonsense µ mRNA in 
VXH is shown in the cell. The exons are indicated by boxes (VH variable; C, constant) and the length of 
translation products by lines below the mRNA. The position of the nonsense codon at the end of the VH 
exon is represented by the X. 
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Construction of a Mammalian Antisense NORF1 Expression Vector 
The complete NORF1 ORF was cloned into the mammalian antisense 
expression vector pHpApr-1-neo (Gunning et al., 1987). The NORF1 ORF was 
excised from plasmid pGem7Z-NORF1(3.6-kb) as a 3.5-kb Hindlll/Xhol fragment 
and cloned in a two-step ligation procedure into the expression vector prepared 
with Hindi 11/BamH I. 
Stable Expression of NORF1 Antisense RNA in Mouse Cells 
To determine whether NORF1 is important for controlling levels of 
nonsense mRNA in mammalian cells, I introduced the mammalian antisense 
NORF1 expression vector into the mouse hybridoma line VXH. VXH transcribes 
an endogenous µ gene with a TAG nonsense codon in its variable (VH) gene 
exon (Figure 45). The nonsense mutation reduces the level of µ mRNA in VXH 
by a factor of -15 when compared to that of functional µ mRNA in the hybridoma 
line FH (Jack and Wabl, 1989). FH cells contain the same µ gene as VXH cells 
except that the TAG nonsense codon in the V exon is changed to TAC (Jack and 
Wabl, 1989). When I analyzed VXH transfectants on western blots, I found that 
antisense clone VXH.3 produced less NORF1 protein (Figure 46A, lane 1) than 
control vector-transfected VXH (lane 3) and untransfected FH cells (lane 4). 
However, transfected and untransfected VXH clones produce about the same 
amount of the heavy chain binding protein, BiP (Haas, 1994). This suggests that 
human NORF1 antisense transcripts downregulated the expression of mouse 
217. 
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FH ~ VH I Cµ1 I Cµ2 lCµ3 lCµ4 lAAA 
µ t--~~~~~-------4 
VXH -1 VHXICµ1 ICµ2 ICµ3 ICµ4 IAAA 
VHI ~---1 
B 
VH81X with Leader to the VXH nonsense codon 
MDFGLSLVFLVLILKSGVQCEVQLVESGGGLVQPRESLKLSCESNEYEFPSHDMSWVRKTPEKR 
LELVAAINSDGGSTYYPDTMERRFIISRDNTKKTLYLQMSSLRSEDTALYYCARHD 
Theoretical Mw for the protein sequence 
MDFGLSLVFL ... TALYYCARHD: Theoretical Mw: 13691.44 
c 
VH81X without Leader to the VXH nonsense codon 
GVQCEVQLVESGGGLVQPRESLKLSCESNEYEFPSHDMSWVRKTPEKRLELVAAINSDGGSTYY 
PDTMERRFIISRDNTKKTLYLQMSSLRSEDTALYYCARHD 
Theoretical Mw for the protein sequence 
GVQCEVQLVE ... TALYYCARHD: Theoretical Mw: 11914.23 
Figure 45. Schematic diagram and sequence of the two predicted polypeptides 
that can be translated from the µ immunoglobulin nonsense mRNA in VXH cells. 
(A) Structures of functional µ mRNA in FH cells and nonsense µ mRNA in VXH 
cells. The exons are indicated by boxes \VH variable; C, constant) and the 
length of translation products by lines below the mRNA. The position of the TAG 
nonsense codon at the end of the VH exon, is represented by the X. The m gene 
in VXH differs from that in the FH cell by the presence of the TAG stop codon. 
(B) Sequence of the polypeptide translated from nonsense mRNA in VXH cells 
before cleavage of the leader sequence. (C) Sequence of the polypeptide after 
cleavage of the leader sequence. The predicted molecular mass of each 
polypeptide is shown below each sequence in bold letters. The nucleotide 
sequences used to caculate the molecular mass were obtained from GenBank 
entries: accession #X01113, and #K02890 and from Wabl et al., ( 1985). 
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Figure 46. Effect of human NORF1 antisense RNA expression on µ mRNA 
levels in transfected mouse cells. (A) Western blot analysis of mouse NORF1 in 
untransfected FH cells (lane 4) and VXH cells stably transfected with the human 
NORF1 antisense expression vector (lanes 1 and 2) and the expression vector 
alone (lane 3). The blot was first probed with anti-NORF1-pep1 antibodies (see 
Figure X) and then, to control for loading, restained with anti-BiP antibodies. (B) 
Northern blot analysis of µ mRNA expression in transfected VXH and 
untransfected FH cells. 5 µg total RNA was analyzed as described in Figure 17. 
The blot was probed with a mouse Cµ and a rabbit GAPDH cDNA probe. The 
positions of m and GAPDH mRNAs are indicated on the right. (C) Western blot 
analysis of polypeptides that react with anti-VH peptide antibodies in transfected 
VXH and untransfected VXH cells. The blot was probed with a rabbit anti-VH 
peptide antiserum that reacts with an epitope encoded by the VH region in FH 
and VXH cells (Hartwell & Jack, unpublished observations). The positions of the 
VH and full length µ polypeptides are indicated on the right. Bands other than 
those indicated by arrows are also detected in cells that do not produce any lg 
chains and thus, result from reactions of rabbit antibodies with non-lg 
polypeptides. To control for loading, the blot was reprobed with a rabbit anti-BiP 
serum and similar signals of a single 70-kDa band (BiP) were observed in all 4 
lanes. 
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NORF1 protein in antisense clone VXH.3. The downregulation of NORF1 
protein correlated with an increase in nonsenseµ mRNA in VXH.3 transfectants. 
On northern blots, I found about 3 times more nonsense µ mRNA in antisense 
clone VXH.3 (Figure 468, lane 1) than in a VXH clone transfected with the 
expression vector alone (lane 4) (Table 10). One possibility to explain why the 
level of nonsense µ mRNA was not restored to that of functional µ mRNA in FH 
cells (Figure 468, lane 5) is that I still detected some NORF1 protein in antisense 
clone VXH.3 (Figure 46A, lane 1 ). Because the levels of nonsense µ mRNA are 
increased in VXH.3 transfectants, I should also detect a shorter lg chain that is 
encoded by the ORF extending from the start codon to the nonsense codon µ 
mRNA (Figure 45.B and C and Figure 46.C). Indeed, I detected a band of 
approximately 15 kDa by western with anti-VH antibodies in antisense clone 
VXH.3 (Figure 46, lane 1), but not in vector-transfected VXH (lane 3) and wild-
type FH cells (lane 4). I conclude that the transfection of an antisense NORF1 
gene into VXH cells resulted in increased levels of nonsense µ mRNA and, 
therefore, that NORF1 is responsible for controlling nonsense µ mRNA levels. 
However, this conclusion is based on the result obtained with this one VXH 
transfectant as well as from one western blot and northern blot of the indicated 
transfectants. The accuracy of the data obtained needs to be confirmed by 
repeating the western and northern blot analysis on these and possibly other 
independent transfectants. 
Table 10. -- Quantitation of Northern Blot Analysis in Figure 463 
Cell line and RNA µ pre-µ GAP DH rel[µ] rel [pre-µ) 
transfectant clone loaded [µ/GAP DH] [pre-µ/GADPH] 
number 
[CPM] [CPM] [CPM] 
FH 5 µg 289.5 11.1 132.3 17 1 
VXH vector 5 µg 7.5 3.9 56.9 1 1 
VXH.1 5 µg 22.5 8.0 101.2 1.7 1.1 
VXH.2 5 µg 22.6 8.2 109.9 1.6 1 
VXH.3 5 µg 35.3 10.7 99.3 2.8 1.5 
3 Radioactivity of respective bands in each Northern blot (CPM) was determined by using a betascope blot analyzer. 
Relative steady-state level of respective RNA was calculated by dividing CPM ofµ by that of GAPDH in the same lane. 
Blots were determined to be free of background by emperical observation so no adjustments of the numbers collected 
were made. 
% [µ] is the percent of[µ] relative to that of the hybridoma VXH by setting VXH value equal to 100%. 
An [*] indicates the absence of data due to either background hybridization or to the absence of this data to perform 
caculations. 
Note: This data is the result of only one experiment. 
N 
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Isolation of a Mouse NORF1 Homologue 
The current work in our lab involves the analysis of immunoglobulin 
mRNA with nonsense codons in murine B cells. To study the function of the 
NORF1 gene in mouse cells, the mouse NORF1 cDNA was isolated. Southern 
blot analysis of mouse genomic DNA using the complete human NORF1 cDNA 
revealed the presence of hybridizing bands under high stringent conditions (data 
not shown). I concluded from this result that the mouse genome likely encodes a 
gene that has nucleotide identity with the human NORF1 gene. Therefore I used 
the human 3.6-kb NORF1 cDNA probe to screen approximately 2 X 105 
individual cDNA plaques from a mouse C2 muscle cell line oligo-d(T)-primed /...-
phage library under low stringency hybridization conditions. The library was 
generated from a mouse muscle cell line and, because NORF1 is likely to be 
expressed in all cells, the library should contain NORF1 cDNA clones. Two 
phage clones were identified that hybridized with the human 3.6-kb NORF1 
probe. One of these clones was plaque purified using low stringency 
hybridization, the plasmid was excised from the phage, and was found to contain 
a 4.5-kb cDNA insert (Appendix Figure 4.A). The plasmid and insert were also 
mapped (Appendix Figure 4.8, C, D, E, F, and G). Northern blot analysis using 
the 4.5-kb mouse insert revealed a single band of about 4.6-kb, the size 
expected for a full-length cDNA clone of NORF1 (Figure 47). 
The nucleotide sequence of the insert was partially determined and was 
very similar at the nt and aa level to that of the corresponding human sequence. 
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Figure 47. Northern blot analysis of total human and mouse RNA using 
human and mouse NORF1 probes. 10 µg of total RNA was separated by 
formaldahyde gel electrophoresis and blotted. Each blot was probed with 
the indicated NORF1 probe onto GeneScreen Plus. Two strips with 
identical RNA samples were cut from the membrane. One was hybridized 
with the 4.5-kb mouse NORF1 and the other with the 5.5-kb human 
NORF1. RNA size markers are indicated in kilobases (kb) on the left and 
the right. The position of the two NORF1 transcripts in the center. The 
blots were exposed to X-ray film for 36 hours at -70°C using an enhancing 
screen. 
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(Figure 48). From these sequence data I conclude that I cloned a murine cDNA 
that exhibits a high degree of identity to the human 3.6-kb NORF1 gene. 
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FIGURE 48. Sequence comparison of 5' sequences of human (h) and mouse 
(m) NORF1. The complementary 5' nucleotide and deduced amino acid 
sequences of hNORF1 were aligned manually with the 5' nucleotide and 
deduced amino acid sequence of the mouse 4.5-kb cDNA fragment. The 
numbers at the right indicate nucleotide and amino acid positions. Untranslated 
regions are shown in lowercase and translated regions in uppercase letters. The 
start codon of NORF1 and the in-frame stop codons upstream of the start codon 
are in bold. The deduced amino acid sequences of hNORF1 and mNORF1 (in 
single letter IUPC code) are shown above and below their corresponding partial 
nucleotide sequences. In the alignments, a period indicates an identical amino 
acid residue, a X an unidentified nucleic and amino acid residue, and a forward 
slash a gap of one amino acid or nucleotide introduced for optimal alignments. 
The cysteine-rich putative zinc finger motifs and the GP-rich motifs are 
underlined in bold. 
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ctataactantggatcccccgggctgcaggaattcggcacragctacggcggttcctgtc 60 
caggggtctgaaacggcggtcggctttgaggcaancancttacggaggggcgcggcggcg 120 
gcggcggcggcggcaactcaaaactcaaaaccggcggcccggctc/tgctttcggaggcc 179 
gcggcggctcggcactgttacctctcggtccggctggcgccgcgggcggtt 51 
gactcggaacccgcccggctctcagggcggcggcagcggctgctccggattacggcctag 239 
tggtcctttccgggcgcgcgggggcgacagcggcagcgacccgaggc/ t/gcggcctag 108 
gcctanccgaascctcgggctcgattgcggtgaggcgcccgctgaaggcgcggcccgggc 298 
gcctcagcgcggcggcgggctcgagtgcagcgcggaaccggcccgagggccctacccgga 168 
16 
ggcaggATRANTGTGGAGGCGTACGGCCCCAGCTCGCAAACACTCACCTTCTTGGACACT 358 
ggcaccATGAGCGTGGAGGCGTACGGGCCCAGCTCGCAGACTCTCACTTTCCTGGACACG 228 
M S V E A Y G P S S Q T L T F L D T 18 
x 35 
GAGGAGGCCGAGCTGCTCGGCGCCGACACCCAGGGCTCCGANTTCGAATTCACCGACTTC 418 
GAGGAGGCCGAGCTGCTTGGCGCCGACACACAGGGCTCCGAGTTCGAGTTCACCGACTTT 288 
E E A E L L G A D T Q G S E F E F T D F 38 
A 51 
ACCCTTCCCAGCCAAA.CNCAAACCCCCCCCGGCGGCCCCGGCGGCGCGGGXXXXXXXXXX 468 
ACTCTTCCTAGCCAGACGCAGACGCCCCCCGGCGGCCCCGGCGGCCCGGGCGGTGGCGGC 348 
T L P S Q T Q T P P G G P G G P G G G G 58 
X G X X F 66 
XXXXXXAGCCCGGGCGGAJl.CGGGCGCANGCGGCGCGGCCGGCCANCTCNACGCACAATTT 522 
GCGGGAAGCCCGGGCGGCGCGGGCGCCGGCGCTGCGGCGGGACAGCTCGACGCGCAGGTT 408 
A G S P G G A G A G A A A G Q L D A Q V 78 
x 85 
GGACCAGAAGGCATCTTGCAAAATGGGGCTGTGGATRACAGTGTGGCCAAAACCAGCCAG 582 
GGGCCCGAAGGCATCCTGCAGAACGGGGCTGTGGACGACAGTGTAGCCAAGACCAGCCAG 468 
G P E G I L Q N G A V D D S V A K T S Q 98 
x 104 
CTGCTAGCTGAGCTGAACTTCAAGGAAGATGAAGAAGACCTNCXTTACCTTAAGGACTCC 641 
TTGTTGGCTGAGTTGA.~CTTCGAGGAAGATGAAGAAGACACCTATTACACGAAGGACCTC 528 
L L A E L N F E E D E E D T Y Y T K D L 118 
X X P X X E X 119 
CANXTCCACCCCTGCANTTACNGTGAAXTCCATGATCCTGGCTGCGTNGTTTACTGTAAT 699 
CCCATACACGCCTGCAGTTACTGTGGAATACACGATCCTGCCTGCGTGGTTTACTGTAAT 588 
P I H A C S Y C G I H D P A C V V Y C N 138 
X X X H X R X N P F 134 
ACCAXCAAN.AAATNGTTCTGCCATGGCCNAAGA.ll.ATACTXCTGGCAACCCCATTTTTAAT 757 
ACCAGCAAGAAGTGGTTCTGCAACGGACGTGGAX\ATACTTCTGGCAGCCACATTGTAAAT 648 
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DISCUSSION 
The yeast UPF1 gene plays a defined role in the accelerated degradation 
of yeast nonsense mRNAs (Leeds et al., 1992; He et al., 1993). The 
identification of the UPF1 homologue, NORF1, in both human and mouse cells 
suggests that mammalian genes reduce levels of nonsense mRNA, at least in 
part, by similar mechanisms as yeast. Two results support the hypothesis that 
NORF1 is a UPF1 homologue. First, the conservation of key functional elements 
of Upf1 p such as the zinc-finger-like domain and RNA helicase region in NORF1 
suggest that it may act in a similar manner. Second, antisense NORf1 
expression partially reduces, the levels of nonsense mRNA in mammalian cells. 
Putative Functions of Motifs Conserved Between UPF1 and NORF1 
The Zinc-finger Motif 
NORF1 and Upf1 p contain very similar cysteine-rich regions which are 
characteristic of proteins that interact with nucleic acids. The cysteine-rich 
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domain contains two zinc-finger-like motifs that can be partially aligned with the 
zinc finger/knuckle motif, CysX2_5CysX4_12Cys/HisX2-4Cys/His. Zinc finger/ 
knuckle motifs are found in some zinc finger DNA binding proteins as well as in 
polypeptides that interact with RNA (Burd and Dreyfuss, 1994). 
The RNA Helicase Domain 
NORF1 and Upf1 p also contain a very similar RNA helicase domain that is 
characteristic of RNA helicases. These enzymes can unwind double stranded 
RNA (reviewed in Schmid and Linder, 1992). Purified Upf1 p is able to unwind 
dsRNA in in vitro tests in an ATP-dependent fashion (Czaplinski et al., 1995). 
Because NORF1 contains a conserved superfamily I ATP-dependent RNA 
helicase region, it is possible that NORF1 is also able to unwind dsRNA and 
uses ATP as the energy source. How this activity may affect nonsense mRNA is 
discussed below. 
The Acidic Region 
NORF1 and Upf1 p contain a stretch of acidic amino acids without 
conserved residues and NORF1 has an additional stretch with the same net 
charge as the acidic stretch shared by Upf1 p and NORF1. Some DNA-binding 
proteins require these domains to allow transcriptional activation (Umesono and 
Evans, 1989). This region, as well as regions discussed below, could bind to 
other proteins that are part of the machinery that recognize nonsense mRNA. 
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Possible Functions of Other Motifs in NORF1 
The predicted NORF1 protein contains at its N- terminal end a proline-
glycine rich region motif that is not present in Upf1 p. When DNA databases 
were searched with the praline-glycine rich region of the NORF1 gene, matches 
were found with transcription factors that contained praline-glycine rich regions at 
their N-terminal ends. When these praline-glycine rich regions are changed, the 
activity of a transcription factor can decrease or is completely abolished 
(Umesono and Evans, 1989). It is thought that this region is important for 
interactions of transcription factors with DNA. In NORF1 this region could 
interact with double stranded RNA. 
NORF1 contains a number of SQ-space (serine and glutamine) and SQP-
space (serine, glutamine and praline) di- and tri-residue repeats at the carboxy 
end of the protein. Searches of protein and DNA databases with the C-terminal 
end of NORF1 containing the SQ and SOP repeats did not reveal any significant 
matches. I speculate that it is possible that a SQ-space-SQ repeat could 
produce a highly hydrophillic region of polypeptide responsible for interactions 
with proteins that modifiy the activity of NORF1, that is, NORF1 might gain a 
function different from that of Upf1 p. Alternatively, it might interact with a 
mammalian homologue of Upf2p. 
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Expression of NORF1 
Northern blot analysis with the 3.6-kb NORF1 probe revealed a 5.5-kb 
and 3.6-kb transcript in all cell lines used in the analysis. Results of restriction 
and sequence analysis suggest that both transcripts encode NORF1. Although I 
did not quantitate the transcript levels in various cell lines, the result of the 
northern blot analysis in Figure 34 suggests that the ratio of the 3.6-kb and 5.5-
kb transcripts might be different from cell line to cell line. It is possible that the 
3.6-kb transcript represents a constitutively expressed mRNA, whereas levels of 
the 5.6-kb are regulated depending on the level of truncated polypeptides. It is 
tempting to speculate that sequences in the 3' UTR of the 5.6-kb species, about 
2-kb, might be responsible for this regulation. The complete sequence of the 5' 
UTR of clone 5.6 and a repeat of northern blot analysis with different cell lines 
and tissues might support this idea. It is hard to imagine how a truncated protein 
can signal the upregulation of a mRNA. However, truncated and mis-folded 
polypeptides that bind to the ER chaperone protein BiP could trigger an 
intracellular signal pathway activating a protein that binds to the 5' UTR of the 
5.6-kb NORF1 mRNA. Alternatively, NORF1 might directly be involved. We 
detected a putative tyrosine phosphorylation site in NORF1. 
The finding that an antiserum against human NORF1 detects a 130-kDa 
polypeptide in human and mouse cells (Figure 41) suggests some protein 
conservation. This is supported by Southern blot analysis of mouse DNA with 
the human probe as well as by sequence data of the mouse NORF_1 cDNA. 
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Interestingly, western blot analysis of rabbit proteins using the anti-human 
NORF1 peptide antiserum revealed a band of 115 kDa (data not shown). This 
may indicate that certain regions of the mouse and human NORF1 are 
dispensable for nonsense mRNA reduction. Therefore, the cloning and 
sequence of the rabbit NORF1 gene should identify regions that are different 
from mouse and human and possibly dispensable for NORF1 function. 
Function of NORF1 
To test whether NORF1 is able to promote nonsense mRNA reduction, I 
generated stable transfectants of a human NORF1 antisense cDNA into a mouse 
cell that expresses a nonsense µ mRNA. We found in one experiment and in 
one antisense transfectant that the expression of antisense-NORF1 mRNA 
correlated with a decrease of mouse NORF1 protein, an increase in nonsense µ 
mRNA, and the detection of a shorter polypeptide encoded by the nonsense µ 
mRNA. The reason why the level of nonsense µ mRNA was not restored to that 
of functional µ mRNA in FH could be that low levels of NORF1 protein can still be 
detected in antisense clone VXH.3. This raises the question of why the human 
NORF1 antisense transcripts do not completely decrease the level of mouse 
NORF1 protein. One possibility is that differences in the nucleotide sequence 
between human and mouse NORF1 result in a sense/antisense RNA hybrid that 
is only partially able to inhibit ribosomal translation of the mouse NORF1 protein. 
Indeed, partial sequence comparison of the mouse and human NORF1 genes 
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reveals that the two cDNAs contain nucleotide differences. Nevertheless, the 
most straightforward interpretation of these functional tests is that NORF1 is 
responsible for reducing nonsense µ mRNA levels. These results suggest that 
NORF1 is the first mammalian gene product that can affect the steady state level 
of a nonsense mRNA. However, this conclusion is based on the result obtained 
with this one VXH transfectant as well as from one western blot and northern blot 
of the indicated transfectants. The accuracy of the data obtained needs to be 
confirmed by repeating the western and northern blot analysis on these and 
possibly other independent transfectants. 
Another approach involved transforming a yeast upf1 mutant with a 
NORF1 expression plasmid to test for its ability to complement the upf1 defect. 
The presence of the NORF1 expressing plasmid, and presumed NORF1 
expression, did not result in yeast with an upf1 phenotype as determined by no 
change in the Leu- phenotype. There may be a number of reasons that NORF1 
did not complement the upf1 defect. First, the yeast may not have expressed 
NORF1 mRNA and protein. This is unlikely as the yeast grew readily in the 
presence of galactose, indicating the presence of endogenous yeast factors 
needed for metabolism as well as induction of the NORF1 cDNA. Additionally, 
the NORF1 cDNA was found to be in the correct orientation in the expression 
vector (data not shown). Because experiments confirming the presence of 
NORF1 mRNA and protein were not performed, these possibilities cannot be 
excluded. Second, NORF1 may not complement upf1 because it may .not have 
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the ability to interact with factors also required to rapidly degrade nonsense 
mRNA. The alignment of NORF1 with UPF1 (Figure 37) has revealed that not all 
regions of UPF1 are conserved in NORF1. For example, both proteins have 
different N- and C-terminal tails. It could be that these are the regions of Upf1 p 
that interact with the other UPF factors required to promote nonsense mRNA 
reduction. Because NORF1 lacks this region(s), it may not interact with other 
UPF factors. 
In another attempt to determine if NORF1 promotes nonsense mRNA 
reduction, I transformed yeast containing a wild-type UPF1 gene with a NORF1-
expression plasmid to determine if NORF1 could act in a dominant-negative 
fashion on Upf1p. The presence of the NORF1-expressing plasmid, and 
presumed expression of NORF1 protein, did not result in yeast with an upf1 
phenotype. There may be a number of reasons that NORF1 did not act in a 
dominant-negative fashion. First, the yeast may not have expressed NORF1 
mRNA and protein as discussed above. Second, there may be differences 
between NORF1 and Upf1 p that do not allow direct interaction. The differences 
between Upf1 p and NORF1 at their N- and C-terminal ends may prevent such 
interactions. 
The final test of NORF1 function should be perfomed in a cell line that 
lacks NORF1 expresion. The next experiments to be done are 1) isolating of a 
genomic fragment and disrupting the NORF1 gene in a mouse cell line, 2) 
finishing the sequence of the mouse NORF1 cDNA to identify conserved and 
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possible functional residues, 3) isolating clones that encode proteins interacting 
with NORF1 in a yeast two-hybrid system, and 4) generating antibodies against 
mouse NORF1 to localize the intracelluar localization of NORF1 by immuno 
electron microscopy. 
Models to Explain How NORF1 Reduces Nonsense mRNA levels 
In yeast, nonsense mRNA seems to be selectively degraded in the 
cytoplasm in an UPF-dependent manner (reviewed in Maquat, 1995). However, 
cytoplasmic levels of nonsense mRNA in mammalian cells seem to be reduced 
by both nuclear and cytoplasmic events (reviewed in Maquat, 1995). NORF1, in 
concert with other NORF factors, could be involved in both events. It is tempting 
to speculate that the two zinc-finger-like motifs of the NORF1 may facilitate the 
recognition of nonsense codons either in mature mRNA in the nucleus and/or the 
cytoplasm or in looped-out nuclear pre-mRNA, in which the exons have been 
aligned to form a continuous translational reading frame (Dietz and Kendzior, 
1994). One way in which the zinc-finger motif of NORF1 could be involved in 
nonsense codon recognition is that it could interact with a dsRNA region formed 
by the association of ribosomal subunits. The formation of dsRNA between 
ribosomal subunits is supported by experiments that have shown that the RNA 
components of mammalian ribosomes become less accessible to chemical 
modification after the 408 and 608 subunits have assembled into the BOS 
ribosome (Holmberg et al., 1994). From these results the authors believed that 
the RNA regions that are not modified are involved in rRNA subunit interactions. 
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Alternatively, rRNA could pair with tRNA molecules and form ds-rRNA/tRNA 
regions. That rRNA interacts with tRNA is suported by studies in prokaryotes 
that have shown that rRNA molecules are involved in tRNA selection and 
translational accuracy (reviewed by Noller, 1994). It may be possible that the 
zinc-finger motif of NORF1 binds to dsRNA or ds-rRNA/tRNA complexes. When 
these double-stranded regions are changed, either because tRNA is absent from 
the ribosomal A site, or ribosomal subunits disassociate, the binding of the zinc-
finger to its double-stranded RNA binding site might be disrupted, which could 
result in the activation of the RNA helicase domain. Consequently, the helicase 
is activated, which leads to the degradation of nonsense mRNA as described 
below. That a zinc-finger motif could bind to dsRNA has been proposed for the 
ribosomal elongation factor elF-2p. In elF-2p, the zinc-finger motif is required for 
the recognition of the AUG start codon during the ribosome-mediated 
translational scanning process (Donahue et al., 1988). It has been suggested 
that the zinc-finger motif of elF-2P could participate in start site selection by 
either scanning for an AUG or by stabilizing the AUG codon-anticodon 
interaction (a dsRNA interaction). Because a stop codon has no tRNA with an 
anticodon, NORF1 may only participate in interactions with ribosomal rRNA to 
recognize stop codons, similar to the way elF-2P could interact with tRNA to 
stabilize AUG codon-anticodon interactions, and when activated by ribosomal 
disassociation, promote nonsense mRNA reduction (Figure 49). The importance 
5' 
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3' 
Alterations in rRNA or tRNA/rRNA 
interactions due to an empty P site 
lead to disruption in Zn finger binding 
and activation of RNA Helicase 
Figure 49. Model for activation of NORF1 leading to decay of an mRNA with a nonsense codon. 
The tRNA and rRNA present in the BOS ribosome are shown as squiggles. 
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of the zinc-finger motif in Upf1 p has already been shown, because mutations in 
the zinc-finger motif of Upf1 p eliminate its ability to recognize a nonsense codon 
but does not influence the RNA helciase activity of Upf1 p (personal 
communication with K. Czaplinski) (see Table 2). These experiments were 
discussed in Chapter 11. 
The RNA helicase region of the Upf1 p is critical for its ability to promote 
the decay of nonsense mRNAs (Leeds et al., 1992). It has been suggested that 
upon activation (discussed above), Upf1 p could melt any secondary structure 
downstream of a nonsense codon by using its RNA helicase region, thereby 
leaving the mRNA exposed to nucleases (Figure 50.B; Peltz et al., 1993). For 
example, the ATP-dependent RNA helicase elF-4A can render RNA susceptible 
to nucleases (Ray et al., 1985). NORF1 may also act in this way (Figure 50.B). 
Another way in which Upf1 p is thought to influence the degradation of a 
nonsense mRNA is to promote the rapid de-capping of the nonsense message 
(Muhlrad and Parker, 1994). One way to explain how the RNA helicase activity 
of NORF1 could facilitate the rapid de-capping of a nonsense mRNA is that 
Upf1 p could unwind a trans-RNA interaction between the RNA portion of a 
RNA/protein complex and the capped end of a nonsense mRNA (Figure 50.C). 
This complex could somehow be involved in protecting the cap complex. 
Alternatively, the RNA helicase activity of NORF1 could unwind rRNA 
interactions in the ribosome which might result in the activation of other NORF 
factors that induce decapping (Figure 50.C). Yet, another way by which the RNA 
helicase activity of NORF1 could activate de-capping is to disrupt interactions 
A 5'~ 3' D ~ . < ~AAA 
B 5'~ 3' -
c 
~· 3' 
• 
Figure 50. Models to explain NORF1 helicase action induces the rapid decay of a nonsense mRNA. The 5' and 3' end 
of a mRNA are indicated. The inactive NORF1 factor (indicated by a diamond) is associated with the translating 
ribosomes, becomes active (indicated by hands) after encountering a nonsense codon. (A) Schematic diagram of a 
nonsense mRNA with extensive secondary structure downstream of the nonsense codon. (B) Activation of NORF1 
leads to removal of secondary structure downstream of the nonsense codon by the RNA helicase region, resulting in 
the production of a target for an endonuclease. (C) Activation of NORF1 induces RNA helicase activity. This results 
in the removal of a cap-protecting ribonucleo-complex, which results in decapping and degradation of the mRNA. 
Alternatively, NORF1 actication can lead to ribosomal disassembly and activation of other NORF factors. (D) 
Activation of NORF1 prevents 5' 3' RNA interaction, either directly (as shown) or indirectly by disruption of ribosomes. 
The inhibition of 5' 3' interactions leads to decapping and subsquent mRNA degradation. 
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between the 5' cap and 3' poly(A)-tail (Figure 50.D). This would expose the cap 
to a decapping enzyme and, subsequently, to 5'-3' exonuclease attack. That 
poly(A)/cap interactions might be required to protect mRNA from rapid 
degradation, comes from experiments that show that translation and 
deadenylation are prerequisites to decapping (Muhlrad et al., 1994) and from 
electron micrograph studies that show circular polysomes (Christensen et al., 
1987). 
If NORF1 can activate nonsense codon mRNA reduction, it raises the 
question of why mRNA with normal stop codons are not affected by the action of 
NORF1. It may be that NORF1 is a labile factor and may only be associated 
with an elongating ribosome for a limited time. The further a ribosome 
elongates, the greater its chance of loosing NORF1. After a certain distance, 
any ribosome encountering a stop codon will not recognize it as a nonsense 
codon because it lacks NORF1. 
As mentioned above, nonsense mRNA in yeast seems to be selectively 
degraded in the cytoplasm in an UPF1-dependent manner (Peltz et al., 1994). 
However, cytoplasmic levels of nonsense mRNA in mammalian cells are 
apparently reduced by both nuclear and cytoplasmic events (reviewed in 
Maquat, 1995). If NORF1 is not found in the nucleus, other factors might be 
responsible for reducing nuclear levels of nonsense mRNA either by degrading 
mature nuclear mRNA or influencing the splicing of nonsense pre-mRNA 
(reviewed in Maquat, 1995). A mammalian homologue of Upf3p might be a 
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candidtate for a second factor. Upf3p contains a bi-partite nuclear localization 
sequence and thus, is thought to be present in the yeast nucleus (Lee and 
Culbertson, 1995). 
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NORF1: The Big Picture 
The conservation of a protein that reduces levels of nonsense mRNA in 
lower (S. cerevesiae and C. elegans) and higher eukaryotes, such as mouse and 
human, implies an important biological function, presumably because it reduces 
nonsense mRNA levels and, thus, high levels of truncated polypeptides. Most 
truncated proteins might not be deleterious for a single cell. However, it might 
prevent in a dominant-negative fashion the assembly of signal-transducing 
receptors and prevent a cell from proceeding along a differentiation pathway or 
to fulfill its major physiologic function. If applied to the immune system, it is 
possible that nonsense immunoglobulin or T-cell receptor genes generated by 
DNA rearrangements could produce nonsense mRNA that can be translated into 
a truncated polypeptide. Such truncated lg or TCR chains could interfere with 
the assembly of an lg or TCR molecule, respectively, thereby eliminating the 
ability of the cell to respond to foreign antigens. The presence of a truncated 
polypeptide encoded by a stable nonsense mRNA correlates with a number of 
human diseases. For example, certain cases of Larons syndrome (Hashimoto et 
al., 1995), p-thalassemia (Hall and Thein, 1994), cancer associated with altered 
p53 expression (Kawasaki et al., 1994), Marfan syndrome (Dietz et al., 1994), 
and many others diseases are all thought to be the result of a dominant-negative 
protein product being translated from a mRNA containing a nonsense codon 
(see Table 1 for additional examples and references). It may be possible that 
these patients also have a defect in NORF1 (or another NORF gene) making 
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them susceptible to protein products produced from nonsense mRNAs that are 
not eliminated. Therefore, NORF1 not only protects a cell from nonsense 
mRNAs but also from the deleterious effect of truncated polypeptides encoded 
by nonsense mRNA. 
APPENDIX 
243 
A B 
..__ 
..__ 
(J) (J) 
"'O "'O 
-"'O ..__ "'O :J ..__ 
~ (J) ~ u (J) 
"'O c "'O 
"'O :J "'O 
"6 ..- N ..- N ..- ..- ..- N ..- ~ "6 N N ..- ~ ..- ..- ..- ..--
.s ....... 
..- ..- N N ..- ..- ..- ..- .0 .s N N ..- ..- .0 ..-- ..- ..- N :r: ..- :r: ..-
..-- ..- ..- ..-
"" 
LO ..- N ~ ..- ..- ..-
"" 
~ LO ..- N 
cO ..- I cO 
I ..-
r< ..- ..- ..- ..- ..- ..- N N N ..- r< ..- ..- ..- ..- ..- N N ..-
~ 
Additional Figure 1. Determination of insert size and restriction enzyme mapping of 'A YES cDNA clones that 
hybridize with EST clone R13609. (A) Determination of insert size in phage excised plasmid DNA. Plasmid DNA 
was analyzed by TAE/agarose gel electrophoresis using Xhol digestion. Molecular weight markers are in the 
indicated lanes. The band representing the 'A YES vector DNA is indicated by the arrow on the right. (B) 
Mapping of inserts in phage excised plasmid DNA by C. Kampershorer (5/16/96). Plasmid DNA was digested 
with BstXI and Xhol and analyzed by TAE/agarose gel electrophoresis. The faint 900 bp fragment identified in 
certian lanes is indicated by a white circle. (C) Table listing the phage clone picks and their insert sizes in kb. 
(D) Schematic representation of results from restriction enzyme mapping in B using diagnostic BstXI (8) and Xhol 
(X) mapping. Clone 22.1.1 gave no results and clone 11.1.1 was not tested (CK). 
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Additional Figure 2. DNA restriction enzyme analysis of the set of human NORF1 clones isolated from the 
Jurkat random-primed cDNA library. Lanes and DNA analyzed are indicated using TAE/agarose gel 
electrophoresis. Molecular weight markers are in the indicated lanes. The band representing the 4.6-kb 
pBluescript SK vector is indicated on the right by the arrow. 
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Additional Figure 4. DNA restriction enzyme analysis of mouse 4.5-kb NORF1 clone (20.1.1.1 ). (A) Initial 
analysis of insert size in mouse cDNA clones 20.X.X.X. Plasmids were digested with EcoRI to excise the 
insert but as the results show, apparently only linearized it. Small non-photographable band at -450 bp is 
indicated by the arrow on the right. Molecular weight markers are shown in the indicated lanes. (B, C, D, E, 
and F) DNA restriction enzyme analysis of mouse NORF1 clone 20.1.1.1. Mouse NORF1 was digested with 
the indicated enzymes and mapped. (B) 4.5-kb cDNA insert is indicated by the arrow on the right. Molecular 
weight markers are shown in the indicated lanes. (G) Schematic representation of the pBluescript SK 
plasmid containing the 4.5-kb NORF1 cDNA clone. 
I\.) 
~ 
co 
09l 
N 
0 
->. 
N 
0 
->. 
N 
0 
->. 
c 
A. Hindlll ladder 
Bg/11 
-1· BstXI 
·1~ Oral 
.~, Eco47111 
·;r Pstl 
'j Sall 
Xbal 
i-:$~i:';;;c.5!:<:.2i&>'.:?!\'. Xhol 
m 
A. Hindlll ladder 
1-kb ladder 
uncut 
Bg/11 
Bg/11/BamHI 
Bg/11/Hindlll 
,, 
A. Hindlll ladder 
1-kb ladder · 
uncut 
BamHI 
Hindlll 
BstXI 
BamHl/Hindlll 
BamHl/BstXI 
Hindlll!BstXI 
~gz: 
BstXI 
Notl 
Xbal 
BamHI 
Smal 
Pstl 
r--~-EcoRI 
~ 
BamHI (11) 
Pstl (27) 
EcoRI (404) 
BstXI (-1300) 
Bg/11 (-1500) 
Pstl (-2000) 
BstXI (-4200) 
1 ' EcoRI (destroyed) 
EcoRV 
Hindlll 
Sall 
Xhol 
Apa I 
Kpnl 
G) 
252 
REFERENCES 
(GCG), G. C. G. (1994). Program Manual for the Wisconsin Package (Madison, 
WI: Genetics Computer Group) 
Ahmad, M. and Bussey, H. (1986). Yeast arginine permease: nucleotide 
sequence of the CAN1 gene. Current Genetics 10, 587-92. 
AK, C., LE, K. and CM, B. (1987). Circular polysomes predominate on the rough 
endoplasmic reticulum of. American Journal of Anatomy 178, 1-10. 
Altamura, N., Groudinsky, 0., Dujardin, G. and Slonimski, P. P. (1992). NAM7 
nuclear gene encodes a novel member of a family of helicases with a Zn-ligand 
motif and is involved in mitochondrial functions in Saccharomyces cerevisiae. 
Journal of Molecular Biology 224, 575-87. 
Altschul, S.F., Gish, W., Miller, W., Myers, E.W. and Lipman, D.J. (1990). Basic 
local alignment search tool. Journal of Molecular Biology 215, 403-10. 
Aoufouchi, S., Yelamos, J. and Milstein, C. (1996). Nonsense mutations inhibit 
ma splicing in a cell-free system - recognition of mutant codon is independent of 
protein synthesis. Cell 85, 415-22. 
Applequist, S. E., et al. (1995). Sequence of the rabbit glyceraldehyde-3-
phosphate dehydrogenase-encoding cDNA. Gene 163, 325-6. 
Atkin, A. L., Altamura, N., Leeds, P. and Culbertson, M. R. (1995). The majority 
of yeast UPF1 co-localizes with polyribosomes in the cytoplasm. Molecular 
Biology of the Cell 6, 611-25. 
Ausbel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. 
A., and Struhl, K. eds. (1990). Current protocols in molecular biology. New York, 
NY: Green Publishing and Wiley lnterscience. 
Bach, G., Moskowitz, S. M., Tieu, P. T., Matynia, A. and Neufeld, E. F. (1993). 
Molecular analysis of Hurler syndrome in Druze and Muslim Arab patients in 
Israel: multiple allelic mutations of the IDUA gene in a small geographic area. 
American Journal of Human Genetics 53, 330-8. 
Back, A. L., Kwok, W.W. and Hickstein, D. D. (1992). Identification of two 
molecular defects in a child with leukocyte adherence deficiency. Journal of 
Biological Chemistry 267, 5482-7. 
Baird, P. N., Santos, A., Groves, N., Jadresic, L. and Cowell, J. K. (1992). 
Constitutional mutations in the WT1 gene in patients with Denys-Drash 
syndrome. Human Molecular Genetics 1, 301-5. 
253 
Baserga, S. J. and Benz, E. J. (1992). Beta-globin nonsense mutation: deficient 
accumulation of mRNA occurs despite normal cytoplasmic stability. Proceedings 
of the National Academy of Sciences of the United States of America 89, 2935-9. 
Bassett, D. J., et al. (1995). Comparative genomics, genome cross-referencing 
and XREFdb. Trends in Genetics 11, 372-3. 
Bassi, M. T., et al. (1995). Cloning of the gene for ocular albinism type 1 from the 
distal short arm of the X chromosome. Nature Genetics 10, 13-9. 
Baumann, B., Potash, M. J. and Kohler, G. (1985). Consequences of frameshift 
mutations at the immunoglobulin heavy chain locus of the mouse. EMBO J. 4, 
351-9. 
Beck, E. G., Jack, H. M. and Wabl, M. (1987). Allelic inclusion in a pre-B-cell line 
that generates immunoglobulin heavy chain genes in vitro. Proceedings of the 
National Academy of Sciences of the United States of America 84, 1060-4. 
Beelman, C. A. and Parker, R. (1995). Degradation of mRNA in eukaryotes. Cell 
81, 179-83. 
Belgrader, P., Cheng, J. and Maquat, L. E. (1993). Evidence to implicate 
translation by ribosomes in the mechanism by which nonsense codons reduce 
the nuclear level of human triosephosphate isomerase mRNA. Proceedings of 
the National Academy of Sciences of the United States of America 90, 482-6. 
Belgrader, P., Cheng, J., Zhou, X., Stephenson, L. S. and Maquat, L. E. (1994). 
Mammalian nonsense codons can be cis effectors of nuclear mRNA half-life. 
Molecular and Cellular Biology 14, 8219-28. 
Belgrader, P. and Maquat, L. E. (1994). Nonsense but not missense mutations 
can decrease the abundance of nuclear mRNA for the mouse major urinary 
protein, while both types of mutations can facilitate exon skipping. Molecular and 
Cellular Biology 14, 6326-36. 
Bijlsma, E. K., et al. (1994). Analysis of mutations in the SCH gene in 
schwannomas. Genes, Chromosomes and Cancer 11, 7-14. 
Boguski, M. S., Lowe, T. M. and Tolstoshev, C. M. (1993). dbEST--database for 
"expressed sequence tags". Nature Genetics 4, 332-3. 
254 
Boles, D. J. and Proia, R. L. (1995). The molecular basis of HEXA mRNA 
deficiency caused by the most common Tay-Sachs disease mutation. American 
Journal of Human Genetics 56, 716-24. 
Bonaventure, J., Chaminade, F. and Maroteaux, P. (1995). Mutations in three 
subdomains of the carboxy-terminal region of collagen type X account for most 
of the Schmid metaphyseal dysplasias. Human Genetics 96, 58-64. 
Bradstock, K. F., et al. (1985). Myeloid progenitor surface antigen identified by 
monoclonal antibody. British Journal of Haematology 61, 11-20. 
Brawerman, G. and. B., J. (1993). Control of mRNA Stability (San Diego, CA: 
Academic Press, Inc.) 
Buluwela, L., Forster, A., Boehm, T. and Rabbitts, T. H. (1989). A rapid 
procedure for colony screening using nylon filters. Nucleic Acids Research 17, 
452. 
Burd, C.G. and Dreyfuss, G. (1994). Conserved structures and diversity of 
functions of RNA-binding proteins. Science 265, 615-621. 
Burrows, P. D., Beck, G. B. and Wabl, M. R. (1981). Expression of mu and 
gamma immunoglobulin heavy chains in different cells of a cloned mouse 
lymphoid line. Proceedings of the National Academy of Sciences of the United 
States of America 78, 564-8. 
Bussaglia, E., et al. (1995). A frame-shift deletion in the survival motor neuron 
gene in Spanish spinal muscular atrophy patients. Nature Genetics 11, 335-7. 
Carothers, A. M., Urlaub, G., Grunberger, D. and Chasin, L.A. (1993). Splicing 
mutants and their second-site suppressors at the dihydrofolate reductase locus 
in Chinese hamster ovary cells. Molecular and Cellular Biology 13, 5085-98. 
Chen, D. C., Yang, B. C. and Kuo, T. T. (1992). One-step transformation of yeast 
in stationary phase. Current Genetics 21, 83-4. 
Cheng, J. and Maquat, L. E. (1993). Nonsense codons can reduce the 
abundance of nuclear mRNA without affecting the abundance of pre-mRNA or 
the half-life of cytoplasmic mRNA. Molecular and Cellular Biology 13, 1892-902. 
Cheng, J., Belgrader, P., Xhou, X., and Maquat, L. E. (1994). Intrans are cis 
effectors of the nonsense-codon-mediated reduction in nuclear mRNA 
abundance. Molecular and Cellular Biology 14, 6317-25. 
255 
Christensen, A. K., Kahn, L. E. and Bourne, C. M. (1987). Circular polysomes 
predominate on the rough endoplasmic reticulum of somatotropes and 
mammotropes in the rat anterior pituitary. American Journal of Anatomy 178, 1-
10. 
Coutts, M. and Brawerman, G. (1993). A 5' exoribonuclease from cytoplasmic 
extracts of mouse sarcoma 180 ascites cells. Biochimica et Biophysica Acta 
1173, 57-62. 
Crick, F. H. C., Barnet, L., Brenner, S., and Whatts-Tobin, R. J. (1961). The 
general nature of the genetic code. Nature 192, 1227-30. 
Cui, Y., Hagan, K. W., Zhang, S. and Peltz, S. W. (1995). Identification and 
characterization of genes that are required for the accelerated degradation of 
mRNAs containing a premature translational termination codon. Genes and 
Development 9, 423-36. 
Czaplinski, K., Weng, Y., Hagan, K. W. and Peltz, S. W. (1995). Purification and 
characterization of the Upf1 protein: a factor involved in translation and mRNA 
degradation. RNA 1, 610-23. 
Das, S., et al. (1994). Diverse mutations in patients with Menkes disease often 
lead to exon skipping. American Journal of Human Genetics 55, 883-9. 
DeMarini, D. J., Winey, M., Ursic, D., Webb, F. and Culbertson, M. R. (1992). 
SEN1, a positive effector of tRNA-splicing endonuclease in Saccharomyces 
cerevisiae. Molecular and Cellular Biology 12, 2154-64. 
Dietz, H. and Kendzior, R. J. J. (1994). Maintenance of an open reading frame 
as an additional level of scrutiny during splice site selection. Nature Genetics 8, 
183-8. 
Dietz, H. C., et al. (1993). Four novel FBN1 mutations: significance for mutant 
transcript level and EGF-like domain calcium binding in the pathogenesis of 
Marfan syndrome. Genomics 17, 468-75. 
Dietz, H. C., et al. (1993). The skipping of constitutive exons in vivo induced by 
nonsense mutations. Science 259, 680-3. 
Ding, J., Stitzel, J., Berry, P., Hawkins, E. and Kashtan, C. E. (1995). Autosomal 
recessive Alport syndrome: mutation in the COL4A3 gene in a woman with Alport 
syndrome and posttransplant antiglomerular basement membrane nephritis. 
Journal of the American Society of Nephrology 5, 1714-7. 
256 
Donahue, T.F., Cigan, A.M., Pabich, E.K., Valavicius, B.C. (1987). Mutations at a 
Zn(ll) finger motif in the yeast elF-2 beta gene alter ribosomal start-site selection 
during the scanning process. Cell 54, 621-32. 
Duriez, B., et al. (1994). An exon-skipping mutation in the btk gene of a patient 
with X-linked agammaglobulinemia and isolated growth hormone deficiency. 
FESS Letters 346, 165-70. 
Elion, E. A. and Warner, J. R. (1984). The major promoter element of rRNA 
transcription in yeast lies 2 kb upstream. Cell 39, 663-73. 
Elledge, S. J., Mulligan, J. T., Ramer, S. W., Spottswood, M. and Davis, R. W. 
(1991 ). Lambda YES: a multifunctional cDNA expression vector for the isolation 
of genes by complementation of yeast and Escherichia coli mutations. 
Proceedings of the National Academy of Sciences of the United States of 
America 88, 1731-5. 
Feussner, G., Dobmeyer, J., Grone, H. J., Lehmer, S. and Wohlfeil, S. (1996). A 
10-bp deletion in the apolipoprotein epsilon gene causing apolipoprotein E 
deficiency and severe type Ill hyperlipoproteinemia. American Journal of Human 
Genetics 58, 281-91. 
Gibson, R. A., Hajianpour, A., Murer, 0. M., Buchwald, M. and Mathew, C. G. 
(1993). A nonsense mutation and exon skipping in the Fanconi anaemia group C 
gene. Human Molecular Genetics 2, 797-9. 
Green, E. D., et al. (1991). Systematic generation of sequence-tagged sites for 
physical mapping of human chromosomes: application to the mapping of human 
chromosome 7 using yeast artificial chromosomes. Genomics 11, 548-64. 
Gunning, P., Leavitt, J., Muscat, G., Ng, S. Y. and Kedes, L. (1987). A human 
beta-actin expression vector system directs high-level accumulation of antisense 
transcripts. Proceedings of the National Academy of Sciences of the United 
States of America 84, 4831-5. 
Haas, I. G. (1994). BiP (GRP78), an essential hsp70 resident protein in the 
endoplasmic reticulum. Experientia 50, 1012-20. 
Hagan, K. W., Ruiz, E. M., Quan, Y. and Peltz, S. W. (1995). Characterization of 
cis-acting sequences and decay intermediates involved in nonsense-mediated 
mRNA turnover. Molecular and Cellular Biology 15, 809-23. 


Koonin, E.V. (1992). A new group of putative RNA helicases. Trends in 
Biochemical Science 17, 495-7. 
Kozak, M. (1994). Determinants of translational fidelity and efficiency in 
vertebrate mRNAs. Biochimie 76, 815-21. 
259 
Krawczak, M. and Cooper, D. N. (1991 ). Gene deletions causing human genetic 
disease: mechanisms of mutagenesis and the role of the local DNA sequence 
environment. Human Genetics 86, 425-41. 
Laemmli, U. K. (1970). Cleavage of structural proteins during the assembly of the 
head of bacteriophage T4. Nature 227, 680-5. 
Lee, B. S. and Culbertson, M. R. (1995). Identification of an additional gene 
required for eukaryotic nonsense mRNA turnover. Proceedings of the National 
Academy of Sciences of the United States of America 92, 10354-8. 
Leeds, P., Peltz, S. W., Jacobson, A. and Culbertson, M. R. (1991). The product 
of the yeast UPF1 gene is required for rapid turnover of mRNAs containing a 
premature translational termination codon. Genes and Development 5, 2303-14. 
Leeds, P., Wood, J.M., Lee, B. S. and Culbertson, M. (1992). Gene products 
that promote mRNA trunover in Saccharomyces cerevisiae. Molecular and 
Cellular Biology 12, 2165-77. 
Legrain, P. and Rosbash, M. (1989). Some cis- and trans-acting mutants for 
splicing target pre-mRNA to the cytoplasm. Cell 57, 573-83. 
Lewin, B. (1994). Genes IV (New York, NY: Oxford University Press). 
Lim, S. K. and Maquat, L. E. (1992). Human beta-globin mRNAs that harbor a 
nonsense codon are degraded in murine erythroid tissues to intermediates 
lacking regions of exon I or exons I and II that have a cap-like structure at the 5' 
termini. EMBO Journal 11, 3271-8. 
Lohse, P., et al. (1992). Familial apolipoprotein E deficiency and type Ill 
hyperlipoproteinemia due to a premature stop codon in the apolipoprotein E 
gene. Journal of Lipid Research 33, 1583-90. 
Longo, N., Langley, S. D., Griffin, L. D. and Elsas, L. 2. (1992). Reduced mRNA 
and a nonsense mutation in the insulin-receptor gene produce heritable severe 
insulin resistance. American Journal of Human Genetics 50, 998-1007. 
260 
Lozano, F., Maertzdorf, B., Pannell, R. and Milstein, C. (1994). Low cytoplasmic 
mRNA levels of immunoglobulin k light chain genes contanining nonsense 
codons correlate with inefficient splicing. EMBO J. 13, 4617-22. 
Luce, M. C., Binnie, C. G., Cayouette, M. C. and Kam, M. L. (1996). Identification 
of DNA mismatch repair gene mutations in hereditary nonpolyposis colon cancer 
patients. International Journal of Cancer 69, 50-2. 
Maquat, L. E. (1995). When cells stop making sense: Effects of nonsense 
codons on RNA metabolism in vertebrate. RNA 1, 453-65. 
Maquat, L. E., Kinniburgh, A. J., Rachmilewitz, E. A. and Ross, J. (1981). 
Unstable beta-globin mRNA in mRNA-deficient beta o thalassemia. Cell 27, 543-
54. 
Mcinnes, B., Brown, C. A. and Mahuran, D. J. (1992). Two small deletion 
mutations of the HEXB gene are present in DNA from a patient with infantile 
Sandhoff disease. Biochimica et Biophysica Acta 1138, 315-7. 
Meinkoth, J. and Wahl, G. (1984). Hybridization of nucleia acids immobolized on 
solid supports. 138, 267-84. 
Migliaccio, G., Nicchitta, C. V. and Blobel, G. (1992). The signal sequence 
receptor, unlike the signal recognition particle receptor, is not essential for 
protein translocation. Journal of Cell Biology 117, 15-25. 
Mooslehner, K., Muller, U., Karls, U., Hamann, L. and Harbers, K. (1991). 
Structure and expression of a gene encoding a putative GTP-binding protein 
identified by provirus integration in a transgenic mouse strain. Molecular and 
Cellular Biology 11, 886-93. 
Muhlrad, D., Decker, C. J. and Parker, R. (1994). Turnover mechanisms of the 
stable yeast PGK1 mRNA. Molecular and Cellular Biology 15, 2145-56. 
Muhlrad, D. and Parker, R. (1994). Premature translational termination triggers 
mRNA decapping. Nature 370, 578-81. 
Myerowitz, R. and Costigan, F. C. (1988). The major defect in Ashkenazi Jews 
with Tay-Sachs disease is an insertion in the gene for the alpha-chain of beta-
hexosaminidase. Journal of Biological Chemistry 263, 18587-9. 
Naeger, L. K., Schoborg, R. V., Zhao, Q., Tullis, G. E. and Pintel, D. J. (1992). 
Nonsense mutations inhibit splicing of MVM RNA in cis when they interrupt the 
reading frame of either exon of the final spliced product. Genes and 
Development 6, 1107 -19. 
Naylor, J. A., Green, P. M., Rizza, C.R. and Giannelli, F. (1993). Analysis of 
factor VIII mRNA reveals defects in everyone of 28 haemophilia A patients. 
Human Molecular Genetics 2, 11-7. 
261 
Noguchi, M., et al. (1993). lnterleukin-2 receptor gamma chain mutation results 
in X-linked severe combined immunodeficiency in humans. Cell 73, 147-57. 
Noller, H.F. (1993). tRNA-rRNA interactions and peptidyl transferase. FASEB 
Journal 7, 87-9. 
Ono, B. I., lshino, Y. and Shinoda, S. (1983). Nonsense mutations in the can1 
locus of Saccharomyces cerevisiae. Journal of Bacteriology 154, 1476-9. 
Orkin, S. H. and Kazazian, H. J. (1984). The mutation and polymorphism of the 
human beta-globin gene and its surrounding DNA. Annual Review of Genetics 
18, 131-71. 
Pastor, S. N., Rafi, M.A., Hoffman, J. D., Hu, D. and Wenger, D. A. (1994). 
Metachromatic leukodystrophy in the Navajo Indian population: a splice site 
mutation in intron 4 of the arylsulfatase A gene. Human Mutation 4, 199-207. 
Paw, B. H., Neufeld, E. F. (1988). Normal transcription of the ~-hexosaminidase 
a-chain gene in Ashkenazi Tay-Sach mutation. Journal of Biological Chemistry 
263, 3012-15. 
Peltz, S. W., Brown, A. H. and Jacobson, A. (1993). mRNA destabilization 
triggered by premature translational termination depends on at least three cis-
acting sequence elements and one trans-acting factor. Genes and Development 
7, 1737-54. 
Posnett, D. N. and Tam, J.P. (1989). Multiple antigenic peptide method for 
producing antipeptide site-specific antibodies. Methods in Enzymology 178, 739-
46. 
Prehn, S., et al. (1990). Structure and biosynthesis of the signal-sequence 
receptor. European Journal of Biochemistry 188, 439-45. 
Pulak, R. and Anderson, P. (1993). mRNA surveillance by the Caenorhabditis 
elegans smg genes. Genes and Development 7, 1885-97. 
Qian, L., Theodor, L., Carter, M., Vu, M. N., Sasaki, A. W., and Wilkinson, M. F. 
(1993). T cell receptor-beta mRNA splicing: regulation of unusual splicing 
intermediates. 13, 1686-96. 
Rabbani, H., et al. (1993). A 40-base-pair duplication in the gp91-phox gene 
leading to X-linked chronic granulomatous disease. European Journal of 
Haematology 51, 218-22. 
262 
Ray, B. K., et al. (1985). ATP-dependent unwinding of messenger RNA structure 
by eukaryotic initiation factors. Journal of Biological Chemistry 260, 7651-8. 
Ross, J. (1995). mRNA stability in mammalian cells. Microbiological Reviews 59, 
423-50. 
Ross, J. and Pizarro, A. (1983). Human beta and delta globin messenger RNAs 
turn over at different rates. Journal of Molecular Biology 167, 607-17. 
Sambrook, J., Fritsch, E.F. and Maniatis, T. eds. (1989). Molecular cloning: a 
laboratory manual. New York, NY: Cold Spring Harbor Press. 
Sanger, F., Nicklen, S. and Coulson, A. R. (1977). DNA sequencing with chain-
terminating inhibitors. Proceedings of the National Academy of Sciences of the 
United States of America 74, 5463-7. 
Satoh, K., et al. (1988). Emphysema associated with complete absence of alpha 
1- antitrypsin in serum and the homozygous inheritance [corrected] of a stop 
codon in an alpha 1-antitrypsin-coding exon [published erratum appears in Am J 
Hum Genet 1988 May;42(5):789]. American Journal of Human Genetics 42, 77-
83. 
Satokata, I., Tanaka, K., Yuba, S. and Okada, Y. (1992). Identification of splicing 
mutations of the last nucleotides of exons, a nonsense mutation, and a missense 
mutation of the XPAC gene as causes of group A xeroderma pigmentosum. 
Mutation Research 273, 203-12. 
Schlegel, N., et al. (1995). The molecular genetic basis of Glanzmann's 
thrombasthenia in a gypsy population in France: identification of a new mutation 
on the alpha lib gene. Blood 86, 977-82. 
Schmid, S. R. and Linder, P. (1992). D-E-A-D protein family of putative RNA 
helicases. Molecular Microbiology 6, 283-91. 
Senapathy, P. (1986). Origin of eukaryotic intrans: a hypothesis, based on codon 
distribution statistics in genes, and its implications. Proceedings of the National 
Academy of Sciences of the United States of America 83, 2133-7. 
Senapathy, P., Shapiro, M. B. and Harris, N. L. (1990). Splice junctions, branch 
point sites, and exons: sequence statistics, identification, and applications to 
genome project. Methods in Enzymology 183, 252-78. 
Serova, 0., et al. (1996). A high incidence of BRCA1 mutations in 20 breast-
ovarian cancer families. American Journal of Human Genetics 58, 42-51. 
263 
Sherratt, T. G., Vulliamy, T., Dubowitz, V., Sewry, C. A. and Strong, P. N. (1993). 
Exon skipping and translation in patients with frameshift deletions in the 
dystrophin gene. American Journal of Human Genetics 53, 1007-15. 
Simpson, S. B. and Stoltzfus, C. M. (1994). Frameshift mutations in the v-src 
gene of avian sarcoma virus act in cis to specifically reduce v-src mRNA levels. 
Molecular and Cellular Biology 14, 1835-44. 
Simsek, S., et al. (1994). Identification of a homozygous single base pair deletion 
in the gene coding for the human platelet glycoprotein lb alpha causing Bernard-
Soulier syndrome. Thrombosis and Haemostasis 72, 444-9. 
Slightom, J. L., Siemieniak, D. R., Sieu, L. C., Koop, B. F. and Hood, L. (1994). 
Nucleotide sequence analysis of 77.7 kb of the human V beta T-cell receptor 
gene locus: direct primer-walking using cosmid template DNAs. Genomics 20, 
149-68. 
Stover, M. L., Primorac, D., Liu, S. C., McKinstry, M. B. and Rowe, D. W. (1993). 
Defective splicing of mRNA from one COL 1A 1 allele of type I collagen in 
nondeforming (type I) osteogenesis imperfecta. Journal of Clinical Investigation 
92, 1994-2002. 
Struhl, K. (1989). Molecular mechanisms of transcriptional regulaion in yeast. 
Annula Revies of Biochemistry 58, 1051-1077. 
Takahashi, T., Suchi, M., Desnick, R. J., Takada, G. and Schuchman, E. H. 
(1992). Identification and expression of five mutations in the human acid 
sphingomyelinase gene causing types A and B Niemann-Pick disease. Molecular 
evidence for genetic heterogeneity in the neuronopathic and non-neuronopathic 
forms. Journal of Biological Chemistry 267, 12552-8. 
Tavtigian, S. V., et al. (1996). The complete BRCA2 gene and mutations in 
chromosome 13q-linked kindreds. Nature Genetics 12, 333-7. 
Thein, S. L. (1992). Dominant beta thalassaemia: molecular basis and 
pathophysiology. British Journal of Haematology 80, 273-7. 
Tsigos, C., Arai, K., Hung, W. and Chrousos, G. P. (1993). Hereditary isolated 
glucocorticoid deficiency is associated with abnormalities of the 
adrenocorticotropin receptor gene. Journal of Clinical Investigation 92, 2458-61. 
264 
Tugendrich, S., Basset, J. D. E., McKusick, V. A., Boguski, M. S. and Hieter, P. 
(1994). Genes conserved in yeast and humans. Human Molecular Genetics 3, 
1509-17. 
Turco, A. E., et al. (1995). A novel nonsense mutation in the PKD1 gene 
(C3817T) is associated with autosomal dominant polycystic kidney disease 
(ADPKD) in a large three-generation Italian family. Human Molecular Genetics 4, 
1331-5. 
Umesono, K., and Evans, R.M (1989). Determinants of target gene specificity for 
steroid/thyroid hormone receptors. Cell 266, 1139-46. 
Urlaub, G., Mitchell, P. J., Ciudad, C. J. and Chasin, L.A. (1989). Nonsense 
mutations in the dihydrofolate reductase gene affect RNA processing. Molecular 
and Cellular Biology 9, 2868-80. 
Vailly, J., et al. (1995). Identification of a homozygous one-basepair deletion in 
exon 14 of the LAMB3 gene in a patient with Herlitz junction al epidermolysis 
bullosa and prenatal diagnosis in a family at risk for recurrence. Journal of 
Investigative Dermatology 104, 462-6. 
van Bokhoven, H., et al. (1994). Mutation spectrum in the CHM gene of Danish 
and Swedish choroideremia patients. Human Molecular Genetics 3, 1047-51. 
Vieira, L. M., Kaplan, J.C., Kahn, A. and Leroux, A. (1995). Four new mutations 
in the NADH-cytochrome b5 reductase gene from patients with recessive 
congenital methemoglobinemia type II. Blood 85, 2254-62. 
Vreken, P., et al. ( 1995). A point mutation in an invariant splice acceptor site 
results in a decreased mRNA level in a patient with severe coagulation factor XIII 
subunit A deficiency. Thrombosis and Haemostasis 74, 584-9. 
Wabl, M., Burrows, P.O., von Gabain, A. and Steinberg, C. (1985). 
Hypermutation at the immunoglobulin heavy chain locus in a pre-B-cell line. 
Proceedings of the National Academy of Sciences of the United States of 
America 82, 479-82. 
Walker, G. J., et al. (1995). Mutations of the CDKN2/p161NK4 gene in Australian 
melanoma kindreds. Human Molecular Genetics 4, 1845-52. 
Walker, J. E., Saraste, M., Runswick, M. J. and Gay, N. J. (1982). Distantly 
related sequences in the alpha and beta subunits of ATP synthase, myosin , 
kinases and other ATP-requiring enzymes and a common nucleotide binding 
fold. EMBO J. 1, 945-51. 
Wengler, G. S., et al. (1995). High prevalence of nonsense, frame shift, and 
splice-site mutations in 16 patients with full-blown Wiskott-Aldrich syndrome. 
Blood 86, 3648-54. 
265 
Wiedmann, M., Kurzchalia, T. V., Hartmann, E. and Rapoport, T. A. (1987). A 
signal sequence receptor in the endoplasmic reticulum membrane. Nature 328, 
830-3. 
Wilmette, R., et al. (1994). A deletional frameshift mutation in spectrin beta-gene 
associated with hereditary elliptocytosis in spectrin Napoli. British Journal of 
Haematology 88, 437-9. 
Woodcock, D. M., et al. (1989). Quantitative evaluation of Escherichia coli host 
strains for tolerance to cytosine methylation in plasmid and phage recombinants. 
Nucleic Acids Research 17, 3469-78. 
Yun, D. F. and Sherman, F. (1995). Initiation of translation can occur only in a 
restricted region of the CYC1 mRNA of Saccharomyces cerevisiae. Molecular 
and Cellular Biology 15, 1021-33. 
Zhang, J. and Maquat, L. E. (1996). Evidence that the decay of nucleus-
associated nonsense mrna for human triosephosphate isomerase involves 
nonsense codon recognition after splicing. RNA 2, 235-43. 
Zhang, S., Ruiz, E. M., Quan, Y. and Peltz, S. W. (1995). Identification and 
characterization of a sequence motif involved in nonsense-mediated mRNA 
decay. Molecular and Cellular Biology 15, 2231-44. 
VITA 
The author, Steven E. Applequist, was born in St. Louis, Missouri, United 
States of America on May 26th, 1968 son of James and Sandra Applequist. 
He attended Lindbergh High school graduating in 1986. He then entered 
Southwest Missouri State University in 1986 and received a Bachelors of 
Science in the field of Biology in 1990. Mr. Applequist began his graduate 
studies in the Program in Molecular Biology in 1990 and joined the laboratory of 
Hans-Martin Jack, Ph.D., in February, 1991. Mr. Applequist was the recipient of 
the GraduateSchool Assistantship from August 1990 to July 1994. In the 
academic year of 1994-1995, Mr. Applequist was awarded a University 
Dissertation Fellowship. 
Mr. Applequist has accepted a position as a postdoctoral fellow in the 
laboratory of Birgitta Heyman, Ph.D., M.D., at the department of Pathology, 
University of Uppsala, Sweden. He will study the effect of antigen/allergen 
uptake through the low affinity lgE receptor among other things. 
266 
APPROVAL SHEET 
The dissertation submitted by Steven E. Applequist has been read and approved 
by the following committee: 
Dr. Hans-Martin Jack, Ph.D., Principal Investigator 
Assistant Professor, Department of Microbiology and Immunology 
Loyola University of Chicago 
Dr. Katherine Knight, Ph.D., Chair 
Professor and Chain, Department of Microbiology and Immunology 
Loyola University of Chicago 
Dr. Sally A. Amero, Ph.D. 
Assistant Professor, Department of Molecular and Cellular Biochemistry 
Loyola University of Chicago 
Dr. Mike Fasullo, Ph.D. 
Assistant Professor, Department of Radiotherapy 
Loyola University of Chicago 
Dr. William Walden, Ph.D. 
Professor, Department of Microbiology 
University of Illinois at Chicago 
The final copies have been examined by the director of the dissertation and the 
signature which appears below verifies the fact that any necessary changes 
have been incorporated and that the dissertation is now given the final approval 
by the Committee with reference to content and form. 
This dissertation is, therefore, accepted in partial fulfillment of the requirements 
for the degree of Doctor of Philosophy. 
Date 
